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ABSTRACT
Status epilepticus (SE) is a life-threatening neurologic emergency
occurring when the brain is in an unrelenting state of seizure activity.
Approximately 40% of people who encounter a single event of SE go on to
develop epilepsy, characterized by spontaneously occurring seizures. While the
exact mechanisms underlying seizure origin are not understood, at a
fundamental level seizures initiate due to an imbalance between inhibitory and
excitatory neurotransmission.
development

of

neurotransmission

epilepsy
and

We explored the impact of SE and the
on

kainate

GABAA
receptor

receptor

mediated

inhibitory

(KAR)

mediated

excitatory

neurotransmission.
Stiripentol (STP), a positive allosteric modulator of the GABA A receptor,
was found to terminate both brief and prolonged SE with the development of less
pharmacoresistance than is observed with the benzodiazepine (BZD), diazepam
(DZP). In addition STP, but not DZP, retained its ability to potentiate both phasic
and tonic GABAergic transmission post-SE. These findings are supported by
previous studies demonstrating that the actions of STP do not require the BZDsensitive γ2-containing GABAARs which are internalized during prolonged SE.
These

data

demonstrate

that

prolonged

SE

significantly

impacts

pharmacological profile of GABAA receptors and potential therapeutics.
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the

KARs densely populate the hippocampal mossy fiber – CA3 pathway
where they mediate a portion of excitatory neurotransmission. Significant
alterations in KAR subunit expression in the dentate gyrus and CA3 regions were
observed in animals at 5, 60 and 200 day post-SE. These changes were dynamic
and region specific. In agreement with observed alterations in subunit
expression, KAR-mediated neurotransmission was significantly reduced at
mossy fiber – CA3 synapses in epileptic animals. In addition, synaptic integration
by KARs during repetitive stimulation was also significantly impaired. These data
demonstrate

that

SE

significantly

impacts

KAR-mediated

excitatory

neurotransmission.
Together these studies provide new insight into the impact of SE and the
development of epilepsy on both GABAA and KAR-mediated neurotransmission.
The observed alterations following SE may contribute to the generation of
seizures or may be compensatory mechanisms to reduce the likelihood of
seizure initiation. Furthermore, these findings demonstrate the dramatic
alterations observed in the diseased brain and emphasize the importance of
acknowledging these differences for the development of effective therapeutics.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 SIGNIFICANCE
Epilepsy is the fourth most common neurological disorder after migraine,
stroke and Alzheimer’s disease. The prevalence of the disorder is greater than
that of autism spectrum disorders, cerebral palsy, multiple sclerosis and
Parkinson’s disease combined (Epilepsy Foundation, 1993). Despite the
magnitude of the disease-awareness, understanding and treatment of epilepsy
are severely limited. Epilepsy is characterized by the presence of recurring,
unprovoked abnormal synchronous brain activity that results in the disruption of
normal brain function (Briggs and Galanopoulou, 2011). The World Health
Organization has estimated that at least 65 million people worldwide, or nearly
1% of the population, are afflicted with a type of epilepsy syndrome (England et
al., 2012). Several precipitating events are linked to the development of epilepsy,
including trauma, stroke and tumors (Chang and Lowenstein, 2003). However,
epilepsy is considered the most challenging long-term consequence associated
with status epilepticus (SE), as nearly 40% of people who endure a single event
of SE develop epilepsy (Hesdorffer et al., 1998).
Status epilepticus is a neurologic emergency, characterized as a seizure
that lasts longer than 5 minutes, or when two seizures occur without complete

1

recovery between them (Epilepsy Foundation, 1993). SE occurs with an
incidence of 100,000 – 160,000 people per year in the United States (Manno,
2003), and results in death in approximately 20% of patients (Theodore et al.,
1994). While SE affects people of all ages, it is considered the most common
neurologic condition in childhood with an incidence of 10 – 27 per 100,000
children ranging from 1 month to 15 years of age, with the majority of events
occurring in children less than four years of age (DeLorenzo et al., 1996;
Hesdorffer et al., 1998; Coeytaux et al., 2000; Chin et al., 2006; Govoni et al.,
2008). Both the etiology (Huff and Fountain, 2011) and duration of SE
dramatically impacts the prognosis, with a longer duration of SE correlated to
increased morbidity and mortality (Pellock et al., 2004).
Through a combination of anti-epileptic drugs (AEDs) and/or brain
surgery, adequate control of seizures is obtained in nearly 60% of patients
(Jacobs et al., 2009). However, nearly 20 – 40% of patients diagnosed with
epilepsy will develop refractory status epilepticus (RSE), and will be unable to
manage their seizures with available AEDs (French, 2007). Patients suffering
from

RSE have

increased hospitalization and

more

frequent

medical

complications (Mayer et al., 2002). There are a wide variety of factors that
contribute to the development of RSE, including age of onset, seizure etiology,
infection, as well as genetic and environmental factors (French, 2007). In
addition, in both SE-experienced patients (Grigorenko et al., 1997; Mathern et al.,
1998; Loup et al., 2000; Das et al., 2012; Houser et al., 2012) and animal models
of SE (Lason et al., 1997; Mikuni et al., 1999; Porter et al., 2006; Goodkin et al.,
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2008; Sun et al., 2009; Rajasekaran et al., 2012), both inhibitory and excitatory
receptor populations are altered, a consequence of SE that may dramatically
impact the effectiveness of prescribed AEDs and contribute to RSE. Despite
these changes, little is known about how these alterations in receptor populations
affect receptor pharmacology and neuronal signaling in the SE-experienced
brain.

Understanding these alterations is crucial to being able to develop

effective therapies for the treatment of status epilepticus and the progression to
spontaneously occurring seizures.
At the core of status epilepticus is the inability of the inherent cellular
mechanisms to terminate seizure activity (Coulter and DeLorenzo, 1999). These
sustained seizure events can yield devastating consequences including
becoming refractory to available AEDs and the increased risk for the
development of epilepsy.
The following studies provide new evidence regarding how status
epilepticus alters hippocampal inhibitory and excitatory receptor populations, and
the physiological impact of these alterations on neuropharmacology and neuronal
signaling.

1.2 EPILEPSY
The International League Against Epilepsy and the International Bureau of
Epilepsy have defined epilepsy as a disorder of the brain characterized by an
enduring predisposition to the generation of epileptic seizures. In addition
neurobiological, cognitive, psychological and social consequences associated
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with the disease have been identified. In accordance with a variety of diagnostic
tests, the diagnosis of epilepsy requires the occurrence of at least one epileptic
seizure, defined as a transient occurrence due to abnormal, excessive or
synchronous brain activity (Fisher et al., 2005). Epilepsy is a heterogeneous
disease with no obvious geographic, racial or social boundaries. Despite its
diversity, epilepsy tends to be more frequent within the African American
population, slightly more common in men than women, and is more commonly
diagnosed in infants and adults over 65 years of age (Theodore et al., 2006).
Epilepsy is believed to affect nearly 65 million people worldwide, and may affect
as many as 2.8 million Americans (England et al., 2012). In the United States the
total annual hospital charges billed for the treatment of epilepsy totaled nearly $3
billion (Vivas et al., 2012). However the annual economic burden of the disease,
including lost employment, wages and productivity, has been estimated at $17.6
billion. In addition to the economic burden, the diagnosis of epilepsy carries with
it an increased risk for the development of social stigma and severe
comorbidities.

1.2.1 EPILEPSY STIGMA
The earliest written description of seizure disorders dates back to nearly
2000 B.C. in the region known as Mesopotamia, while the first medical
documentation of the disease was crafted by Hippocrates in 400 B.C.
(Magiorkinis et al., 2010). Despite the vast amount of time in which people have
known about epilepsy the lack of understanding and knowledge about the
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disease led people to believe that seizures were the result of demonic
possession, sin and even lunacy. Despite the efforts of modern scientific and
medical research to cast light on the disease many of the original social stigmas
continue to impact epilepsy patients, caregivers and family members. In addition,
patients who feel they experience the stigma often report increased levels of
depression and anxiety, reduced self-esteem, and an overall decrease in quality
of life (Jacoby and Austin, 2007). In addition to the social stigma associated with
the disease, people suffering from epilepsy have difficulty obtaining driver’s
licenses, proper medical insurance, and face limited job opportunities as careers
in teaching, medicine, and police or fire enforcement may be restricted (Jacoby
and Austin, 2007). In order to reduce the stigma associated with epilepsy the
scientific community must join efforts with the millions of people suffering from
seizure disorders and begin to raise public awareness and knowledge about the
disease.

1.2.2 COMORBIDITIES OF SEIZURE DISORDERS
While people suffering from epilepsy continue to face the stigma
associated with their disease they are also at risk for a myriad of moderate to
severe psychiatric, cognitive and behavioral comorbidities. For decades it was
believed that these comorbid conditions were side-effects of the seizures,
however more recent data suggest that some conditions may precede the
seizures. In addition, control of seizures through available AEDs may not
alleviate the symptoms associated with the comorbid conditions. Comorbidities
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associated with seizure disorders require adequate attention as these conditions
may be more severe and debilitating than the seizures themselves. Alterations in
comorbidities are also observed during the progression of epilepsy and have
been correlated with age of onset, seizure frequency and duration of seizures
(Jacobs et al., 2009).
Psychiatric and cognitive comorbidities are commonly observed in patients
suffering from seizure disorders. Diagnosis of psychiatric comorbidities including
depression, anxiety, mood disorders and attention-deficit hyperactivity disorder
are increased in epileptic patients (Lin et al., 2012). Of these conditions
depression is the most common with some studies reporting upwards of 55% of
patients suffering from depressive like symptoms (Jackson and Turkington,
2005). Depression is not a uniform comorbidity in epilepsy, as it appears to be
more common in complex partial (temporal lobe) seizures, than in generalized
seizure disorders (Jackson and Turkington, 2005). In addition to depressive
symptoms, suicide is also increased from 1.4% in the non-epileptic population to
nearly 5% in epileptic patients (Jackson and Turkington, 2005).
As observed with psychiatric comorbidities, the impact of seizures on
cognition appears to be related to seizure etiology, frequency, duration and
severity (Saling et al., 1993; Jones-Gotman, 2000; Helmstaedter and Kurthen,
2001; Jokeit and Ebner, 2002; Aldenkamp and Arends, 2004; Dodrill, 2004). In
addition cognitive impairments are more prevalent in patients suffering from
temporal (van Rijckevorsel, 2006) and frontal lobe epilepsies (Hernandez et al.,
2003). Commonly reported symptoms include impairments in memory, attention
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and a general mental slowness (van Rijckevorsel, 2006). More recently, it has
become evident that impaired cognitive abilities may precede the development of
epilepsy, as studies have demonstrated academic underachievement in children
(Austin et al., 2001; Dunn et al., 2002; Oostrom et al., 2003; Hesdorffer et al.,
2004; Berg et al., 2005) as well as adults (Hesdorffer et al., 2000; Hesdorffer et
al., 2006) prior to seizure onset. Furthermore, commonly prescribed AEDs may
initiate comorbid side-effects or exacerbate existing symptoms, as they have
been shown to negatively impact cognition, as well as increase depression,
anxiety and nervousness (Bootsma et al., 2006; Meador, 2006; Schmitz, 2006;
Gomer et al., 2007).

1.2.3 SEIZURE CLASSIFICATION
In April of 1964, led by Henri Gastaut, several European branches of the
International League Against Epilepsy met to develop an international
classification of epileptic seizures. This initial system has been continuously
amended and improved as knowledge and understanding of epilepsy and
differences in seizure types emerged. In 1981 a detailed version of the
classification system, which included seizure video and electroencephalogram
(EEG) recordings, was approved by the General Assembly of the International
League Against Epilepsy and has become the hallmark for seizure classification
by clinicians.
As approved in 1981, seizures can be classified into two broad categories,
partial (also referred to as focal) and generalized seizures. Partial seizures
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account for approximately 60% of new cases of epilepsy (Hauser et al., 1991),
and generally only impact a specific region of the brain. Depending upon the
brain region affected symptoms may impact motor, cognitive, sensory, or
autonomic abilities. Partial seizures are further classified depending upon
alterations in consciousness. Consciousness is not altered in simple partial
seizures; however it is lost during complex partial seizures, also referred to as
temporal lobe or psychomotor seizures. These types of seizures occur in about
35% of patients, who have no memory of the event and usually report feelings of
confusion and tiredness following the seizure event (Kammerman and
Wasserman, 2001). Given that partial seizures occur in a specific region of the
brain, they do have the ability to spread throughout the brain, a term referred to
as secondary generalization.
The second seizure category is referred to as generalized seizures
(primary generalized) and account for approximately 40% of epilepsy cases
(Hauser et al., 1991).

Unlike partial seizures, which are focal in nature,

generalized seizures affect the entire brain, specifically the motor cortex and
involve a loss of consciousness and impaired memory of the event. Six types of
generalized seizures have been described. However, the most common is the
grand-mal (tonic-clonic) seizure, which accounts for about 25% of all generalized
seizures. Other types of generalized seizures include petit-mal (absence),
myoclonic, clonic, tonic, and atonic. Each of the six types of generalized seizures
is accompanied by distinct physical characteristics and movements by the patient
(Kammerman and Wasserman, 2001).
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Both partial and generalized seizures are considered self-limiting, as they
will terminate within seconds to minutes of onset. However a separate category
of seizures exists, those referred to as continuous seizures or SE. Similar to selflimiting seizures, SE can also be divided into two broad categories; general
convulsive SE (GCSE) and non-convulsive SE (NCSE). GCSE is the most
common form of SE, associated with higher morbidity and mortality and
characterized by continuous, rhythmic movements. In contrast, NCSE manifests
as confusion, psychosis without overt alterations in motor activity. Patients with
GCSE or NCSE will demonstrate bilateral impairments on EEGs, however due to
the lack of physical manifestations in NCSE an EEG is required for this
diagnosis. Figure 1.1 serves as a modified diagram illustrating the different
seizure categories discussed.
The current project will focus on general convulsive status epilepticus and
the progression to spontaneously occurring seizures.

1.3 STATUS EPILEPTICUS
Status epilepticus (SE) is classically defined as the occurrence of two or
more seizures without recovery of consciousness or 30 minutes of continuous
seizure activity. However, due to the seriousness of SE more recent literature
has reduced this time to merely 5 minutes of seizure activity (Huff and Fountain,
2011). Unlike more classic seizure disorders, SE represents the inability of
inherent cellular mechanism to terminate the seizure (Coulter and DeLorenzo,
1999), and thus the seizure persists. This sustained seizure activity suggests that
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Figure 1.1. Seizure classification. Two broad categories of seizures
exist, those that are self-terminating and those that are sustained, referred to as
status epilepticus (SE). Self-terminating seizures can be further classified into
partial and generalized seizures. Partial seizures are localized to a particular
brain region whereas generalized seizures can affect the entire cortex. These
categories are further identified based upon behavioral consequences including
loss of consciousness. Partial seizures can spread to more severe generalized
seizures. Sustained seizures, SE, can be subdivided into non-convulsive SE
(NCSE) and generalized convulsive SE (GCSE). Additional types of SE exist but
are not easily classified into NCSE or GCSE categories.
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SE is composed of both an activation and a maintenance phase (Mazarati et al.,
1998). The proposed phases of SE are likely regulated by the several different
receptor

populations

which

can

mediate

excitatory

and

inhibitory

neurotransmission.
In the United States there are approximately 150,000 cases of SE each
year (Chapman et al., 2001), of which at least 50% are diagnosed as the more
severe GCSE. SE is associated with nearly a 20% mortality rate, a figure even
higher in cases of RSE (Aminoff and Simon, 1980; Towne et al., 1994). In 20 –
40% of patients a single SE event eventually leads to the development and
diagnosis of epilepsy (Hesdorffer et al., 1998; Sankar et al., 2000). While 50% of
SE cases occur in patients with no known seizure disorder, a previous diagnosis
of epilepsy does significantly increase the risk of SE (Hesdorffer et al., 1998),
with approximately 15% of epilepsy patients experiencing an episode of SE
during their lifetime (Trinka et al., 2012). While risk factors for the development of
SE are limited it is acknowledged that one factor is age, as approximately 40% of
SE patients are under 2 years of age and the greatest incidence of SE occurs in
adults over 60 years of age (Shinnar et al., 1997). Additional risk factors include
possible genetic factors and lower socioeconomic standing.
There are two general categories of underlying causes of SE, acute and
chronic. Acute etiology includes an imbalance in electrolytes, drug toxicity,
infection of the central nervous system (CNS), cerebral trauma, etc., while more
chronic etiologies include a pre-existing seizure disorder, alcoholism, cerebral
tumors or lack of AED compliance (Trinka et al., 2012). Understanding the
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possible origin for the development of SE greatly influences potential treatment
protocols for the patient.

1.3.1 SEIZURE MECHANISMS
At a basic level seizures initiate due to abnormal neuronal firing or
imbalance within the inhibitory and excitatory systems of the brain. Due to the
highly interconnected network of the brain, epileptiform activity in one area or
within one population of neurons can easily spread to neighboring areas and may
eventually alter transmission throughout the entire cerebrum. The majority of
seizures are considered self-limiting, in that within seconds to minutes the
seizure will terminate without the need for intervention. However when a seizure
does not self-terminate it may continue indefinitely, a neurologic emergency
referred to as SE. The exact mechanism by which seizures terminate is not clear.
It is postulated that mechanisms involved in seizure termination occur at the level
of a single neuron or within a network of neurons, and that in some individuals
these mechanisms may simply fail (Lado and Moshe, 2008).
One of the most critical mechanisms involved in regulation of neuronal
firing is proper regulation of the afterhyperpolarization (AHP) which occurs at the
level of the single neuron. Action potential invasion into a neuron produces an
increase in intracellular Ca2+ which activates voltage-gated K+ channels that
allow for K+ to flow out of the cell. This efflux of K+ leaves the intracellular space
more negatively charged and the cell hyperpolarizes, which prevents further
excitability (Alger and Nicoll, 1980; Timofeev et al., 2004). Network regulation of
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seizures includes depletion of synaptic glutamate which serves to limit burst
activity (Staley et al., 1998), and acidification of both the intracellular and
extracellular spaces due to the increase in CO2 levels during prolonged seizure
activity (Chesler and Kaila, 1992). Network synchronization, a hallmark of
seizures, is partly regulated by interneuronal gap junctions (Mancilla et al., 2007).
The acidification during a seizure also results in the decoupling of these gap
junctions, which serves to limit neuronal discharge and network synchronization
(de Curtis et al., 1998). There are many different mechanisms that serve to limit
seizure activity, any number of which could be altered resulting in prolonged
status epilepticus.

1.3.2 TREATMENT OF REFRACTORY STATUS EPILEPTICUS
A major component to successful termination of SE is the ability of the
patient to receive rapid treatment. It has been demonstrated that treatment even
prior to arrival at a hospital is critical (Pellock et al., 2004). In a study
investigating seizure treatment it was determined that over half of patients who
were not successfully treated prior to a hospital were twice as likely to require
intensive care (Alldredge et al., 2001). Fast and effective treatment of SE is so
essential that standard treatment algorithms have been developed that indicate
the hierarchy of available drugs (Pellock et al., 2004). In agreement with clinical
studies indicating the need for pre-hospital treatment of SE, treatment algorithms
begin with conventional antiepileptic drugs (AEDs) including benzodiazepines
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(BZDs) and advance to the use of barbiturates and even anesthesia in extreme
cases.
BZDs, including diazepam, are considered the first line of treatment of SE.
To achieve the highest rate of seizure termination BZDs should be administered
within minutes of seizure onset. One rationale for immediate treatment is that
while BZDs are considered the safest of the available AEDs they have been
shown to lose effectiveness during the progression of SE (Walton and Treiman,
1988; Kapur and Macdonald, 1997; Jones et al., 2002; Grosenbaugh and Mott,
2013).

Patients who develop pharmacoresistance to BZDs and other

medications may develop RSE. Despite adequate treatment with available AEDs
nearly 45% of patients with SE will develop RSE, which brings with it an
increased risk for a variety of neuropathological consequences including death in
nearly 25% of cases (Mayer et al., 2002; Holtkamp et al., 2005; Rossetti et al.,
2005). In cases of RSE when available AEDs are ineffective patients are often
put into medically induced comas through exposure to a variety of anesthetics
(Knake et al., 2009).
Chapter 3 will explore the use of stiripentol, a novel AED, for the treatment
of BZD-refractory status epilepticus.

1.4 THE HIPPOCAMPUS
The term ‘hippocampus’, derived from the Greek word for seahorse, was
first coined by anatomist Giulio Cesare Aranzi in 1587. Investigation into this
newly discovered structure continued and by the mid 1900’s it was evident that
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the early neuroanatomists such as Camillo Golgi, Karl Schaffer, and Santiago
Ramon y Cajal, where incredibly accurate in their initial description and depiction
of this region. In fact a rendering of the hippocampus by Ramon y Cajal in his
book Histologie du Systeme Nerveux (1911) is widely used today. Despite a
rapidly growing understanding of the anatomy and structure of the hippocampus
the function of this region was not as clear. This changed in 1957 with the patient
H.M. who underwent a bilateral mesial temporal lobectomy in which his
hippocampus, among other limbic structures, was removed in an attempt to cure
his epilepsy. The studies and observations of H.M. by William Scoville and
Brenda Milner (Scoville and Milner, 1957) concluded that while the surgery was
successful in reducing the seizures, the patient was left with global amnesia. This
was the first time a direct link between memory and the hippocampus had been
detected as prior to this event the hippocampus was believed to be involved in
the limbic ‘emotional’ circuitry of the brain.
The connection between the hippocampus and memory is nearly
universally agreed upon, despite discrepancies regarding its precise role.
However, it is generally accepted that the hippocampus is critical for both
declarative memory and spatial memory (Burgess et al., 2002). Declarative, or
explicit, memory is thought to include both episodic memory which is the capacity
to remember personal experiences, as well as semantic memory which involves
factual knowledge related to meanings and general concepts. As the name would
indicate, spatial memory involves encoding information regarding one’s spatial
orientation and environment. Consistent with the understanding of the
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hippocampus’s role in spatial memory is the presence of hippocampal ‘place
cells’ that encode an animal’s location independent of its orientation (O'Keefe,
1976; Wilson and McNaughton, 1993; Muller et al., 1994). In addition to encoding
specific types of information the hippocampus is also involved in memory
retrieval. While research in this area is complicated it is believed that damage to
the hippocampus, including lesions, sclerosis or atrophy, results in the inability to
form new memories (anterograde amnesia), as well as difficulty recalling events
just prior to the injury (temporally graded retrograde amnesia) (Squire, 1992;
Hodges, 1994; Squire and Alvarez, 1995).
The importance and central role for the hippocampus in learning and
memory is without question. In accordance, hippocampal atrophy or sclerosis is a
hallmark of many diseases linked to severe cognitive impairment, including
Alzheimer’s disease (Jack et al., 1999; Wang et al., 2006), schizophrenia
(Heckers, 2001), and as is the focus of this document, epilepsy (Chang and
Lowenstein, 2003). The ability to develop therapeutics for the treatment of these
diseases and their severe comorbidities (i.e. cognitive impairment) likely lies
within our understanding of the hippocampus. As this region is highly organized
and relatively encapsulated its anatomical structure and circuitry in the healthy
brain has been well characterized.

1.5 HIPPOCAMPAL ANATOMY AND CIRCUITRY
The hippocampal formation lies deep within the mesial temporal lobes and
is just one of several brain structures located within the limbic system. The
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hippocampal

formation

contains

several

brain

structures

including

the

presubiculum, parasubiculum, entorhinal cortex (EC), subiculum, dentate gyrus
(DG), and hippocampus proper. The hippocampus proper is composed of three
distinct cellular subdivisions; CA1, CA2 and CA3, where ‘CA’ comes from the
term cornu ammonis or Ammon’s horn. Most commonly, and throughout this
document, the term hippocampus refers collectively to the dentate gyrus and to
areas CA1, CA2, and CA3.
A unique feature of the hippocampus is the highly organized and
unidirectional flow of information. This feature is apparent in what is referred to
as the ‘trisynaptic circuit’. The EC is considered the first step in this circuit as the
axons from cells in the EC project into the dentate gyrus through the perforant
path. The axons of the principal cells within the dentate gyrus are called mossy
fibers which then connect the dentate gyrus to area CA3. In turn, the CA3
pyramidal cells serve as the major source of input into area CA1 through the
Schaffer collaterals. Finally CA1 projections exit the hippocampus as they enter
the subiculum (Figure 1.2). This trisynaptic pathway emphasizes the concept
that the major source of input into the hippocampus comes from within the
hippocampus itself.

1.5.1 DENTATE GYRUS ANATOMY AND CIRCUITRY
The dentate gyrus (DG) is the first hippocampal structure to receive input
directly from the entorhinal cortex and is classically comprised of three distinct
layers. The most superficial layer, located closest to the hippocampal fissure, is
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Figure 1.2. Hippocampal organization and the trisynaptic pathway.
Transmission from layer II of the entorhinal cortex (EC) enters the dentate gyrus
(DG) through the perforant pathway (1. green). Signaling continues from the DG
into area CA3 via the mossy fiber pathway (2. blue). From area CA3 signaling
persists into area CA1 (3. red) before exiting the hippocampus through the
subiculum (Sub) and terminating in layer V of the EC. In addition, layer III of the
EC can directly synapse in area CA1, creating the temporoammonic pathway,
and the perforant pathway can terminate directly in area CA3 (not shown).
This study will explore the impact of SE on transmission from the perforant
pathway into the DG as well as alterations in the mossy fiber – CA3 pathway.
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the molecular layer, stratum moleculare. This layer is subsequently divided into
the inner and outer-layers, each receiving slightly different inputs from the EC.
The principal cells of the DG are termed granule cells and form a very dense
cellular layer, stratum granulosum. The cell layer located between regions CA1
and CA3 is termed the suprapyramidal blade, while the layer opposite of this,
which extends beneath area CA3 is the infrapyramidal blade. The U-shaped
structure of these blades encompasses the polymorphic layer, commonly
referred to as the hilus, which serves as the third layer of the dentate gyrus.
Dentate granule cells (DGCs) are formed within the ventricular
germinative layer of the hippocampus, located near area CA1. During embryonic
development newly generated DGCs can migrate directly to stratum granulosum,
or into a second germinative layer located in the hilus prior to entering stratum
granulosum. Later during postnatal development and during the process of
neurogenesis, newly generated DGCs enter the granule cell layer through the
hilar germinative layer. The morphology of granule cells is highly conserved,
despite differences in how they may enter the cell body layer and which blade of
the DG they are located along. Granule cells display spiny dendrites that project
toward the superficial portion of the molecular layer, with the dendrites
terminating near the hippocampal fissure. The majority of granule cell axons,
termed mossy fibers, project to area CA3, while axon collaterals innervate mossy
cells located in the hilus. Mossy cells reside in the hilar region of the DG, and
have axons that project to both the ipsilateral and contralateral inner molecular
layer (associational/commissural pathways). In addition, the proximal dendrites of
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the mossy cells are covered in large complex spines called thorny excrescences
that serve as the termination site for the mossy fibers. These neuroanatomical
projections within the dentate gyrus are illustrated in Figure 1.3.

1.5.2 CA3 ANATOMY AND CIRCUITRY
Similar to the dentate gyrus, areas CA1 – 3 are comprised of principal cells and
are composed of several distinct cellular layers. While the principal cells of the
DG are called granule cells, in areas CA1 – 3 they are referred to as pyramidal
cells (i.e. CA3 pyramidal cells). In each of these regions pyramidal cells are very
tightly packed to form the pyramidal cell layer, stratum pyramidale (SP). Located
deep to the pyramidal cell layer is stratum oriens (SO), which contains several
types of interneurons. SO also contains the CA3 – CA3 associational fibers,
which provide input from CA3 neurons to other CA3 neurons in the same
hemisphere, as well as a portion of the Schaffer collaterals that connect CA3 and
area CA1. Directly above the CA3 pyramidal cell layer is stratum lucidum (SL),
which is composed of mossy fibers originating in the DG. Stratum lucidum,
meaning “clear layer” is appropriately named, as the unmyelinated mossy fibers
and lack of cells within this layer contribute to its translucent appearance.
Superficial to SL is another distinct cellular layer referred to as stratum radiatum
(SR). In areas CA2 and CA1, SR is located directly above the pyramidal cell
layers, as CA3 is the only region to contain stratum lucidum. Similar to SO, SR
also contains interneurons, CA3 – CA3 associational fibers and a portion of the
Schaffer collaterals entering
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Figure 1.3. Anatomical projections of the dentate gyrus. Dentate
granule cells (black circles) reside in the dentate granule cell layer and have
dendrites that extend into the molecular layer (purple). The axons of granule cells,
termed mossy fibers (blue) travel through the hilus and terminate in area CA3
stratum lucidum. Mossy fibers can also synapse on hilar mossy cell dendrites
(green), which extend throughout the hilar region. The axons of mossy cells (red)
terminate in both the ipsilateral and contralateral inner molecular layer.

21

area CA1. The most superficial layer of the hippocampus is stratum lacunosummoleculare (SLM), which is the thin layer in which fibers from the entorhinal
cortex terminate and serves as the home for several different types of
interneurons.
Pyramidal cells, like DGCs, originate in the ventricular germinative layer of
the hippocampus and migrate into their respective regions during embryonic
development. Mature pyramidal cells located in area CA3 (as well as CA2 and
CA1) are composed of a cell body which lies within the pyramidal cell layer, basal
dendrites that extend into stratum oriens and apical dendrites that extend to
stratum lacunosum-moleculare, near the hippocampal fissure. The axons of
these cells bifurcate and often send a branch of the axon back towards the soma
of the neuron. In area CA3 these axon collaterals project to areas CA1 – CA3 of
both the ipsilateral and contralateral hemispheres, referred to as the
associational and commissural pathways, respectively. In addition to these
abundant projections, a smaller number of CA3 axon collaterals also terminate
within the hilar region of the DG. Together, this extensive network of excitatory
CA3

projections

is

believed

to

make

up

approximately

80%

of

all

intrahippocampal synapses (Amaral and Witter, 1989). These complex
neuroanatomical projections through area CA3 are depicted in Figure 1.4.

1.5.3 MOSSY FIBER PATHWAY
Projections stemming from area CA3 pyramidal cells overwhelmingly
contribute to the intrahippocampal network. In order for this to occur it is essential
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Figure 1.4. Anatomical projections of area CA3. CA3 pyramidal cells
(black triangles) reside in the pyramidal cell layer. The apical dendrites of these
pyramidal cells extend into stratum lacunosum-moleculare while the basal
dendrites extend into stratum oriens (green). Collateralized axons of CA3
pyramidal cells extend through stratum oriens before terminating in area CA1
creating the Schaffer collaterals (red). Axons also give rise to associational
(purple) and commissural (black) projections between the ipsilateral and
contralateral hippocampi, respectively. Mossy fibers, comprised of large en
passant terminals (blue fibers and circles), originate from dentate granule cells
and synapse on the large thorny excrescences located on the apical dendrite of
CA3 pyramidal cells (orange circles).

23

that the dentate gyrus effectively communicate with area CA3. The manner in
which this occurs is through the mossy fiber pathway, first documented in the late
1800s (Golgi, 1886; Sala, 1891). In rats, each of the approximately one million
granule cells (approximately 15 million in humans) produces a single mossy fiber
that travels into area CA3 through stratum lucidum. Prior to entering area CA3
each mossy fiber gives rise to roughly 7 collaterals that synapse onto hilar mossy
cells which mediate both inhibitory and excitatory transmission. A distinct
characteristic of mossy fibers is that unlike any other hippocampal principal cell,
granule cells have more than one type of terminal along their axons (Ramón y
Cajal, 1911). The first type is the large terminals that occur along the length of
the axon and so were given the name ‘en passant’ meaning ‘in passing’. Each
mossy fiber is believed to contain approximately 15 of these large (3 – 8 µM in
diameter) en passant terminals, also referred to as mossy fiber expansions. Each
expansion forms highly complex and intertwined connections with the thorny
excrescences located on hilar mossy cells and the proximal dendrites of CA3
pyramidal cells. Furthermore, a single mossy fiber expansion can make as many
as 37 synaptic contacts with a single dendrite from a CA3 pyramidal cell.
However, typically these large expansions do not contact two different spines on
a single dendrite and thus do not contact two different pyramidal cells. In addition
to the large en passant terminals that synapse onto mossy cells and CA3
pyramidal cells, mossy fibers also contain smaller en passant terminals and
filopodial extensions that innervate GABAergic interneurons (Acsady et al.,
1998).
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The expansiveness and intricacy of the mossy fiber pathway allows for a
single granule cell to communicate with up to 15 CA3 pyramidal cells, and with a
single CA3 pyramidal cell receiving input from nearly 72 dentate granule cells.
Furthermore, as DGCs are continuously generated through the process of
neurogenesis, each newly formed granule cell also generates a newly formed
mossy fiber. Thus the mossy fiber pathway would be highly plastic and
undergoing constant reorganization. The unique ability for the dentate gyrus and
CA3 to communicate via the mossy fiber pathway has drawn considerable
attention in an attempt to understand its role in hippocampal synaptic
transmission.

1.6 MOSSY FIBER SYNAPTIC PLASTICITY
Synaptic transmission at the mossy fiber – CA3 synapse is predominately
regulated by the excitatory neurotransmitter glutamate. Glutamate is contained in
vesicles located within the presynaptic terminal which upon release activate
postsynaptic glutamate receptors such as NMDA, AMPA and/or kainate
receptors. These synapses have the ability to modify their strength and efficacy
through an activity-dependent manner, a phenomenon referred to as synaptic
plasticity. Synaptic plasticity is a hallmark of the mossy fiber – CA3 synapse and
is believed to be essential in the ability to form memories, a function of the
hippocampus as a whole. Activity at these synapses can either enhance or
depress synaptic transmission, alterations can persist for milliseconds to minutes
(short-term plasticity) or may continue for hours or days and in some cases may
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become permanent (long-term plasticity). Two components of short-term
plasticity include paired pulse facilitation and frequency facilitation. The strength
of this form of plasticity is a distinguishing characteristic of the mossy fiber – CA3
synapse and will be discussed in detail.

1.6.1 SHORT-TERM PLASTICITY
The process of neurotransmission is initiated when an action potential
(AP) invades the presynaptic terminal resulting in its depolarization.

This

depolarization allows for voltage-gated Ca2+ channels to open and Ca2+ to enter
the presynaptic terminal. The increase in the internal Ca2+ concentration initiates
a process in which presynaptic vesicles fuse with the membrane and release
their contents (i.e. glutamate) into the synapse to active post-synaptic receptor
populations. If two APs occur close in time (milliseconds), the second AP may
result in enhanced transmitter release, due to the build-up of residual Ca2+ in the
presynaptic terminal, a phenomenon referred to as paired-pulse facilitation (PPF)
(Katz and Miledi, 1968; Zucker, 1989). The ratio of PPF, or paired pulse
depression (PPD) is inversely related to the presynaptic release probability
(Dobrunz and Stevens, 1997). A synapse that demonstrates PPF would be
suggestive of a low basal release probability in that a second stimulus is required
to increase both internal Ca2+ stores and subsequent transmitter release. The
mossy fiber – CA3 synapse has a low probability of transmitter release (Jonas et
al., 1993; Lawrence et al., 2004), and as would be expected demonstrates PPF.
However, PPF at this synapse is 2 – 3x greater than what is observed at other
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synapses in the brain (Salin et al., 1996).
A second form of short-term plasticity is frequency facilitation, in which low
stimulus frequencies enhance synaptic transmission and synaptic strength.
Increasing the frequency of stimulation at the mossy fiber – CA3 synapse from a
basal 0.05Hz to 0.2Hz stimulation dramatically increases the amplitude of the
post-synaptic

event,

while

the

parameters

do

not

impact

the

associational/commissural (A/C) input into CA3 (Salin et al., 1996). In addition,
the maximal facilitation at the CA3 – A/C pathway was about 125%, whereas the
mossy fiber synapse potentiation was nearly 600% (Salin et al., 1996). Similar to
the high level of PPF, the mossy fiber – CA3 synapse also demonstrates
dramatically enhanced frequency facilitation compared to other synapses.
The characteristic low basal transmitter release probability is likely
responsible for the high level of both PPF and frequency facilitation that is
observed at the mossy fiber – CA3 synapse in comparison to other synapses.
This dramatic difference is one reason in which this synapse has been
extensively studied. For synaptic integration to occur DGCs and mossy fibers
need to fire at similar frequencies. However, DGCs fire at very low frequencies
(Jung and McNaughton, 1993). The broad frequency in which mossy fibers can
function allows them to fire in a manner in which they can process information in
the relevant range of granule cells. This strengthens the network activity between
DGCs and mossy fibers and promotes effective neurotransmission (Salin et al.,
1996).
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1.7 ALTERATIONS IN HIPPOCAMPAL CIRCUITRY IN EPILEPSY
The relationship between seizures and damage to the hippocampus has
been known since the early 1800s. In patients suffering from seizure disorders
researchers noted neuronal loss and a hardening of the mesial temporal lobe,
the area encompassing the hippocampus (Bouchet and Cazauvieilh, 1825). This
hardened, or sclerotic, hippocampus is observed in 50 – 70% of patients and
includes sizeable cell loss within areas CA1 and CA3 of the hippocampus
(Margerison and Corsellis, 1966). In addition to the dramatic cell loss in those
regions, a smaller amount of cell loss has been detected in the dentate gyrus,
hilus and presubiculum (Corsellis and Bruton, 1983; Mathern et al., 1997).
Within the last two decades, the abnormal growth of mossy fiber axons into the
supragranular region of the dentate gyrus, as opposed to area CA3, has also
been identified (Tauck and Nadler, 1985; Represa et al., 1987; Sutula et al.,
1989; Houser et al., 1990; Babb et al., 1991; Sutula and Dudek, 2007). The
aberrant formation of these axons is referred to as ‘mossy fiber sprouting’ and is
now considered a hallmark of seizure disorders. In addition, these newly
sprouted mossy fibers form functional synapses believed to create a recurrent
excitatory network within the hippocampus (Sutula et al., 1988; Cronin et al.,
1992; Wuarin and Dudek, 1996).
Several different animal models of epilepsy exist, each producing distinct
anatomical alterations. However, the lithium-pilocarpine and pilocarpine models
used in the proposed set of experiments remain the most relevant models to the
human disease (Curia et al., 2008). The mechanism of SE induction by
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pilocarpine is through activation of the cholinergic system, as pilocarpine is a
muscarinic agonist and atropine, a muscarinic antagonist, blocks pilocarpineinduced SE (Clifford et al., 1987). However, once induced it is believed that the
continuation and maintenance of SE is through a glutamatergic mechanism
(Nagao et al., 1996; Smolders et al., 1997). As has been observed during the
course of the current experiments a high dose of pilocarpine (390 mg/kg) does
not always result in production of SE. To enhance the actions of pilocarpine,
lithium chloride can be administered nearly 24 hours prior to pilocarpine
treatment. In addition to increasing the effectiveness of pilocarpine, preadministration of lithium chloride also significantly reduces the amount of
pilocarpine needed to induce SE (Honchar et al., 1983; Clifford et al., 1987;
Morrisett et al., 1987).
The prolonged SE that follows administration of pilocarpine (with or
without administration of lithium chloride) brings with it an increased risk of
mortality but it also initiates a severe and widespread cellular loss that persists
for up to months following the event and eventually leads to tremendous
neurodegeneration within the hippocampus and surrounding limbic regions.
(Turski et al., 1983; Turski et al., 1984; Leite et al., 1990; Cavalheiro, 1995). In
the present study, by 60 days post induction of SE, animals demonstrated nearly
a 20% loss of both CA1 and CA3 pyramidal cells and a nearly 40% loss of hilar
interneurons, while dentate granule cells remained essentially unaltered (Figure
1.5).
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Figure 1.5. Neuronal cell loss in animals 60d post-SE. A.
Representative images of NeuN labeling from sham (left) and pilo-treated (right)
animals 60 days post treatment. B. Optical density measurements from NeuN
labeling in four hippocampal regions. 1. CA1: 81.5 ± 4.0% of control, n = 7 – 9 2.
CA3: 83.0 ± 2.9% of control, n = 7 – 9 3. DG: 93.3 ± 2.5% of control, n = 8 – 9 4.
Hilus: 62.7 ± 8.1% of control, n = 6 – 7. **p < 0.01; ***p < 0.001, Scale bar, 200
µM.
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In addition to cell specific neuronal loss, the pilocarpine model also
produces similar mossy fiber sprouting that is observed in patients with seizure
disorders (Figure 1.6) (Turski et al., 1983; Turski et al., 1984; Leite et al., 1990;
Cavalheiro, 1995; Sutula et al., 1998; Buckmaster and Dudek, 1999). The
pilocarpine model is also associated with increased levels of astrocytes (Figure
1.7) (Garzillo and Mello, 2002; Binder and Steinhauser, 2006), a characteristic
not as widely noted in epilepsy patients. Overall the anatomical alterations
observed within the hippocampus of both humans and animals demonstrate the
dramatic impact that seizures have on the network organization and functionality
of the hippocampus.
The pilocarpine model provides an excellent animal model for studying
status epilepticus and the development of epilepsy, however there are some
disparities that should be acknowledged. One important consideration is the age
in which the event occurs. As stated previously, SE is most common in children
and precipitating injuries are also more common in childhood (Mathern et al.,
2002). However the anatomical and physiological alterations associated with SE
are difficult to reproduce in animals younger than about 21 days of age (Curia et
al., 2008). Additionally, human epilepsy is often associated with more brief and
focal seizures. These patients demonstrate limited, asymmetric brain damage
and likely appear healthy in other neurological aspects. However the pilocarpine
model of SE is composed of a prolonged generalized status epilepticus event.
Animals exhibit more widespread, bilateral brain damage, both cognitive and
behavioral alterations and frequent spontaneous seizures (Sloviter, 2005). A final
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Figure 1.6. ZnT-3 labeling of mossy fiber sprouting in animals 60 and
200d post-SE. A., C. ZnT-3 labeling in a sham-treated animal at the 200 day
time point, demonstrates robust labeling throughout mossy fibers and the hilar
region. In animals 60d (D.) and 200d post-SE (B, E.) robust ZnT-3 labeling is
observed within the inner molecular of the dentate gyrus (white arrows) indicative
of aberrant mossy fiber sprouting. Scale bars, A, B, 200 µM; C – D, 100 µM.
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Figure 1.7. Increase in GFAP labeling of astrocytes in animals 60 and
200 days post-SE. A., C. Minimal GFAP labeling in the hippocampus and area
CA3 in a sham-treated animal at the 200 day time point. In animals 60d (D.) and
200d post-SE (B, E.) robust GFAP labeling is apparent within area CA3. GFAP
expression was significantly increased in area CA1, CA3 and DG at 5d, 60d and
200d post-SE. Scale bars, A, B, 200 µM; C – D, 100 µM.
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consideration is the evidence that the site of spontaneous seizure generation in
pilocarpine-treated animals is not the same as epilepsy patients (Mello and
Covolan, 1996; Harvey and Sloviter, 2005; Sloviter et al., 2007). Differences in
the site of seizure initiation may be due to differential neuronal damage or basic
hippocampal circuitry. Despite the differences between the pilocarpine model and
human epilepsy, this model is widely used and yields reproducible alterations
sufficient for studying the epileptic condition.

1.8 GABA
γ-Aminobutyric acid (GABA) was originally synthesized in 1883, however it
was not until 1950 that it was identified to be an integral part of the mammalian
central nervous system (Petroff, 2002). The brain and spinal cord contain an
abundance of GABA, whereas trivial amounts are found in peripheral tissue such
as the liver, spleen and heart. GABA is synthesized by the alpha-decarboxylation
of glutamate by the enzyme L-glutamic acid decarboxylase (GAD) and its
cofactor

pyridoxal

phosphate

(Petroff,

2002).

GABA

is

an

inhibitory

neurotransmitter responsible for mediating the preponderance of inhibition within
the brain. Three distinct forms of the GABA receptor exist; GABA A receptors
which mediate fast synaptic neurotransmission (Sieghart and Sperk, 2002;
Rudolph and Mohler, 2004), GABAB receptors responsible for mediating slow
metabotropic actions (Couve et al., 2000; Bettler and Tiao, 2006), and GABAC
receptors which mediate fast synaptic current in the retina (Bormann and
Feigenspan, 1995).

34

1.8.1 GABAA RECEPTORS
GABAA receptors (GABAARs) are members of the ligand-gated ionchannel superfamily, which also includes nicotinic acetylcholine receptors, 5hydroxytryptamine 3 receptors and glycine receptors (Unwin, 1989; Barnard et
al., 1998). GABAARs are heteropentamers with each available subunit containing
a large extracellular amino-terminal domain, four transmembrane domains (TM),
a large intracellular domain between TM3 and TM4, and a smaller extracellular
carboxy-terminal domain. The large amino-terminus serves as the binding site for
GABA as well as other compounds such as benzodiazepines, and the large
intracellular loop provides a site for receptor modulation via protein interactions
and post-translational modifications (Jacob et al., 2008). At this time 18 different
GABAAR subunits have been identified and divided into seven different subunit
classes, some with additional members: α (1 – 6), β (1 – 3), γ (1 – 3), δ, ε (1 – 3),
θ, and π.
While many different subunit combinations are possible, the majority of
functional GABAARs are comprised of two α subunits, two β subunits and one γ
subunit; although the γ subunit can be replaced by the δ, ε, θ, or π subunit
(McKernan and Whiting, 1996; Rudolph and Mohler, 2004). The large aminoterminus of the subunit regulates the assembly of particular subunits.
Unassembled or misfolded proteins, as well as homomeric subunits are
degraded in the endoplasmic reticulum (ER) (Gorrie et al., 1997; Bedford et al.,
2001). Receptors that survive the ER are trafficked to the Golgi apparatus where
they are packaged into vesicles, transported and inserted into the plasma
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membrane. Several factors aid in the translocation of receptors out of the ER,
including GABAA receptor-associated protein (GABARAP) which interacts with
the intracellular domain of the γ subunit (Wang et al., 1999), and Nethylmaleimide-sensitive factor (NSF) a protein involved in intracellular vesicle
fusion (Kittler et al., 2001; Zhao et al., 2007). Once inserted into the plasma
membrane the β (1 – 3) and /or γ2 subunit of the GABAAR directly bind to a
particular subunit of a clathrin-adaptor protein 2 (AP2) complex. This interaction
initiates the clathrin-dependent endocytosis, the major mechanism by which
receptors are internalized and recycled (Kittler et al., 2000).
GABAA receptor subunits are ubiquitously expressed throughout the brain,
however the one focus of this document is on GABAARs within the dentate gyrus.
Within this region of the adult hippocampus GABAAR subunits α1, α2, α4, β3, γ2,
and δ are most highly expressed, followed by the β1subunit, α3, α5, β2 and γ3
subunits are weakly expressed, and nearly undetectable levels of γ1 subunit are
observed (Sperk et al., 1997). Expression of these subunits is also
developmentally regulated not only within the dentate gyrus but also throughout
the hippocampus and other brain regions (Laurie et al., 1992). GABAAR subunits
are targeted to different regions along the plasma membrane where they impart
distinct physiological and pharmacological properties, including agonist affinity.

1.8.2 FUNCTION OF HIPPOCAMPAL GABAA RECEPTORS
Upon invasion of an action potential, presynaptic GABA is released in high
concentrations into the synaptic cleft where it binds to the postsynaptic GABA A
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receptor. Binding of the ligand allows for negatively charged Cl- ions to flow
through the channel pore and into the cell. The increase in Cl- ions allows for the
inside of the cell to become more negatively charged and the cell hyperpolarizes.
This hyperpolarization increases the threshold for an action potential and
ultimately reduces neurotransmission.
As previously stated the majority of inhibitory neurotransmission is
mediated by the GABAA receptor, and the particular subunit composition of the
receptor imparts distinct characteristics. Synaptically located GABA ARs mediate
fast phasic inhibition (Rudolph and Mohler, 2004), whereas extrasynaptic
receptors mediate tonic inhibition (Brunig et al., 2002). In addition to influencing
the localization of the receptor the subunit composition dramatically influences
receptor pharmacology. GABAARs are modulated by a variety of compounds
including benzodiazepines, barbiturates and neurosteroids. The BZD sensitivity
of the GABAAR has been well studied, particularly in relation to seizure disorders,
and will be discussed in detail in Chapter 3. Generally, seizures may result from
a reduction in GABAAR-mediated inhibition in the brain (Jacob et al., 2008), thus
understanding

the

precise

manner

in

which

these

receptors

regulate

neurotransmission is essential.

1.8.3 PHASIC INHIBITION
The presynaptic release of GABA yields high, millimolar concentrations
within the synaptic cleft (Mody et al., 1994) which binds to the synaptically
located GABAARs and produces an inhibitory post-synaptic current (IPSC).
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IPSCs regulate the rapid and precise, and near-synchronous, phasic inhibition.
Studies have demonstrated that the high concentration of GABA within the cleft
dissipates, either through re-uptake or diffusion, with a time constant of 100 –
500 µs (Overstreet et al., 2000; Mozrzymas et al., 2003; Mozrzymas, 2004). As
opposed to mass quantities, GABA can also be released by a single synaptic
vesicle. This spontaneously occurring event, results in a miniature inhibitory postsynaptic current (mIPSC). Phasic inhibition is typically mediated by GABA ARs
composed of α1, 2, 3 or 5 subunits together with β and γ subunits (Rudolph and
Mohler, 2004). Most notable for synaptically located GABAARs is the presence of
the γ2 subunit, which is essential for the synaptic clustering of GABA ARs (Essrich
et al., 1998).

1.8.4 TONIC INHIBITION
In addition to the well-characterized rapid phasic inhibition, it is recognized
that ionotropic receptors may also mediate a slower form of transmission (Mody,
2001), including a tonic activation of the receptor. As opposed to synaptically
located GABAARs that interact with millimolar concentrations of GABA, the
extrasynaptic receptors must have a higher affinity for GABA, as the
concentration in the extracellular space is likely within the micromolar range
(Nyitrai et al., 2006). In addition to their high affinity, extrasynaptic receptors must
demonstrate little desensitization (Mtchedlishvili and Kapur, 2006; Glykys and
Mody, 2007), a process by which receptor channels close despite the continued
presence of agonist bound to the receptor. The tonic activation of extrasynaptic
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GABAARs would be significantly reduced if the receptors became desensitized to
the sustained presence of extrasynaptic GABA. Tonic inhibition is generally
mediated by GABAARs composed of α4 or 6 subunits, together with β and δ
subunits (Barnard et al., 1998). Most notable for extrasynaptic receptors is the
presence of the δ subunit, which is exclusively located in the extrasynaptic
membrane (Nusser et al., 1998; Wei et al., 2003).

1.9 GABAA RECEPTORS IN EPILEPSY
At a fundamental level seizures result from an imbalance between the
excitatory

and

inhibitory

transmission

within

the

brain.

While

several

glutamatergic receptors, including kainate receptors which will be discussed
later, regulate excitatory neurotransmission, the GABAA receptor is responsible
for regulating the majority of the inhibitory tone in the brain. Studies have
demonstrated that both the trafficking of GABAA receptors as well as their subunit
composition is altered in animal models and patients with seizure disorders such
as status epilepticus and temporal lobe epilepsy (for review see, Jacob et al.,
2008).
One pharmacological consequence of SE is alterations in the surface
expression of GABAA receptor subunits. Subsequently these alterations impact
receptor pharmacology and even the network physiology. It has been shown that
during the progression of SE the surface expression of the γ2 and β2/3 GABA A
receptor is significantly reduced, while other receptor subunits such as the
extrasynaptic δ subunit remain constant (Goodkin et al., 2008). This finding
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supported the pharmacological observation that SE patients and animal models
of SE develop pharmacoresistance to BZDs (Walton and Treiman, 1988; Kapur
and Macdonald, 1997; Jones et al., 2002; Grosenbaugh and Mott, 2013). BZDs,
such as diazepam, bind to the GABAAR at a specific allosteric site, located at the
interface of α1, α2, α3, or α5 and the γ2 subunit (Sigel, 2002). Activation of the
BZD-binding site results in a prolonging or increase in GABAAR-mediated
synaptic current (Otis and Mody, 1992). The sensitivity of the GABAAR to BZDs
is conferred by the presence of the γ1 - 3 subunit (Sieghart and Sperk, 2002),
which is significantly reduced during SE, and thus explains reduced efficacy in
patients. In addition, alterations in pharmacological changes in the subunit
expression can also impact the network physiology of the brain. Given that
extrasynaptic δ-containing GABAAR subunits remain functional during SE, the
increase in extracellular GABA during prolonged SE (Naylor et al., 2005), is able
to produce an increase in the overall tonic inhibitory tone of the network (Naylor
et al., 2005; Grosenbaugh and Mott, 2013). As GABAA receptors mediate the
majority of the inhibitory neurotransmission within the cerebrum, it is critical to
understand how SE alters their subunit expression and the subsequent
alterations on receptor pharmacology and physiology.

1.10 GLUTAMATE RECEPTORS
Two classes of receptors, ionotropic and metabotropic, are responsible for
mediating excitatory neurotransmission within the CNS. Ionotropic receptors,
commonly referred to ligand-gated ion channels, are responsible for mediating
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the fast neurotransmission that occurs at the synapse. Specific binding of a
ligand or neurotransmitter to the receptor results in a conformational shift
allowing for the flow of ions (i.e. Na+, Ca2+, K+, Cl-) through the channel. Three
distinct classes of excitatory ionotropic receptors have been established- αamino-3-hydroxy-S-methylisoxazole-4-propionic

acid

(AMPA),

N-methyl-D-

aspartate (NMDA), and kainate (KA). In contrast to ionotropic receptors are
metabotropic receptors which activate a second-messenger system, following
binding of a ligand or neurotransmitter. Unlike ionotropic receptors which always
mediate excitatory neurotransmission, the second-messenger system associated
with metabotropic glutamate receptors (mGluRs) allows them to regulate either
inhibitory or excitatory neurotransmission. Eight different mGluRs (mGluR1-8)
have been identified and classified into three distinct groups (Group 1 – III). Of
particular interest is the ability of kainate receptors (KARs) to mediate both
ionotropic and metabotropic transmission, however the focus of the proposed
experiments will be on the ionotropic action of KARs.

1.10.1 KAINATE RECEPTOR ASSEMBLY AND LOCALIZATION
Kainate receptors (KARs) were identified as a separate class of ionotropic
glutamate receptors based on their sensitivity to the agonist kainate (kainic acid),
a naturally occurring compound found in seaweed. Studies conducted throughout
the early 1990's concluded the presence of five distinct kainate receptor subunits,
GluK1 – 5 (Hollmann and Heinemann, 1994), which form functional tetramers.
Each of the available KAR subunits contains a large extracellular amino-terminal
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domain, involved in subunit assembly, followed by the extracellular ligand binding
domain. The membrane region is composed of three transmembrane domains
(TM1, TM3, TM4) and a re-entrant P-loop (TM2), which does not fully span the
membrane. The M4 domain gives way to the intracellular carboxy-terminus of the
subunit (Mayer, 2006).
GluK1 – 5 subunits are divided into two families based on their sequence
homology, functionality and agonist affinity. GluK1 – 3 subunits (Bettler et al.,
1990; Egebjerg et al., 1991; Bettler et al., 1992; Sommer et al., 1992) and GluK4
– 5 subunits (Werner et al., 1991; Herb et al., 1992; Sakimura et al., 1992) are
each about 70% identical within their family, but share only a 40% identity with
each other. In addition to differences in the sequence homology of the two
groups, GluK1 – 3 subunits can form functional homomeric receptors (Egebjerg
et al., 1991; Sommer et al., 1992; Schiffer et al., 1997), while GluK4 – 5 subunits
must be co-expressed with GluK1 – 3 (Werner et al., 1991; Herb et al., 1992).
Binding assays from recombinant KARs have demonstrated that GluK4 – 5
subunits have significantly higher agonist affinity than do the GluK1 – 3 subunits
(Monaghan and Cotman, 1982; Monaghan et al., 1989). In addition to the
differences between GluK1 – 3 and GluK4 – 5 subunits, GluK1 and GluK2 are
also subject to mRNA editing that alters Ca2+ permeability and sensitivity to
intracellular polyamines (Sommer et al., 1991; Rosenthal and Seeburg, 2012).
Furthermore, two membrane proteins that interact with KAR subunits were
identified, Neuropilin and Tolloid-like 1 and Neuropilin and Tolloid-like 2 (Neto1
and Neto2, respectively) (Zhang et al., 2009; Straub et al., 2011b; Tang et al.,
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2011). These proteins have been shown to dramatically alter the basic properties
of KARs (Copits et al., 2011; Straub et al., 2011a; Fisher and Mott, 2012, 2013).
KARs composed of GluK2/GluK5 subunits are believed to be the most
prominent within the brain (Petralia et al., 1994), thus the majority of studies
investigating KAR assembly and trafficking have focused on these two subunits.
One check-point involved in proper receptor assembly is the occupancy of the
ligand-binding site. Recombinant studies have demonstrated that mutations that
reduce agonist affinity results in the subunits being retained within the ER and
not inserted into the plasma membrane (Mah et al., 2005; Gill et al., 2009; Fisher
and Housley, 2013). For homomeric GluK2 receptors, glutamate binding
promotes proper folding resulting in a conformational change that is essential for
assembly and trafficking of the receptor (Gill et al., 2009). The GluK5 subunit was
found to contain several ER retention motifs that prevented surface expression
unless this subunit was bound to a GluK1 – 3 subunit (Gallyas et al., 2003; Ren
et al., 2003), a process that promotes formation of heteromeric receptors.
Furthermore it was recently determined that agonist binding to the GluK5 subunit
alone was sufficient to promote the formation of heteromeric GluK2/5 subunits
(Fisher and Housley, 2013). Together these studies demonstrate the complexity
of receptor assembly and trafficking as well as represent a key role for both the
GluK2 and GluK5 subunits.
Early studies have conclusively demonstrated that mRNA for a portion of
kainate receptor subunits is expressed throughout the brain and spinal cord
(Wisden and Seeburg, 1993; Bahn et al., 1994; Bettler and Mulle, 1995). Similar
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results were noted in the hippocampus, in which mRNA for all of the KAR
subunits was also observed, however the expression within the hippocampus
varies between regions and cell types. Furthermore, the mossy fiber – CA3
synapse was the first hippocampal region shown to utilize kainate receptors
(Castillo et al., 1997; Vignes and Collingridge, 1997). In this region the CA3
pyramidal cells, as well as dentate granule cells, show elevated mRNA levels for
GluK2, GluK4 and GluK5. GluK3 mRNA appears to be restricted to dentate
granule cells, while interneurons predominately express GluK1, in addition to
GluK2 – 3 (Bahn et al., 1994; Bureau et al., 1999; Paternain et al., 2000; Darstein
et al., 2003).
Variability in subunit localization, differences in the biophysical properties
of the subunits and regulation by Neto1 and Neto2 make it difficult to study KARs
in vivo. Furthermore, these differences become more apparent when attempting
to use pharmacological agents to activate or block the receptor, as each subunit
may behave differently to agonists and antagonists. As a result of this variability
the role of KARs in regulating excitatory neurotransmission, specifically within the
diseased brain, is not fully understood.

1.11 FUNCTION OF HIPPOCAMPAL KAINATE RECEPTORS
Kainate

receptors

are

ubiquitously expressed

in the brain and

hippocampus (Wisden and Seeburg, 1993), and are heavily expressed
throughout the mossy fiber – CA3 pathway.

Specifically, KARs have been

localized on postsynaptic CA3 pyramidal cells, on the presynaptic terminals of
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the mossy fibers and on the mossy fiber axons extending from dentate granule
cells.

At

these

sites

KARs

regulate

specific

forms

of

excitatory

neurotransmission, and given the relationship between the CA3 region and the
generation of seizures (Lothman et al., 1991; Ben-Ari and Cossart, 2000), KARs
pose an interesting avenue to explore.

1.11.1 POSTSYNAPTIC KAINATE RECEPTORS
Throughout the brain the majority of glutamatergic transmission is
mediated by postsynaptic AMPA and NDMA receptors, while excitatory
transmission mediated by KARs is limited to only a few synapses in the brain
(Cossart et al., 1998; Frerking et al., 1998; Li and Rogawski, 1998; Kidd and
Isaac, 1999; Li et al., 1999; Bureau et al., 2000). KARs located on postsynaptic
CA3 cells regulate transmission originating from presynaptic mossy fiber
terminals, but not inputs from the A/C fibers (Castillo et al., 1997; Vignes and
Collingridge, 1997). At the mossy fiber – CA3 synapse postsynaptic KARs are
activated by synaptically released glutamate which generates an excitatory
postsynaptic current (EPSC) (Cossart et al., 2002). The KAR-mediated EPSC
has two characteristic features; a small amplitude, approximately 10% of the total
peak observed for AMPA receptors, and significantly slower deactivation kinetics
(Castillo et al., 1997; Vignes and Collingridge, 1997; Frerking et al., 1998; Kidd
and Isaac, 1999).
As stated previously, the mossy fiber – CA3 synapse is likely comprised of
receptors composed of GluK2, GluK4 and GluK5 subunits, which would heavily

45

impact agonist affinity as well as the decay kinetics of the response. Heteromeric
receptors, presumed to be more common, containing the GluK4 or GluK5 subunit
would have significantly higher affinity for glutamate than would homomeric
GluK2 receptors (Monaghan and Cotman, 1982; Monaghan et al., 1989). In
addition, the GluK5 subunit confers a slower decay than does the GluK4 subunit
(Contractor et al., 2003). While many studies suggest that GluK2/5-containing
receptors are the principal KAR at the mossy fiber – CA3 synapse, it remains
possible that the chief receptor at this synapse is in fact comprised of the
GluK2/4 subunit combination. However lack of selective and reliable KAR
antagonists have limited the understanding of precisely which KAR subunits
regulate the majority of transmission at this synapse.
Relative to the much larger AMPA receptor-mediated currents, the
characteristic slow decay and small amplitude of the KAR-mediated EPSC may
have little impact on excitatory transmission. However, the slow decay allows for
KAR-mediated EPSCs to develop a large depolarization envelope at frequencies
as low at 3Hz (Frerking and Ohliger-Frerking, 2002). In addition, the summation
produced by KARs has a more global and consistent impact on membrane
activity than do AMPA receptors which produce substantial variability (Frerking
and Ohliger-Frerking, 2002). Collectively, while the postsynaptic KAR-mediated
EPSC may be significantly smaller than that observed by the AMPA receptors,
the significant levels of depolarization and temporal summation that are observed
suggest that KARs may play a significant role in regulating CA3 network activity.
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1.11.2 PRESYNAPTIC KAINATE RECEPTORS
Initial studies exploring KAR subunit localization suggested that the
majority of subunits may actually be restricted to the presynaptic mossy fiber, as
opposed to the postsynaptic CA3 cell (Agrawal and Evans, 1986; Represa et al.,
1987). In support of the heavily presynaptic localization of KARs was the finding
that selective destruction of the mossy fibers results in a dramatic decrease in
high affinity [3H] kainate binding, whereas it remains chiefly intact following
destruction of the CA3 pyramidal cells (Represa et al., 1987). It is now well
known and accepted that presynaptic KARs regulate neurotransmission, and in
fact do so in a bidirectional manner, at both excitatory and inhibitory synapses
(Lerma, 2003). Furthermore, presynaptic KARs are heavily implicated in the
short-term synaptic plasticity which was discussed in section 1.6.1.
Presynaptic regulation of glutamate release has been extensively studied
at the mossy fiber – CA3 synapse where KARs modulate release in a bimodal
manner. Several studies have confirmed that low nanomolar concentrations of
kainate facilitate glutamate release, while larger concentrations depress release
(Contractor et al., 2000; Lauri et al., 2001; Schmitz et al., 2001a). In addition to
regulating transmitter release there is substantial evidence that presynaptic
KARs also act as autoreceptors that sense synaptically released glutamate and
subsequently increase glutamate release (Contractor et al., 2001; Lauri et al.,
2001; Schmitz et al., 2001b).
The exact mechanism by which presynaptic KARs regulate transmitter
release is unknown. However, similar to the postsynaptic KARs, quantal release

47

of glutamate is also sufficient to activate presynaptic KARs (Contractor et al.,
2001; Schmitz et al., 2001b), which increases release from internal Ca2+ stores
and promotes subsequent transmitter release (Lauri et al., 2003; Scott et al.,
2008). However, other studies have proposed that released glutamate
depolarizes the presynaptic terminal to facilitate release (Kamiya and Ozawa,
2000; Schmitz et al., 2000; Schmitz et al., 2001b; Schmitz et al., 2001a; Schmitz
et al., 2003). Regardless of its action, presynaptic KARs are heavily involved in
short-term synaptic plasticity, predominately in the frequency-dependent
facilitation that is a hallmark of the mossy fiber – CA3 synapse. Despite the lack
of availability of specific KAR subunit antagonists, the use of some antagonists
coupled with genetically modified mice have demonstrated that presynaptic
mossy fibers are likely composed predominately of GluK2 (Contractor et al.,
2001; Schmitz et al., 2003; Breustedt and Schmitz, 2004) and GluK3 (Pinheiro et
al., 2007) subunits.

1.11.3 MOSSY FIBER KAINATE RECEPTORS
In addition to their localization on postsynaptic CA3 pyramidal cells and
presynaptic mossy fiber terminals, KARs are also located along mossy fiber
axons where they regulate axonal excitability (Kamiya and Ozawa, 2000;
Schmitz et al., 2000; Mott et al., 2008). Similar to the biphasic actions on
transmitter release, low agonist concentrations facilitate axon excitability while
higher concentrations suppress excitability (Kamiya and Ozawa, 2000; Schmitz
et al., 2000; Mott et al., 2008). KARs located along the mossy fiber axons are
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sensitive to both synaptically released glutamate as well as glutamate located in
the extracellular space (Contractor et al., 2003; Schmitz et al., 2003). It is
believed that KARs located on mossy fiber axons are predominately composed
of GluK2, GluK4 and GluK5 subunits (Wisden and Seeburg, 1993). In a GluK4
knockout mouse it was observed that the amount of axon excitability normally
produced by low nanomolar concentrations of kainate was significantly reduced
(Catches et al., 2012), suggestive of a role for GluK4-containing KARs in
regulating mossy fiber axon excitability. Alterations in KAR sensitivity and
regulation of mossy fiber axon excitability would affect neuronal transmission and
communication between the dentate gyrus and area CA3, as well as alter
synaptic plasticity at the mossy fiber – CA3 synapse.

1.12 KAINATE RECEPTORS IN EPILEPSY
Kainate receptors have prominently been implicated in seizure disorders
[for review see, (Ben-Ari and Cossart, 2000; Vincent and Mulle, 2009; Contractor
et al., 2011; Lerma and Marques, 2013)], but have also been linked to a variety
of diseases (Lerma and Marques, 2013). In particular, alterations in KAR subunit
expression have been observed in psychiatric conditions including anxiety,
depression and schizophrenia (Lerma and Marques, 2013), all disorders with
increased prevalence in epilepsy (Jacobs et al., 2009). Systemic administration
of kainate has been used for decades as a reliable animal model of epilepsy and
produces similar pathologies as seen with human epilepsy (Nadler, 1981; BenAri, 1985). Following administration of kainate, animals develop limbic seizures
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followed by a latent period of epileptogenesis and finally the development of
persistent spontaneously recurring seizures (Ben-Ari, 1985; Leite et al., 1990;
Cavalheiro et al., 1991). In addition GluK1-selective antagonists block
pilocarpine-induced seizures (Smolders et al., 2002), and genetic knockout of the
GluK2 subunit significantly reduces seizure susceptibility (Mulle et al., 1998).
As described earlier, the aberrant sprouting of mossy fiber axons in the
DG has become an anatomical hallmark of seizures in both human and animal
models. This newly formed circuit predominately regulates excitatory glutamate
transmission (Buckmaster et al., 2002), and it was recently determined that newly
formed KARs partly regulate this transmission (Epsztein et al., 2005). KARs have
also been linked to the excitotoxicity that occurs in epilepsy (Vincent and Mulle,
2009). Specifically, KARs are densely located in area CA3, a cellular region that
is highly susceptible to excitotoxicity (Nadler et al., 1978). Furthermore, KARs
have also been linked to pyramidal cells in layer III of the medial entorhinal
cortex, a region that rapidly degenerates due to excitotoxic cell death following
administration of kainate (Du et al., 1995; West et al., 2007).
Alterations in hippocampal KAR subunit expression have also been
examined in patients with seizure disorders (Grigorenko et al., 1997; Mathern et
al., 1998; Li et al., 2010; Das et al., 2012). Despite a true consensus, possibly
due to the type of seizure disorder, duration of the disease and therapeutics,
these studies clearly demonstrate that KAR subunit expression is altered in the
epileptic brain. Animal models have also demonstrated dramatic changes in KAR
subunits, findings that persist despite differences in the seizure model utilized
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(Lason et al., 1997; Tandon et al., 2002; Zhang et al., 2004; Ullal et al., 2005;
Porter et al., 2006). However, while a minimal number of studies have addressed
these alterations even fewer have addressed changes in KAR subunit expression
that occur during the progression of the disease (Ullal et al., 2005). Furthermore,
the majority of these studies examined alterations in KAR mRNA expression
within the hippocampus as a whole. Given that KAR subunit localization is not
uniform within the hippocampus, there is reason to believe that alterations in the
epileptic brain would be region specific and that protein levels would provide
more relevant information than mRNA. Despite the evidence linking KARs to
epilepsy, currently there are no antiepileptic drugs that target KARs. This may be
partially due to the limited understanding of KAR-mediated expression and
physiology in the epileptic brain, two areas examined in the current document.
Chapters 4 – 6 will explore alterations in KAR subunit expression and the
functional impact of those changes on mossy fiber – CA3 neurotransmission and
hippocampal axon excitability.

1.13 SIGNIFICANCE REVISITED
Status epilepticus is a neurologic emergency characterized by the inability
of inherent cellular mechanisms to terminate seizure activity. The occurrence of a
single SE event leads to the development of epilepsy in upwards of 40% of
patients, making the development of epilepsy the most challenging long-term
consequence associated with SE. Currently available AEDs are successful in
treating SE in approximately 60% of patients. However this leaves a large portion
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of the patient population suffering from uncontrolled SE, thus increasing their risk
for the development of epilepsy and associated comorbidities. This project
undoubtedly demonstrates that the ability to develop safe and effective
therapeutics for the treatment of SE and seizure disorders lies within the
understanding that a single SE event can drastically alter the brain.
The overarching hypothesis of this project is that status epilepticus and
the development of epilepsy produce striking alterations in GABAA and kainate
receptor populations. Furthermore, these alterations significantly impact receptor
pharmacology and neurotransmission in the SE-experienced brain.
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CHAPTER 2
GENERAL METHODS
2.1 ANIMAL MODEL OF STATUS EPILEPTICUS
The ability to understand the epileptic brain and to develop therapeutics is
dependent upon the use of animal models. These models must as closely as
possible replicate the distinct anatomical and physiological alterations seen in the
human disease including sclerosis and cell loss. When exploring potential
models several features are identified that are similar to the human pathology.
Some

of

these

features

include

the

appropriate

seizure

phenotype

(convulsive/non-convulsive), similar neuropathological consequences, chronic
hyperexcitability and appropriate responsiveness to AEDs. Commonly used
animal models fall into five distinct categories; electrical, chemical, thermal, in
vitro, and refractory (Reddy and Kuruba, 2013).
The current study will utilize a chemical model involving administration of
pilocarpine and lithium-pilocarpine to initiate status epilepticus followed by a
period of epileptogenesis and eventually the development of spontaneously
recurring seizures. As discussed in section 1.7 both of these models very closely
replicate the hippocampal injury associated with human epilepsy.
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2.1.1 ANIMAL CARE AND USE
All animal care and use procedures were carried out in accordance with
protocols written under the guidance of the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and approved by the Institutional Animal
Care and Use Committee at the University of South Carolina. Male SpragueDawley rats were purchased from Harlan, and housed at 1 – 3 rats per cage with
ad libitum access to food and water. Rats were housed in a climate controlled
facility with a light/dark cycle of 12/12 hours.

2.2 LITHIUM PILOCARPINE MODEL OF STATUS EPILEPTICUS
Young male Sprague-Dawley rats (15 – 23 days; Harlan, Indianapolis, IN)
received intraperitoneal (i.p.) injections of lithium chloride (127 mg/kg) followed
15 – 20 hours later by scopolamine methyl bromide (2 mg/kg). Status epilepticus
was then induced 15 – 30 minutes later by injection with pilocarpine
hydrochloride (60 mg/kg). As pilocarpine is a muscarinic agonist, scopolamine is
pre-administered in order to block peripheral muscarinic receptors and ensure
selectivity of pilocarpine. Following pilocarpine injections, rats were observed
continuously for the occurrence of behavioral seizures and were scored based
upon the Racine scale (Racine, 1972) (Table 2.1). Diazepam (DZP, 0.3 – 100
mg/kg) or stiripentol (STP, 10 – 1000 mg/kg) was administered either at the
onset of the first stage 3 seizure (brief SE) or 45 minutes after the first stage 3
seizure (prolonged SE; pSE). This experimental protocol of the lithium
pilocarpine (Li-Pilo) model was used in Chapter 3 when exploring the actions of
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STP and DZP on behavioral SE and GABAergic neurotransmission.

Table 2.1. Racine scale of epileptic seizures
Score

Observed Motor Behavior

0

Normal behavior (exploring, walking, grooming, etc.)

1

3

Immobility, staring ‘curled up’ posture
Automatisms
(Chewing, head bobbing, twitching, wet-dog shakes)
Forelimb/hindlimb myoclonic jerking, head tremor

4

Rearing and whole-body clonus

5

Rearing and falling over; loss of posture
Tonic-clonus seizures with tonic forelimb flexion/extension,
whole-body clonus

2

6
7

Wild-running with bouncing; death

2.3 PILOCARPINE MODEL OF STATUS EPILEPTICUS
Adult male Sprague-Dawley rats (37 – 47 days; Harlan, Indianapolis, IN)
received intraperitoneal (i.p.) injections of scopolamine methyl bromide and
terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min by pilocarpine
hydrochloride (390 mg/kg). In addition to administration of scopolamine to block
peripheral muscarinic receptors, animals also received terbutaline which acts as
a bronchodilator to prevent respiratory depression associated with prolonged SE.
Following pilocarpine injection, rats were observed continuously for the
occurrence of behavioral seizures and were scored on the Racine scale (Racine,
1972) (Table 2.1). Approximately 75% of rats experienced a seizure score of 5
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on the Racine scale. Animals that did not exhibit SE after 45 mins were given an
additional ‘booster’ of pilocarpine (200 – 300 mg/kg). Nearly 90% of animals
receiving a pilocarpine ‘booster’ experienced sufficient SE. After 2 hours of status
epilepticus, DZP (25 mg/kg) was administered intraperitoneally. This group of
animals served as the ‘pilo’ group. In order to limit physical distress and any
peripheral effects of pilocarpine animals received additional doses of the
scopolamine/terbutaline cocktail approximately one-hour into SE as well as upon
termination of SE with DZP.

A separate group of animals was treated

identically, but received saline (390 mg/kg) instead of pilocarpine hydrochloride.
This group of animals served as the ‘sham’ group. Approximately 1 – 2 hours
after seizures were terminated animals received a subcutaneous dose of the
scopolamine/terbutaline cocktail (2 mg/kg), lactated Ringer’s solution (2 mL), and
rat chow that had been softened and sweetened in high sucrose water. Animals
that did not enter SE were excluded from the study.
All animals were housed overnight in the animal facility and checked as
early as possible on the following day to determine if they had successfully
recovered from treatment (normal posture, movement and activity levels).
Animals still experiencing side-effects from treatment (lethargy, immobility) were
given additional subcutaneous injections of lactated Ringer’s solution and the
scopolamine/terbutaline cocktail and placed on a heating pad. For animals who
endured the first night post-treatment the survival rate was nearly 100%. This
experimental protocol was used in Chapters 4 – 6 to explore alterations in
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kainate

receptor

subunit

expression

and

kainate

receptor-mediated

electrophysiological alterations in the epileptic brain.
Video monitoring of animals a minimum of 30 days post-treatment
confirmed the appearance of spontaneously occurring seizures in pilocarpine
treated animals. In addition, by approximately 60 days post-SE animals began to
demonstrate neuronal cell loss and the appearance of mossy fiber sprouting.

2.4 DETERMINATION OF BRAIN-PLASMA STP CONCENTRATION
Brain and plasma concentrations of STP were determined in four separate
groups of male Sprague-Dawley rats: 1) naïve juvenile (20 – 27 days old), 2)
prolonged SE-experienced juvenile (20 – 21 days old), 3) naïve adult (62 – 63
days old) and 4) prolonged SE-experienced adult (61 days old). Fifteen minutes
following i.p. administration of 300 mg/kg STP, naïve and prolonged SE rats were
anesthetized and decapitated in order to collect brain and blood samples. Trunk
blood was collected in 6 mL sodium heparin lined BD vacutainers and
centrifuged for 10 min at 2000 rpm at 4°C to collect blood plasma. Brains were
removed and rapidly frozen on dry ice. Brain tissue and plasma were stored at
-80°C until use.
Brain and plasma concentrations of STP were measured by highperformance liquid chromatography (HPLC) with ultraviolet detection. For plasma
analysis 100 µl of internal standard (2 µg of AB1191 per mL of 50/50
methanol/H2O) and 50 µL of 50/50 methanol/H2O with 2 mL of tert-Butyl methyl
ether were added to a 50 µL plasma sample. Following agitation for 15 min,
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decantation and freezing in a dry ice/acetone bath, the organic layer was
transferred and evaporated to dryness under nitrogen at 45°C.
For brain tissue analysis, 100 µL of internal standard (50 µg of AB1191
per mL of 50/50 methanol/H2O) and 50 µL of 50/50 methanol/H2O with 2 mL of
H2O were added to the weighed brain sample and mixed. A 0.5 mL volume of
homogenate was extracted with 3 mL of pentane. Following agitation for 15 min,
decantation and freezing in a dry ice/acetone bath, the organic later was
transferred and evaporated to dryness under nitrogen at 45°C.
Residues from plasma and brain samples were reconstituted with 200 µL
of mobile phase (acetonitrile/H2O; 60/40) and used for HPLC analysis. UV
detection was accomplished at 264 nm with a limit of sensitivity of 0.5 µg/mL for
plasma and 0.45 µg/g or 0.35 µg/g in juvenile and adult brain respectively. The
concentration levels of STP in plasma (µg/mL) and brain (µg/g) were expressed
as total drug concentration. The coefficients of variations for intra- and interassays were 0.2 – 13% and 3 – 14% respectively.

2.5 INTRODUCTION TO BRAIN SLICE ELECTROPHYSIOLOGY
Neuronal function is based on the ability of cells to integrate and
propagate electrical signals such as action potentials. Electrophysiology is the
study of this electrical activity within the brain and provides detailed information
on the functionality of individual neurons and networks of neurons. In the 1950’s
Henry McIlwain developed the brain slice preparation and demonstrated the
ability of brain slices to retain their metabolic activity as well as their cellular

58

membrane potentials (Mc et al., 1951; McIlwain and Buddle, 1953; Li and Mc,
1957; Yamamoto and McIlwain, 1966). These studies set the foundation for brain
slice electrophysiology by demonstrating that neurons could be kept alive in an
artificial setting while their electrical properties were explored.
In vitro brain slice electrophysiology can be conducted on many, if not all,
brain regions. However successful experiments are dependent upon quality
slices which are defined by the ease and reliability in which the tissue is
prepared, the visibility of structural landmarks and the extent in which fibers and
synaptic fields are observed within the slice (Lynch and Schubert, 1980). In
regards to these properties, one structure in particular lends itself to the
technique of brain slice electrophysiology, the hippocampus. The hippocampus is
a region that can be easily removed from the brain without the need for a
microscope. In addition once sectioned, little to no magnification is needed to
visualize its unique structure composed of pyramidal and granule cell layers.
Furthermore, the laminar organization of the hippocampus allows for properly
sectioned slices to contain cell bodies, dendrites and axons which often extend
throughout the slice (Lynch and Schubert, 1980). Together these properties of
the hippocampus increase the ease of experiments as well as provide the ability
to study individual intrinsic cell properties (whole-cell electrophysiology), as well
as extracellular network activity (field-potential electrophysiology). The following
sections will detail the concept and methods used for both whole-cell and fieldpotential electrophysiology in the rat hippocampus.
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2.6 WHOLE-CELL ELECTROPHYSIOLOGY
Patch clamp electrophysiology is an intracellular recording technique that
allows for the study of ion flow through a single channel and was first
demonstrated in 1976 by Erwin Neher and Bert Sakmann (Neher and Sakmann,
1976), who in 1991 won the Nobel Prize in Physiology or Medicine. Several
different configurations of this technique exist, one of which is whole-cell
recording. To acquire a whole-cell configuration a glass electrode is placed on
the surface of a cell and mild suction is then applied to rupture the membrane,
allowing for a diffusional exchange of the contents of the cell cytoplasm and the
glass pipette (Figure 2.1). The whole-cell configuration produces a convenient
method to directly apply substances into the cell in order to study the electrical
currents and properties from the entire cell.
Whole-cell electrophysiology is used to study the movement of electrically
charged ions, commonly through voltage-gated or ligand-gated channels. The
GABAA receptor is selectively permeable to negatively charged Cl- ions. When
the receptor is open, Cl- ions flow into the cell creating a more negative
intracellular environment. This hyperpolarization of the cell brings it further away
from the threshold of firing an action potential (~-40mV) and thus reduces
neuronal firing. The postsynaptic current produced by activation of GABA
receptors is referred to as an inhibitory postsynaptic current (IPSC). In contrast,
glutamatergic receptors such as kainate or AMPA are permeable to Na + and K+
ions. When these receptors are open, the concentration gradient maintained by a
Na+/K+-ATPase pump, allows for Na+ to enter the cell creating a more positive
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Figure 2.1. Schematic of whole-cell recording configuration. One of several
configurations of patch-clamp electrophysiology. A glass electrode filled with
experiment-specific internal solution is applied to the surface of a cell. Slight
suction is applied to rupture the cell membrane allowing the contents of the
electrode and the cell to easily diffuse. Schematics of receptor complexes,
including Cl-, Na+ and K+ are expressed on the surface of the cell. In addition the
Na+/K+-ATPase pump is essential to maintain concentration gradients.
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intracellular environment. If this depolarization of the cell is sufficient it will fire an
action potential. Thus activation of these glutamatergic receptors, in contrast to
GABAergic receptors, generally increase neuronal firing, and produce an
excitatory postsynaptic current (EPSC).

2.6.1 EXPERIMENTAL PROTOCOL FOR WHOLE-CELL RECORDINGS
Chapter 3- Transverse 300 µm thick slices from isoflurane-anesthetized
animals were cut using a vibratome (Leica VT1000S, Nussloch, Germany). Brain
slices were prepared in cold (4°C), oxygenated (95% O 2 / 5% CO2) sucrosebased ‘cutting’ artificial cerebrospinal fluid (aCSF) that contained (in mM): 248
sucrose, 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 MgS04
(350 mOsm).

Slices were incubated for approximately one hour at room

temperature in oxygenated (95% O2 / 5% CO2) aCSF containing (in mM): 125
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 MgSO4,
0.02 D-APV and 1 kynurenic acid (pH 7.4; 305-312 mOsm).
Currents were recorded from dentate granule cells located in the infrapyramidal blade of the dentate gyrus, visually identified with infrared-differential
interference contrast optics. Currents were recorded using a Multiclamp 700A
amplifier (Molecular Devices, Sunnyvale, CA) and filtered at 1 kHz. Currents
were digitized using a Digidata 1440A A-D board (Molecular Devices, Sunnyvale,
CA) and analyzed using pClamp10 software. GABAA IPSCs were evoked by
stimulation in stratum moleculare of the dentate gyrus near the recording
electrode. Stimuli were 0.1ms, cathodal, monophasic, rectangular constant
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current pulses (10 – 100 μA) delivered through monopolar, platinum-iridium
stimulating electrodes (FHC Inc., Bowdoin, ME). IPSCs and miniature excitatory
post-synaptic currents (mEPSCs) were recorded using borosilicate glass
electrodes ( resistance 5 – 8 MΩ) filled with an internal solution containing (in
mM): 130 D-Gluconic Acid, 130 CsOH, 7CsCl, 10 HEPES, 3 QX-314, 2 MgATP,
0.3 Na2GTP, yielding a chloride reversal potential of -42 mV. Miniature inhibitory
post-synaptic currents (mIPSCs) and tonic currents were recorded using an
internal solution containing (in mM): 140 CsCl, 10 HEPES, 3 QX-314, 4 MgATP,
0.3 Na2GTP, yielding a chloride reversal potential of 0 mV. Voltage-clamp
recordings were made at a holding potential of -20 mV for evoked IPSCs, -60mV
for tonic currents and mIPSCs, and -70mV for mEPSCs. Input and series
resistance were monitored throughout the experiment and recordings in which
either changed significantly were discarded.
Miniature IPSCs (mIPSCs) were pharmacologically isolated using the
glutamate receptor antagonists, D-2-amino-5-phosphopentanoic acid (D-APV,
50μM),

or

5-methyl-10,11-dihydro-5H-dibenzo[a,d]

cyclohepten-5,10-imine

maleate (MK-801, 10 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt
(CNQX, 50 μM), plus the addition of tetrodotoxin (TTX, 1 μM) for mIPSCs and
tonic current. Bicuculline methochloride (Bic, 20 μM) was added at the end of
each experiment to confirm that the recorded IPSCs were mediated by GABA A
receptors. mEPSCs were isolated using 30 μM bicuculline methochloride and 1
μM TTX. Drugs were perfused for a minimum of 20 minutes in order to obtain a
stable baseline.
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Chapter 5- Animals were deeply anesthetized with isoflurane and
transcardially perfused with a sucrose-based aCSF fluid containing (in mM): 248
sucrose, 2 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.4 pyruvate, and 1.3
ascorbic acid (345 – 351 mOsm) for approximately 2 min. The brain was then
rapidly removed and transverse 300 µM thick slices were cut using a vibratome
(Leica VT1000S, Nussloch, Germany). The same sucrose-based solution was
also used to prepare brain slices, with the addition of (in mM): 0.02 D-APV and 1
kynurenic acid, and exclusion of pyruvate and ascorbic acid (pH 7.4; 305 – 312
mOsm). Slices were incubated for approximately one hour in room temperature
oxygenated (95% O2 / 5% CO2) NaCl-based aCSF solution containing (in
mM):125 NaCl, 2.8 KCl, 1.0 NaH2PO4, 26 NaHCO3, 10 glucose, 0.5 CaCl2 and 5
MgSO4, 0.02 D-APV and 1 kynurenic acid (pH 7.4; 300 – 310 mOsm).
Currents were recorded from dentate granule cells visually identified with
infrared-differential interference contrast optics. Recordings were performed
using a Multiclamp 700A amplifier (Molecular Devices, Sunnyvale, CA) and
filtered at 1 kHz. Currents were digitized using a Digidata 1440A A-D board
(Molecular Devices, Sunnyvale, CA) and analyzed using pClamp10 software.
EPSCs were recorded using borosilicate glass electrodes (resistance 4 –
6 MΩ) filled with an internal solution containing (in mM): 130 D-Gluconic Acid,
130 CsOH, 5 CsCl, 10 HEPES, 5 CsBAPTA, 2 MgCl2, 0.5 CaCl2, 2 MgATP, 0.3
NaGTP. Voltage-clamp recordings were made at a holding potential of -70mV
with input and series resistances monitored throughout the experiment. Currents
were evoked with borosilicate glass pipettes (resistance 2 – 3 MΩ) filled with 10
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µM domoate dissolved in external recording solution. Every 60 seconds, a 50 ms
puff was applied approximately 70 µM from the dentate granule cell body using a
Pneumatic PicoPump (PV800, World Precision Instruments, Sarasota, FL).
EPSCs were pharmacologically isolated in an antagonist cocktail
containing

bicuculline

methochloride

(Bic,

15

µM),

[(2S)-3-[[(1S)-1-(3,4-

Dichlorophenyl)ethyl]amino]-2-hydroxypropyl](phenylmethyl)phosphinic

acid

hydrochloride (CGP55845, 1 µM), MK-801 (10 µM), plus the addition of
tetrodotoxin (TTX, 1 µM). KAR-mediated currents were isolated using 1-(4Aminophenyl)-3-methylcarbamyl-4-methyl-3,4,-dihydro-7,8-methylenedioxy-5H2,3-benzodiazepine hydrochloride (GYKI 53655, 50 µM) remaining current was
blocked by application of CNQX (100 µM).

2.7 FIELD POTENTIAL ELECTROPHYSIOLOGY
In contrast to whole-cell electrophysiology which occurs intracellularly,
field-potential electrophysiology is performed extracellularly. Once the tissue is
prepared a stimulating electrode is placed in the tissue in order to sufficiently
active a population of neurons. In contrast to recording from a single neuron, field
potential electrophysiology allows the researcher to record the activity of a
population of neurons by placing the recording electrode within a cell body layer,
or within the dendrites or axons of the neuronal population. Activation of these
neurons results in a summation of the extracellular potentials creating either a
field inhibitory postsynaptic potential (fIPSP) or a field excitatory postsynaptic
potential (fEPSP).
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Due to the fact that these recordings are extracellular, the placement of
the recording electrode, relative to the stimulating electrode is crucial in order to
properly interpret of the data.

Relative to the electrode, neuronal activation can

create what is denoted as an extracellular sink or source. The flow of positively
charged ions into a cell or dendrite leaves the extracellular space more negative,
creating an extracellular sink. In order to maintain electroneutrality the sink is
balanced by an extracellular source comprised of an efflux of positively charged
ions into the extracellular space. Field potential recordings in the mossy fiber –
CA3 synapse are at particular risk for improper electrode placement, as the CA3
region contains mossy fibers input as well as the associational/commissural
fibers. Pure stimulation of the mossy fibers, elicited through activation of dentate
granule cells, would evoke an extracellular sink in area CA3 stratum lucidum.
However, if the placement of the recording electrode was not precise an
extracellular source evoked from the CA3 A/C fibers would contaminant the
response. The overall response would be a fEPSP comprised of both a
downward sink and upward source. Thus in experiments involving the mossy
fiber – CA3 synapse steps were taken to ensure pure mossy fiber stimulation and
recording.

2.7.1 EXPERIMENTAL PROTOCOL FOR FIELD POTENTIAL RECORDINGS
Animals were deeply anesthetized with isoflurane and transcardially
perfused with a sucrose-based aCSF solution containing (in mM): 248 sucrose, 2
KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.4 pyruvate, and 1.3 ascorbic acid
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(345 – 351 mOsm) for approximately 2 min. The brain was then rapidly removed
and transverse 500 µM thick slices were cut using a vibratome (Leica VT1000S,
Nussloch, Germany). The same sucrose-based solution was also used to
prepare brain slices, with the addition of (in mM): 0.02 D-APV and 1 kynurenic
acid, and exclusion of pyruvate and ascorbic acid (pH 7.4; 305 – 312 mOsm).
Slices were prepared in cold (4ºC), and incubated for 30 min in heated (37ºC),
oxygenated (95% O2 / 5% CO2) sucrose-based aCSF. After 30 min incubation in
heated sucrose-based aCSF slices were gradually transitioned to a roomtemperature oxygenated (95% O2 / 5% CO2) NaCl-based solution containing (in
mM): 125 NaCl, 2.8 KCl, 1.0 NaH2PO4, 26 NaHCO3, 10 glucose, 0.5 CaCl2 and 5
MgSO4, 0.02 D-APV and 1 kynurenic acid (pH 7.4; 301 – 307 mOsm).
Following a minimum of 30 min incubation slices were placed in a
submerged chamber that was continuously perfused with the warm, oxygenated
(31 – 34 ºC; 95% O2 / 5% CO2) NaCl-based solution containing (in mM): 125
NaCl, 2.7 KCl, 1.25 NaH2PO4, 25 NaHCO3, 10 glucose, 0.5 CaCl2 and 5 MgSO4
(pH 7.4; 301 – 307 mOsm). Stimuli were 0.1 ms, cathodal, monophasic,
rectangular constant current pulses delivered through monopolar, platinumiridium stimulating electrodes (FHC Inc., Bowdoin, ME) referenced to a bath
ground. fEPSPs and antidromic spikes were recorded through a borosilicate
glass electrode (resistance 2 – 3 MΩ) filled with external recording aCSF. Two
separate stimuli paradigms were used, 1) Mossy fiber – CA3 fEPSPs were
evoked in the dentate gyrus granule cell layer every 30 sec and recorded in CA3
stratum lucidum. Mossy fiber fEPSPs were characterized by their large paired

67

pulse facilitation (Salin et al., 1996) and inhibition by the group II-selective
metabotropic

glutamate

receptor

(mGluR)

agonist

(2S,2’R,3’R)-2-(2’3’-

Dicarboxycyclopropyl) glycine (DCG-IV, 1 µM) (Kamiya et al., 1996). 2)
Recurrent mossy fiber fEPSPs in the dentate gyrus were evoked in the inner
one-third of the molecular layer every 60 sec and recorded in the granule cell
layer (Epsztein et al., 2005). Stimuli recorded in both CA3 and dentate gyrus
were evoked at 50% of the maximal response determined though an input-output
(I/O) curve. Antidromic population spikes were evoked in two distinct pathways.
1) Mossy fibers were stimulated in CA3 stratum lucidum and the response was
recorded in the dentate granule cell layer. 2) CA3 axons were stimulated in
stratum radiatum and the response was recorded in the CA3 pyramidal cell layer.
Figure 2.2 depicts each of the four experimental paradigms utilized in Chapters 5
and 6.
Both antidromic spikes and fEPSPs were pharmacologically isolated in an
antagonist cocktail containing bicuculline methochloride (Bic, 20 µM) and MK-801
(10 µM). AMPA receptor mediated transmission was blocked by application of
GYKI53655 and remaining KAR-mediated transmission was blocked by
application of (S)-1-(2-Amino-2carboxyethyl)-3-(2-carboxythiphene-3-yl-methyl)5-methylprimidine-2,4-dione (UBP310, 3 µM) or (S)-1-(2-Amino-2-carboxyethyl)3-(2-carboxy-5-phenylthiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione
(ACET, 300 nM) and residual transmission was blocked by application of CNQX
(100 µM).
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Figure
2.2.
Experimental
paradigms
for
field
potential
electrophysiology. Blue electrodes: MF – CA3 fEPSPs were elicited by
stimulation of the mossy fibers and recorded in CA3 stratum lucidum. To limit
activation of the recurrent A/C pathway stimulation of the mossy fibers originated
near the dentate granule cell layer. Green electrodes: Recurrent mossy fiber
collaterals were activated by stimulation of the inner one-third of the molecular
layer and recorded in the dentate granule cell layer. Purple electrodes: The
mossy fiber antidromic spike was elicited through stimulation of the mossy fibers
in CA3 stratum lucidum and recorded in the dentate granule cell layer. Red
electrodes: CA3 antidromic spikes were produced by stimulation of the CA3
axons located in stratum radiatum and recorded in the CA3 pyramidal cell layer.
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2.8 WESTERN BLOT ANALYSIS
The technique of western blotting (i.e. protein blotting, immunoblotting)
was first developed during the late 1970’s and has become a widely used tool to
determine the presence and abundance of particular proteins (MacPhee, 2010).
Western blotting begins with successful extraction and isolation of a particular
lysate followed by separation onto a polyacrylamide gel through electrophoresis.
The proteins are then transferred onto a membrane and probed with antisera to
detect the presence of particular proteins. Determining the proper antisera can
require several preliminary runs as both polyclonal and monoclonal antisera are
available, each bringing its own advantages and disadvantages. However, a
chief difference between the antisera is their specificity for an individual protein of
interest. Once the appropriate antisera is bound to the protein, its relative
expression can be determined through processes such as enhanced
chemiluminescence (ECL). The peroxidase conjugated secondary antisera
serves to oxidize the luminol substrate within the ECL to emit light which is then
captured onto film and measured using densitometry.

In general, western

blotting is a widely used and acceptable technique to determine relative
expression and abundance of proteins. The following sections describe in detail
the western blotting protocol utilized in Chapter 4 to determine differences in
kainate receptor subunit abundance within specific brain regions following
pilocarpine-induced status epilepticus.
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2.8.1 MEMBRANE PREPARATION
Animals were anesthetized, the brain removed, and immediately placed
on dry ice. Brains were cut at 100 µM on a freezing microtome (Microm, Waldorf,
Germany). Punches from prefrontal cortex, amygdala and striatum were
collected, while hippocampi were removed and micro-dissected into dentate
gyrus (DG), CA1 and CA3 regions. Microdissected regions collected from the
hippocampus are outlined in Figure 2.3. All tissue collections were immediately
placed in ice-cold homogenization buffer (0.32 M sucrose, 2mM EDTA, 2mM
EGTA, 20mM HEPES, pH 7.6, containing 1:100 protease and phosphatase
inhibitor cocktails (Sigma, St. Louis, MO). The samples were then homogenized
and centrifuged for 10 min at 500 x g at 4ºC to remove the nuclear fraction. The
supernatant containing the total membrane fraction was centrifuged at 31,000 x g
for 30 min at 4ºC.

The resulting pellet, crude plasma membrane, was re-

suspended in phosphate buffered saline (PBS) and stored at -80ºC prior to use.
Protein concentrations were determined by using the Bradford method utilizing
BSA (Bovine Serum Albumin, Thermo Scientific) as a standard. Linear
regression analysis was performed in Microsoft Excel to extrapolate the unknown
protein concentration.

2.8.2 SDS-PAGE AND ANTIBODY DEVELOPMENT
Aliquots of 2 – 10 µg of crude plasma membrane proteins were denatured
by diluting them in a 1:1 ratio with BioRad Laemmli Sample Buffer with 5% β-
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Figure 2.3. Microdissected hippocampal regions for western blot
analysis. Hippocampal sections 100 µM thick were microdissected into Green,
1. Dentate gyrus Blue, 2. CA3 and Red, 3. CA1 regions prior to homogenization
and processing for western blot analysis. This process allowed for increased
resolution of region specific alterations in KAR subunit expression following
pilocarpine-induced SE.
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mercaptoethanol. Samples were then heated at 95ºC for 5 min and loaded into
pre-cast polyacrylamide gels (4 – 15%). Running buffer (in mM: 25 Tris, 240
Glycine, 0.1% SDS) was added to the appropriate tank, BioRad mini PROTEANTetra or BioRad Criterion, and run using the BioRad Power Pack HC for at least
30 min at 175 – 200 V. Following sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) protein separation, proteins were transferred to
polyvinylidene fluoride (PVDF) membranes using the BioRad Trans-Blot SD
Semi-Dry Transfer Cell. Protein transfer was completed using the BioRad Power
Pack HC for 30 min at 25V. Transfer buffer contained (in mM): 25 Tris, 192
Glycine, and 20% methanol. All equipment was acquired from Bio-Rad
Laboratories, Inc.
Following transfer, PVDF membranes were blocked in tris-buffered saline
(TBS) plus 5% non-fat dry milk for 60 min at room temperature.

PVDF

membranes were incubated with primary antisera (in TBS/5% non-fat dry milk)
overnight at 4ºC with gentle shaking. Primary antibodies are listed in Table 2.2.
Normalization for protein loading was performed using a mouse monoclonal
primary antibody selective for β-actin. Following overnight incubation membranes
were washed with TBS plus 0.05% Tween 20 (TBS-T) and incubated in
peroxidase-labeled, species-specific secondary antibodies. PVDF membranes
were washed with TBS-T and developed using enhanced chemiluminescence
reagents (ECL, Pierce) as described by the manufacturer. Images were captured
on Kodak BioMax XAR film and optical densitometric analysis was performed
using ImageJ 1.47v (National Institutes of Health, USA).
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Table 2.2. Primary antibodies for western bot analysis
Manufacturer;
Catalog Number
Millipore; 04-921
SantaCruz; sc8916
Millipore; 06-315
Cell Signaling; 3670
Sigma; A5441

Ligand
GluK2/3
GluK4
GluK5
GFAP
β-Actin

Primary
Concentration
1:8,000
1:200
1:8,000
1:8,000
1:50,000

2.9 IMMUNOHISTOCHEMISTRY
The art of immunohistochemistry (i.e. immunostaining) was first
demonstrated in the mid 1930’s, and the first study was published in the mid
1940’s (Matos et al., 2010). Since this time the technique has evolved into a
commonly used method used to determine the specific expression patterns of
proteins, enzymes or peptides within cells and tissue samples.
generate

reproducible

and

reliable

immunohistochemical

In order to

data,

several

preliminarily experiments may be required to determine the appropriate type of
tissue fixation, sectioning, storage, antisera and analysis. Following tissue
fixation, commonly utilizing paraformaldehyde, tissue may be immediately
sectioned and stored for several days while antibody detection is performed.
Other commonly used techniques involve cryoprotecting the tissue which allows
for more long-term storage while analysis is conducted. In addition, antigen
retrieval steps may be performed which serve to uncover antigenic sites which
may have been shielded during fixation or through handling of the tissue. One
must also consider the ability of the antisera to permeate the tissue and/or cell
membrane. Various concentrations and types of detergents, such as Triton-X-
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100, can be utilized to increase the permeability and penetration of the antisera.
In general, the protein of interest and the available antisera will often dictate the
types of fixation, sectioning and storage of the tissue samples. The use of
immunohistochemistry in determining protein localization and expression
patterns is widely used and simply requires that the protocol be amended to the
particular protein of interest. The following sections describe in detail the
immunohistochemical protocol used in Chapter 4 to determine alterations in
kainate

receptor

subunit

expression

within

the

hippocampus

following

pilocarpine-induced status epilepticus.

2.9.1 PERFUSION AND TISSUE FIXATION
Rats were deeply anesthetized using the anesthetic isoflurane.

Once

anesthetized, a lateral incision to the lower abdomen was made which extended
upwards to expose the chest cavity and the heart. A hemostatic clamp was
placed on the descending vena cava to prevent perfusate flow to the lower
extremities.

A 20 x ½ gauge needle attached to the perfusion pump was

inserted through the apex of the left ventricle and held firmly in place with a
hemostat. Once inserted, the right atrium was clipped to allow perfusate flow. Ice
cold, oxygenated (95% O2 / 5% CO2) 0.05M PBS (pH 7.4) was perfused at
approximately 60mL/min for 4 – 5 min, followed by the ice cold fixative (0.1M
phosphate buffer / 4% paraformaldehyde), for approximately 20 min. Whole
brains were removed and blocked to remove olfactory lobes and cerebellum. The
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remaining portion of the brain was post-fixed at 4ºC for 3 hours in tissue fixative
and then transferred to 0.1M phosphate buffer (PB) until sectioned.
Brains were sectioned at 50 µM-thick coronal sections on a vibratome
(Leica VT1000S, Nussloch, Germany). Sectioning was performed in 0.1M PB
and sections were stored at 4 ºC in 0.1M PB and 0.1% sodium azide to inhibit
bacterial growth until used for immunohistochemical processing.

2.9.2 IMMUNOPEROXIDASE
Free floating tissue sections were transferred from 0.1M PB/0.1% sodium
azide to TBS (0.08M Tris Base, 0.42M Tris Hydrochloride, 1.54M NaCl) for
approximately 40 minutes (4 x 10 min). Tissue was then exposed to an antigen
retrieval step in which sections were placed for 5 min in a Na+-Citrate buffer (10
mM Na-Citrate) heated to 85ºC. Following the 5 min incubation sections were
cooled at room temperature for 5 – 10 min and returned to TBS solution for
approximately 40 min (4 x 10 min) to remove excess Na+-Citrate buffer. Antigen
retrieval was performed prior to labeling with GluK2/3, GluK4 and GluK5 labeling
only. Tissue was then treated with a methanolic peroxide (90 mL TBS, 10 mL
100% methanol, 2 mL 30% hydrogen peroxide) rinse for 15 min at room
temperature. This step was performed to reduce endogenous peroxidase in the
tissue which aids in reducing background exposure during development.
Following the methanolic peroxide step, tissue was then rinsed for 30 min (3 x 10
min) in TBS, and then blocked for 1 hour in solution containing TBS, 3 – 5%
donkey serum, and 0.1 – 0.2% Triton-X-100 (TBS+). The concentration of
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donkey serum and Triton-X-100 is dependent upon the primary antibody; see
Table 2.3 for further detail. Once blocking was complete the tissue was
transferred to TBS+ containing the primary antibody of interest at the appropriate
concentration. Tissue was gently rocked overnight at room temperature.
Following incubation with the primary antibody, tissue was rinsed for 30 min in
TBS (3 x 10 min), and incubated for 1.5 hour at room temperature in the
appropriate biotinylated secondary antibody in TBS+ (1:1,000, Jackson
ImmunoResearch). Tissue was then rinsed again for 30 min in TBS (3 x 10 min)
and incubated for 1 hour in TBS containing 0.1 – 0.2% Triton-X-100 and
horseradish

peroxidase-conjugated

streptavidin

(1:1600,

Jackson

ImmunoResearch). Following the tertiary incubating tissue was rinsed for 50 min
in TBS (5 x 10 min) and developed using nickel ammonium sulfate/cobalt
chloride intensified diaminobenzidine (DAB, Sigma, St. Louis, MO; 0.025% DAB,
50% TBS, 50% Nickel-Cobalt). Reaction was initiated by the addition of 0.3%
hydrogen peroxide. Development time was determined on one slice from a
sham-treated animal and the appropriate development time was used for both
sham and pilocarpine-treated tissue. Development times were dependent upon
the primary antibody in use.

2.9.3 SLIDE PREPARATION AND ANALYSIS
Free floating tissue sections were mounted on slides with a 0.15% gelatin
solution and allowed to dry overnight. Once dry, tissue went through a serial
dehydration step with increasing concentrations of ethanol (50%, 70%, 95%,
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100%, 100%; 3 min/bath) followed by two, 10 min incubations in Xylene. Slides
were immediately cover-slipped using cover glass and DPX mounting solution
(Sigma, St. Louis, MO) and allowed several days to dry prior to analysis and
long-term storage. Analysis of immunohistochemical data was performed on
MCID Elite 7.0 analysis system (Imaging Research, Inc., St. Catharines,
Canada).
Table 2.3. Primary antibodies for immunohistochemical processing
Primary
Antibody
GluK2/3
GluK4
GluK5
GFAP
ZnT-3
NeuN

Manufacturer;
Catalog
Number
Chemicon;
AB5683
SantaCruz;
sc8916
Millipore;
06-315
Cell Signaling;
3670
Synaptic
Systems; 197002
Millipore;
MAB377

Primary
Concentration

[Donkey
Serum]

[Triton-X-100]

1:1,000

5%

1%

1:300

5%

1%

1:1,000

5%

1%

1:1,000

3%

2%

1:300

3%

2%

1:2,000

3%

2%

2.10 STATISTICAL ANALYSIS
Electrophysiological data was analyzed using pClamp10 (Molecular
Devices, Sunnyvale, CA), Origin7.5 (OriginLab, Northampton, MA), GraphPad
Prism (v. 4.00, GraphPad Software, San Diego, CA) and Mini Analysis 6.0
(Synaptosoft, Inc., Decatur, GA). Statistical significance was determined using
one-way analysis of variance (ANOVA) with post-hoc Bonferroni tests or the
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Student’s t-test, with α < 0.05. Values are depicted as the mean ± standard error
of the mean (SEM).
Data collected from western blot analysis and immunohistochemistry was
analyzed using MCID ELITE 7.0 (Imaging Research, Inc., St. Catharine’s,
Canada) or ImageJ 1.47V (National Institute of Health, USA). Optical density
measurements were obtained using a standard curve. Data depicting changes in
KAR subunit expression were obtained by averaging data collected from a
minimum of two separate western blots.
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CHAPTER 3
EFFECTS OF STIRIPENTOL ON BENZODIAZEPINE- REFRACTORY
STATUS EPILEPTICUS

1

3.1 INTRODUCTION
Benzodiazepines (BZDs) are the first-line therapy for the treatment of
status epilepticus (SE) and reduce seizure activity by enhancing GABAA
receptor- mediated inhibition. However, clinical studies have revealed that nearly
35% of patients suffering from SE are refractory to BZDs (Mayer et al., 2002).
While many factors could contribute to this pharmacoresistance, clinical and
animal studies have demonstrated that the likelihood of a patient responding to
BZDs decreases as the duration of SE increases. Sensitivity to BZDs requires
the presence of γ2-containing GABAA receptors (Mayer et al., 2002; Sieghart and
Sperk, 2002). However, following the onset of SE, these BZD sensitive, γ2containing receptors are internalized (Goodkin et al., 2008). This internalization
reduces the number BZD-sensitive receptors on the membrane surface, and thus
during prolonged SE the efficacy of BZDs is significantly reduced. While BZDsensitive receptors are internalized during SE, other populations of BZDinsensitive GABAA receptors, such as those containing α4 and δ subunits, remain
________________________________________
1

Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model
of benzodiazepine-refractory status epilepticus. Grosenbaugh, D.K., and Mott,
D.D. 2013. Neuropharmacology. 67: 136-143.
Reprinted here with permission of publisher.

80

functional (Goodkin et al., 2008).
Stiripentol (STP, Diacomit) is an anticonvulsant drug approved for use in
Europe for the treatment of severe myoclonic epilepsy in infancy (Dravet
syndrome). Typically, STP is co-administered with other anti-epileptic drugs
(AEDs) as it has been shown to increase their efficacy through inhibition of
several hepatic cytochrome P450 enzymes (Tran et al., 1997). However, several
animal models have demonstrated that STP may provide anticonvulsant effects
when administered alone via enhancement of GABAergic inhibition (Poisson et
al., 1984; Quilichini et al., 2006). In support of this finding, Fisher (2009) reported
that STP is a positive allosteric modulator of GABAA receptors containing any of
the α, β or γ-subunits, with greatest activity at α3 or δ-containing receptors.
The subunit selectivity profile of STP suggests its ability to potentiate both
phasic and tonic GABAergic inhibition. In addition, STP may retain this ability to
potentiate GABAergic inhibition during prolonged SE when γ2-containing, BZDsensitive, GABAA receptors have been internalized. The goal of the current
project was to determine the ability of STP to terminate SE in BZD-resistant rats,
and to understand the mechanism by which STP may be anticonvulsant.

3.2 HYPOTHESIS
STP has been previously demonstrated to potentiate GABA A receptors
composed of any of the α, β, or δ-subunits. Given that during status epilepticus
GABAA receptors containing α4 and δ subunits remain functional, we
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hypothesize that STP will remain effective during prolonged SE when seizures
have become resistant to benzodiazepines.

3.3 MATERIAL AND METHODS
3.3.1 BEHAVIORAL EXPERIMENTS
Male Sprague-Dawley rats (15 – 24, and 57 – 63 days old) received
intraperitoneal (i.p.) injections of lithium-chloride (LiCl, 127 mg/kg) followed 15 –
20h later by scopolamine methyl bromide (2 mg/kg). Status epilepticus was then
induced after 15 – 30 min by injection with pilocarpine (60 mg/kg). Diazepam
(DZP; 0.3 – 100 mg/kg) or stiripentol (STP; 10 – 1000 mg/kg) was administered
either at the onset of stage 3 seizures (brief SE) to assess its effect on brief
behavioral convulsions or 45 min after stage 3 seizure onset (prolonged SE;
pSE) to assess its effect during prolonged seizures. Behavioral seizure scores
were recorded throughout the course of SE. Seizure scores reported in this study
correspond to scores 15 min following administration of STP or DZP.

3.3.2 DETERMINATION OF STP CONCENTRATIONS
Four separate groups of male Sprague-Dawley rats: 1) naïve juvenile (20
– 27 days old), 2) prolonged SE-experienced juvenile (20 – 21 days old), 3) naïve
adult (62 – 63 days old) and 4) prolonged SE-experienced adult (61 days old),
were used to determine brain and plasma concentrations of STP. Fifteen minutes
following i.p. administration of 300 mg/kg STP, naïve and prolonged SE rats were
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anesthetized and decapitated in order to collect brain and blood samples. A
detailed description is provided in Chapter 2.4.

3.3.3 WHOLE-CELL RECORDINGS
Transverse (300 µM thick) hippocampal slices were prepared from 5 – 65
day old rats as described in Chapter 2.6. Rats were either naïve or had
experienced prolonged SE, in which slices were prepared 45 min after the first
stage 3 seizure. Animals were selected for slice experiments only if they had an
average seizure score between 3 and 4 during the prolonged SE.
GABA IPSCs were evoked by stimulation in stratum moleculare of the
dentate gyrus near the recording electrode. IPSCs were pharmacologically
isolated using the glutamate receptor antagonist D-APV (50 µM), or MK-801 (10
µM), and CNQX (50 µM), plus the addition of tetrodotoxin (TTX, 1 µM) for
miniature IPSCs (mIPSCs) and tonic current. Bicuculline methochloride (20 µM)
was added at the end of each experiment to confirm that the recorded IPSCSs
were mediated by GABAA receptors. Miniature EPSCs (mEPSCs) were isolated
using 30 µM bicuculline methochloride and 1 µM TTX. Drugs were perfused for a
minimum of 20 min in order to obtain a stable baseline.
Stiripentol was a generous gift from Biocodex. Scopolamine methyl
bromide, pilocarpine, kynurenic acid, diazepam, clobazam and all salts were
purchased from Sigma Chemical Company (St. Louis, MO).

D

-APV, MK-801,

CNQX, flumazenil, tetrodotoxin and bicuculline methochloride were purchased
from Ascent Scientific (Princeton, NJ). For behavioral experiments all drugs were
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made fresh on the day of the experiment and dissolved in 0.9% saline, except for
STP which was dissolved in 20% propylene glycol and 80% ethanol. All drugs
were administered via i.p. injection. For electrophysiological experiments drugs
were bath applied in the perfusion medium. Drugs were diluted from frozen
stocks in water except STP, DZP and clobazam which were diluted from frozen
stocks in dimethyl sulfoxide (DMSO). The final concentration of DMSO in working
solutions was less than 0.3%.

3.4 RESULTS
3.4.1 STP TERMINATION OF BRIEF BEHAVIORAL SE IS AGE DEPENDENT
Behavioral convulsions began approximately 3 min after injection of
pilocarpine. Behavioral seizures progressed through stages, as previously
described in Table 2.1. Stage 3 behavioral convulsions, characterized by forelimb
clonus without rearing and falling began approximately 20 min after
administration of pilocarpine. Treatment with stiripentol at the start of stage 3
seizures was effective in reducing seizures at doses above 10 mg/kg with a dose
of 1000 mg/kg terminating seizures in all tested animals (n = 4). In contrast,
treatment with vehicle alone (20% propylene glycol/80% ethanol) did not reduce
seizures. Dose-response analysis was performed on young rats (15 – 23 days
old) by administration of STP (10 – 1000 mg/kg) at the onset of stage 3 seizures
and yielded an ED50 of 100 (58.1 – 171.8) mg/kg; Figure 3.1A. To determine the
age-dependence of this effect, STP was also tested in adult animals (61 – 63
days old). In these animals the ED50 for STP was shifted approximately 4 fold to
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Figure 3.1. STP and DZP both terminate brief behavioral convulsions.
The anticonvulsant effect of STP and DZP on brief SE was compared in young
(15 – 23 days old) and adult (59 – 63 days old) male rats. Seizure scores in the
presence of STP or DZP were expressed as a percentage of the seizure score at
the same time point from animals that did not receive drug. A. STP dosedependently reduced seizure score in young (closed squares, n = 5 – 10) and
adult animals (open triangles, n = 5 – 9). The anticonvulsant effect of STP in
adult animals was shifted significantly to the right. B. DZP dose-dependently
reduced seizure score in young (closed squares, n = 4 – 19), and adult animals
(open triangles, n = 3 – 10). DZP was similarly effective in both age groups.
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the right (ED50 = 377.6 (256.4 – 555.9) mg/kg; Figure 3.1A). The confidence
intervals of the ED50 did not overlap, indicating a real difference in the STP
potency with maturation, as previously reported (Cao et al., 2012). In
comparison, the 95% confidence intervals for DZP in both young (21 – 23 days
old; ED50 = 3.1 (2.2 – 4.2) mg/kg; Figure 3.1B) and adult (59 – 63 days old; ED50
= 4.2 (2.2 – 7.8) mg/kg; Figure 3.1B) rats did overlap, indicating no real
difference in the ED50 for DZP during maturation. These findings indicate that,
like DZP, STP is able to terminate brief SE in the Li-Pilo model.

3.4.2 PHARMACORESISTANCE

DEVELOPS TO

DZP

BUT NOT

STP

DURING

PROLONGED SE

As with status epilepticus in humans, seizures in the Li-Pilo model become
pharmacoresistant to DZP during prolonged SE (Walton and Treiman, 1988;
Kapur and Macdonald, 1997; Jones et al., 2002). In agreement, we found that in
young (15 – 23 days old) animals the ED50 for DZP increased about 14 fold when
it was administered 45 min after the first stage 3 behavioral seizure (ED 50 = 3.1
(2.2 – 4.2) mg/kg after brief SE; ED50 = 43.1 (33.0 – 56.0) mg/kg after prolonged
SE; Figure 3.2A,B). In contrast, we observed no real difference in the ED 50 for
STP during prolonged SE (ED50 = 100 (58.1 – 171.8) mg/kg after brief SE; ED50
= 216.3 (136.8 – 342.0) mg/kg after prolonged SE; Figure 3.2A,B). Similarly, in
adult (57 – 63 days old) animals the ED50 for DZP increased 11 fold after
prolonged SE (ED50 = 4.2 (2.2 – 7.8) mg/kg after brief SE; ED50 = 47.2 (33.2 –
67.1) mg/kg after prolonged SE; Figure 3.2C,D), while the ED50 for STP was not
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Figure 3.2. Less pharmacoresistance develops to STP than to DZP
following prolonged SE. SE was induced in young (15 – 23 days old, top
panels) and adult (57 – 63 days old, bottom panels) male rats. DZP or STP was
administered at different doses at the onset of the first stage 3 behavioral
convulsion (closed squares) or 45 min following the first stage 3 convulsion
(closed circle) and the dose response curve measured. ED50 values for
anticonvulsant effect of DZP (left panel, n = 3 – 19) and STP (right panel, n = 5 –
29) during brief (Brief) and prolonged SE (pSE) in A. young rats and C. adult
rats. Fold change in ED50 for DZP and STP during prolonged SE relative to brief
SE in B. young rats and D. adult rats.
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different (ED50 = 377.6 (256.4 – 555.9) mg/kg after brief SE; ED50 = 397.2 (290.4
– 544.5) mg/kg after prolonged SE; Figure 3.2C,D).

3.4.3 BRAIN-PLASMA STP
We next wanted to determine if alterations in the bioavailability of STP
during maturation or prolonged SE affected its apparent efficacy. To address this
possibility, we measured plasma and brain concentrations of STP following
administration of 300 mg/kg STP. An initial pilot study in young rats (23 – 27 days
old, n = 4 – 5), showed that exposure to brief seizure activity modified neither
STP plasma levels nor the brain/plasma ratios compared to animals that did not
experience any seizure activity. To further explore this, a larger study of 43
animals was then carried out. This study revealed that STP plasma concentration
was not different in juvenile (96 ± 4.1 µg/mL) or adult (86.8 ± 3.6 µg/mL, p > 0.05)
animals (Table 3.1). The brain/plasma ratio of STP was also not different
between juvenile (0.98 ± 0.04) and adult (0.91 ± 0.04) animals (p = 0.41) and
was similar to that previously reported in adult animals (Shen et al., 1990; Shen
et al., 1992; Arends et al., 1994). Following prolonged SE, neither the plasma
concentration (100.7 ± 11.4 µg/mL, p = 0.67) nor the brain/plasma ratio (1.01 ±
0.09, p = 0.72 compared to naïve animals) changed in juvenile animals (Table
3.1). In contrast, in adult animals the brain/plasma ratio for STP decreased by
approximately 20% following prolonged SE (naïve: 0.91 ± 0.04, post-SE: 0.70 ±
0.11; p = 0.043).
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Table 3.1. Plasma and brain concentrations of STP
Treatment
Groups

[Brain]
µg/mL
94.6 ± 6.2
(n=14)
115.3 ± 16.8
(n=9)

[Plasma]
µg/mL
96.0 ± 4.1
(n=14)
100.7 ± 11.4
(n=10)

Brain/Plasma
Ratio
0.98 ± 0.04
(n=14)
1.01 ± 0.09
1.02 (n=9)

Adult, Naive

80.1 ± 5.6
(n=12)

86.8 ± 3.6
(n=12)

0.91 ± 0.04
(n=12)

Adult, prolonged SE

68.0 ± 17.6
(n=7)

85.1 ± 12.9
(n=7)

0.70 ± 0.11*
(n=7)

Juvenile, Naïve
Juvenile, prolonged
SE

*p < 0.05

3.4.4 STP POTENTIATES EVOKED GABAA RECEPTOR MEDIATED IPSCS
Given the ability of STP to potentiate GABAA receptors (Quilichini et al.,
2006; Fisher, 2009), we hypothesized that STP acted as an anticonvulsant in SE
by enhancing GABAergic inhibition. To test this hypothesis we characterized the
effects of STP on GABAA receptor mediated currents in dentate granule cells.
The effect of STP on evoked IPSCs in dentate granule cells in young (20
– 26 day old) naïve animals was examined in the presence of glutamate
antagonists (CNQX, 50 µM and

D-APV,

50 µM) to block AMPA/kainate and

NMDA receptors, respectively. Bicuculline methochloride (20 µM) completely
blocked this IPSC, indicating that it was mediated by GABA A receptors. DZP (1
µM) increased its decay time (145.6 ± 10.4% of control, n = 5; p < 0.01; Figure
3.3), further confirming that it was mediated by GABA A receptors. STP (100 µM)
had no effect on the IPSC rise time (10 – 90% rise time: 118 ± 11% of control, n
= 6; p = 0.13) or amplitude (92 ± 7% of control, n = 6; p = 0.22). However, STP
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Figure 3.3. STP prolongs IPSC decay in an age-dependent manner. A.
Left, Sample IPSC waveforms from 5 – 7 and 60 – 65 day old animals in the
absence (CON) and presence of 100 µM STP (STP). Right, Concentration
response curves showing the effect of STP on the 50% decay time of the evoked
IPSC in the three age groups tested; postnatal day 5 – 7 (closed squares, n = 4 –
7), postnatal day 20 – 25 (closed circles, n = 5 – 9) and postnatal day 60 – 65
(closed triangles, n = 4 – 8). B. Plot of the EC50 and 95% confidence intervals for
each of the three age groups.
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significantly prolonged the IPSC decay (156 ± 8.9% of control, n = 9; p < 0.01;
Figure 3.3), in agreement with a previous report (Quilichini et al., 2006). This
increase in decay time was concentration dependent (EC50 = 103 µM (85 – 126
µM), n = 5 – 9). While STP had no effect on IPSC amplitude at lower
concentrations, at the highest concentration tested (700 µM) STP significantly
reduced IPSC amplitude (62.5 ± 4.6%, n = 6; p < 0.001).
Since the anticonvulsant effect of STP was age-dependent, we compared
the ability of STP to prolong IPSC decay time in animals of different ages (5 – 8
days old, 20 – 26 days old, and 59 – 65 days old; Figure 3.3A). STP potentiated
IPSCs in granule cells from animals that were postnatal 5 – 8 days to a greater
extent than it potentiated IPSCs in animals from either of the other two age
groups (Figure 3.3B). The ability of STP to produce greater potentiation of IPSCs
in younger animals was similar to the age-dependence of its anticonvulsant
effect.

3.4.5 ACTION

OF

STP

IS INDEPENDENT OF THE

BZD

SITE ON THE

GABAA

RECEPTOR

Stiripentol is approved in Europe for use as add-on therapy in Dravet
Syndrome, and is commonly administered with the 1,5-benzodiazepine,
clobazam (CLB) (Chiron et al., 2000; Ng and Collins, 2007). We investigated
whether CLB and STP act through a common site on the GABA A receptor by
measuring whether a maximally effective concentration of CLB occluded the
effect of STP. STP alone prolonged IPSC decay time (153.3 ± 15.2% of control,
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p < 0.001). CLB maximally potentiates GABAA currents at a concentration of
about 10 µM (Nakamura et al., 1996). At this concentration CLB alone also
significantly prolonged IPSC decay time (187.4 ± 17.8% of control, p < 0.001;
Figure 3.4A). Application of STP (100 µM) in the presence of CLB (10 µM)
significantly increased the IPSC decay time beyond that of CLB alone (350.8 ±
38.2% of control, p < 0.001; Figure 3.4A), suggesting that these drugs act at
separate loci.
In further support of this conclusion, we found that the benzodiazepine-site
antagonist flumazenil (FMZ) had no effect on IPSC decay time (94.3 ± 3% of
control, p > 0.05), but blocked IPSC prolongation produced by 1 µM DZP (85.7 ±
3.2%, p > 0.05) and 10 µM CLB (96.5 ± 4.6%, p > 0.05; Figure 3.4B). However,
FMZ did not prevent IPSC prolongation by STP (200.5 ± 18.3%, p < 0.001;
Figure 3.4B). In agreement with Quilichini et al. (2006), these findings support the
conclusion that STP does not interact with the BZD site of the GABA A receptor.

3.4.6 GABAERGIC

POTENTIATION BY

STP

REMAINS EFFECTIVE FOLLOWING

PROLONGED SE

The ability of STP to retain anticonvulsant potency during prolonged SE
could be explained by the continued ability of the drug to potentiate the IPSC
during SE. To investigate this possibility we compared the effect of STP on
IPSCs in dentate granule cells from naïve animals and from animals that had
experienced 45 min of continuous seizure activity (Figure 3.5A). STP (100 µM)
significantly potentiated the IPSC in granule cells from both groups of animals
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Figure 3.4. STP potentiation of GABAergic transmission is
independent of the BZD-binding site. A. STP (100 µM, n = 7; ***p < 0.001) and
CLB (10 µM, n = 7; ***p < 0.001) increased the 50% decay time of the evoked
IPSC. Co-application of STP (100 µM) and CLB (10 µM) significantly enhanced
decay time compared to control (n = 8; ***p < 0.001) as well as compared to
either STP (###p < 0.001) or CLB alone (##p < 0.01). B. FMZ (10 µM) alone did
not alter IPSC decay time (n = 10; p > 0.05), but blocked potentiation by DZP (1
µM, n = 4) or CLB (10 µM, n = 4). In contrast, STP (100 µM, n = 4) continued to
prolong IPSC decay in the presence of 10 µM FMZ (***p < 0.001).
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Figure 3.5. STP continues to potentiate phasic GABAergic
transmission following prolonged SE. A. Left, Sample traces from naïve and
prolonged SE-experienced animals demonstrate similar potentiation by 100 µM
STP. Right, STP (100 µM) similarly potentiates IPSC decay in both naïve (gray
bar, n = 9) and prolonged SE-experienced animals (black bar, n = 4). B. Left,
Sample traces from naïve and prolonged SE-experienced animals demonstrate a
lack of potentiation by 300 nM DZP in prolonged SE-experienced animals. Right,
Potentiation of IPSC decay by DZP (300 nM) following prolonged SE (black bar,
n = 10) is significantly (*p < 0.05) reduced compared to naïve animals (gray bar,
n = 5).
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(naïve: 156 ± 8.9%, p < 0.01; prolonged SE: 180.2 ± 12.5%, p < 0.001). The
extent of potentiation in both conditions was not different (p = 0.15). In contrast,
IPSC potentiation by DZP (300 nM) was significantly reduced in granule cells
from animals that had experienced prolonged SE (naïve: 147.0 ± 9.7%;
prolonged SE: 117.0 ± 7.2%, p < 0.05; Figure 3.5B). This reduction in DZP
potency during SE agrees with previous reports (Walton and Treiman, 1988;
Kapur and Macdonald, 1997). These findings demonstrate that STP, but not DZP
retains potency following prolonged SE and suggests that the continued ability of
STP to potentiate GABAergic IPSCs underlies its ability to remain effective
during prolonged SE.

3.4.7 STP,

BUT NOT

DZP,

REMAINS EFFECTIVE IN POTENTIATING TONIC

CURRENT FOLLOWING PROLONGED SE

Tonic inhibition in the dentate gyrus is mediated by GABA A receptors
containing α4 and δ subunits as well as those containing α5 and γ2 subunits
(Zhang et al., 2007). The ability of STP to act at receptors containing these
subunits (Fisher, 2009) suggests that potentiation of tonic GABA currents may
contribute to the anticonvulsant effect of STP. We examined the effect of STP on
tonic GABA current in dentate granule cells in young (21 – 23 days old) naïve
animals. Tonic currents were studied in the presence of 50 µM CNQX, 50 µM DAPV/10 µM MK-801, and 1 µM TTX to block AMPA/kainate receptors, NMDA
receptors and Na+ channels, respectively. Tonic currents were blocked by
bicuculline methochloride (20 µM), indicating that they were mediated by GABA A
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receptors. As predicted, STP (100 µM) significantly potentiated the tonic current
(185.5 ± 22.6%, p < 0.01). We then compared the effect of STP on tonic current
in naïve animals to that in animals that had experienced prolonged SE (naïve:
20.4 ± 3 pA, n = 10; prolonged SE: 36.6 pA, n = 9; p < 0.05; Figure 3.6A), a
finding in agreement with a previous study (Naylor et al., 2005). Despite the
increase in tonic current, STP still potentiated this current following prolonged SE
(175.4 ± 23.8%, p < 0.05) by a similar amount to that in naïve animals (p = 0.76;
Figure 3.6A). By comparison, DZP (1 µM) potentiated tonic GABA current (155.3
± 18%, p < 0.05) in granule cells in naïve animals, likely by acting on α5/γ2containing GABAA receptors (Zhang et al., 2007). However, following prolonged
SE, DZP no longer increased the tonic current (95 ± 9.1%, p = 0.60; Figure
3.6B).

3.4.8 STP

RETAINS

ITS

ABILITY

TO

POTENTIATE MIPSCS

FOLLOWING

PROLONGED SE

STP can increase GABA release by acting presynaptically on inhibitory
terminals (Quilichini et al., 2006) and this action could contribute to both the
ability of STP to prolong the IPSC decay and the anticonvulsant effect of the
compound. We examined the presynaptic action of STP by measuring its effect
on the frequency of miniature IPSCs (mIPSCs). Spontaneous mIPSCs were
recorded in the presence of glutamate antagonist (CNQX, 50 µM and D-APV, 50
µM) and TTX (1 µM), to block Na+ channels. In young animals (19 – 26 days old)
STP (100 µM) did not alter the amplitude of mIPSCs (106.8 ± 13.8%, p > 0.05)
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Figure 3.6. STP, not DZP, continues to enhance tonic GABAergic
inhibition following prolonged SE. A. Left, Sample traces from naïve and
prolonged SE-experienced animals demonstrate similar potentiation of tonic
GABAA currents by 100 µM STP. Tonic GABAA current is blocked by 30 µM
bicuculline (BIC). Right, STP (100 µM) similarly potentiates tonic GABAA currents
in naïve (gray bar, n = 6) and prolonged SE-experienced animals (black bar, n =
5). B. Left, Sample traces demonstrate that DZP (1 µM) potentiates tonic GABA A
current in dentate granule cells in naïve animals and that this potentiation is lost
following prolonged SE. Right, DZP (1 µM) enhances tonic GABAA current in
naïve animals (gray bar, n = 4), but does not potentiate this current following
prolonged SE (black bar, n = 4), a value significantly different from naïve (*p <
0.05).
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but increased both the frequency (131.5 ± 5.8%, p < 0.001) and the decay time of
events (150.1 ± 12.1%, p < 0.01; Figure 3.7A). Similarly, in dentate granule cells
from animals that had experienced prolonged SE, 100 µM STP continued to
potentiate both the frequency (140.3 ± 13.6%, p < 0.05) and decay time (140.7 ±
7.5%, p < 0.001) of the mIPSCs, without affecting mIPSCs amplitude (101.5 ±
10.5%, p > 0.05; Figure 3.7A). These findings indicate that STP acts
presynaptically to enhance GABA release and this effect does not change during
prolonged SE. In contrast, in naïve animals DZP (1 µM) significantly potentiated
the decay time (156.7 ± 8.2%, p < 0.001) of mIPSCs, without affecting mIPSC
frequency (95.5 ± 9.6%, p > 0.05; Figure 3.7B), supporting the conclusion that its
action was entirely postsynaptic on GABAA receptors. During prolonged SE, the
effect of DZP on mIPSC decay (118.1 ± 3.8%, p < 0.001) was significantly
reduced (Figure 3.7B).
The mechanism by which STP enhances GABA release is unknown.
However, given its ability to act presynaptically, we also assessed whether it
could enhance glutamate release. The effect of STP on glutamate release was
measured by its ability to alter the frequency of spontaneous miniature excitatory
post-synaptic currents (mEPSCs). mEPSCs were studied in the presence of the
GABAA receptor antagonist bicuculline methochloride (30 µM) and TTX (1 µM).
In young animals (19 – 26 days old) STP (100 µM) significantly increased
mEPSC frequency (128 ± 4.5%, p < 0.001) without altering the amplitude of
decay time of events (Figure 3.8A). Following prolonged SE, the effect of STP on
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Figure 3.7. STP, not DZP, remains effective in potentiating mIPSCs
following prolonged SE. A. Top, Sample waveforms from naïve and prolonged
SE-experienced animals before and after application of 100 µM STP showing
increased mIPSC frequency. Lower Left, Superimposed traces of averaged
mIPSCs in the absence and presence of STP (100 µM) in naïve and prolonged
SE (pSE) animals. Lower Right, STP (100 µM) similarly increased mIPSC
frequency and decay time in both naïve (gray bars, n = 5) and prolonged SEexperienced animals (black bars, n = 6). B. Top, Sample waveforms from naïve
and prolonged-SE experienced animals before and after application of 1µM DZP,
showing no change in mIPSC frequency. Lower Left, Superimposed traces of
averaged mIPSCs in the absence and presence of DZP (1 µM) in naïve and
prolonged SE (pSE) animals. Lower Right, DZP (1 µM) had no effect on mIPSC
frequency in naïve (gray bar, n = 5) or prolonged SE-experienced animals (black
bar, n = 6). DZP (1 µM) significantly prolonged SE-experienced mIPSC decay
time in dentate granule cells from naïve animals (gray bar, n = 5). Following
prolonged SE, this potentiation was significantly reduced (black bar, n = 6; **p <
0.01).
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Figure 3.8. Neither STP nor DZP alter mEPSCs following prolonged
SE A. Top, Sample waveforms from naïve and prolonged SE-experienced
animals before and after application of 100 µM STP, showing increased mEPSC
frequency. Lower Left, Superimposed traces of averaged mEPSCs in the
absence and presence of STP (100 µM) in naïve and prolonged SE (pSE)
animals. Lower Right, STP (100 µM) significantly potentiated mEPSC frequency
in naïve animals (gray bars, n = 5), but did not alter frequency following
prolonged SE (black bars, n = 6), a significant difference from naïve animals (**p
< 0.01). STP had no effect on mEPSC decay time in naïve or prolonged SEexperienced animals. B. DZP (1 µM) did not alter mEPSC frequency or decay
time in naïve (gray bars, n = 5) or prolonged SE-experienced animals (black
bars, n = 6).
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mEPSC frequency was significantly reduced (p < 0.01). In contrast, DZP (1 µM)
did not affect the frequency or decay time of mEPSCs in either naïve animals or
prolonged SE-experienced animals (Figure 3.8B). These findings indicate that
STP affects both inhibitory and excitatory transmission, but that its effects on
inhibitory and excitatory terminals are differentially regulated during SE.

3.5. DISCUSSION
The results of this study suggest that STP may be effective in terminating
prolonged SE, a time when seizures have become resistant to BZDs.
Specifically,

this

study

demonstrates

that

at

therapeutically

relevant

concentrations STP terminates both brief and prolonged behavioral SE. These
actions of STP are due to its enhancement of GABAA receptor mediated
transmission, as STP acts both postsynaptically to prolong IPSC decay and
presynaptically to enhance GABA release.

Despite a significant reduction in

IPSC potentiation by DZP, the actions of STP on GABAergic transmission are
preserved during prolonged SE. Postsynaptically STP potentiates both phasic
and tonic GABAergic currents by acting on the GABAA receptor at a locus
separate from the BZD site.

This study also demonstrated that the

anticonvulsant effects of STP, as well as its effects on IPSC decay, are agedependent with greater effects in younger animals. The results of this study
suggest the potential for the use of STP in treatment of BZD-resistant SE. Figure
3.9 summarizes the changes in GABA AR pharmacology during prolonged-SE.
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Figure 3.9. Summary of changes in GABAA receptor pharmacology
following prolonged-SE. In naïve animals BZD-sensitive γ2-containing
GABAAR dominate the postsynaptic membrane. Extrasynaptic receptors are
composed of a combination of γ2-containing and γ2-lacking GABARs. In
prolonged-SE experienced animals (Post-SE), the γ2 subunit is internalized
leaving mostly BZD-insensitive γ2-lacking GABAARs at synaptic and
extrasynaptic sites. The pharmacological profile of STP preserves its
effectiveness in both conditions while significant pharmacoresistance develops to
BZDs.
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3.5.1 STATUS EPILEPTICUS INDUCED RESISTANCE TO BZDS
The initiation and maintenance of SE is regulated by GABAergic inhibition
within the dentate gyrus and CA1 region of the hippocampus (Kapur and
Lothman, 1989; Kapur et al., 1989). Seizures become self-sustaining because
with time seizures progressively reduce GABAA receptor-mediated inhibition in
the hippocampus.

This reduction in GABAergic transmission leads to the

development of further seizures.

BZDs, such as DZP, are anticonvulsant by

potentiating γ2-containing GABAA receptor currents in this region. However, the
pharmacoresistance to BZDs during prolonged SE results from the rapid activitydependent decrease in surface expression of the BZD-sensitive γ2-containing
GABAA receptors (Naylor et al., 2005; Goodkin et al., 2008). In contrast, BZDinsensitive GABAA receptors containing α4 and δ subunits are preserved
(Goodkin et al., 2008).

3.5.2 STP POTENTIATION OF BOTH PHASIC AND TONIC GABAERGIC INHIBITION
The results of this study suggest that the ability of STP to remain effective
during prolonged SE is due to its unique subunit selectivity profile. STP is a
positive allosteric modulator of GABAA receptors containing any of the α, β or γ
subunits (Fisher, 2009). GABAA receptors containing α4 subunits can mediate
phasic inhibition and remain at the membrane surface following prolonged SE.
STP may retain its ability to potentiate phasic inhibition during prolonged SE by
acting at receptors containing these subunits.
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In addition to potentiating phasic inhibition, the results of this study
demonstrate that STP strongly potentiates tonic inhibition. This finding is in
support of its activity at δ-containing GABAA receptors (Fisher, 2009). The ability
of STP to enhance tonic GABAA currents may have contributed to its
anticonvulsant effect.

The continued effectiveness of STP on tonic inhibition

during prolonged SE was likely due to the persistence of δ-containing GABAA
receptors on the membrane surface (Goodkin et al., 2008). In contrast, DZP does
not act at δ-containing receptors. The observed potentiation of tonic GABA A
current by DZP has been reported to occur through the activity of the drug at
α5/γ2-containing extrasynaptic GABAA receptors (Zhang et al., 2007). However,
this effect of DZP was lost during prolonged SE due to internalization of γ2containing receptors (Naylor et al., 2005). Thus, STP, not DZP, retained efficacy
during prolonged SE. While it seems likely that STP potentiated tonic inhibition
by acting at δ-containing GABAA receptors, the possibility that the presynaptic
action of STP contributed cannot be excluded. The present data suggest that the
ability of STP to remain effective during prolonged SE is likely due to its activity
at BZD-insensitive GABAA receptors containing α4 and δ subunits as well as its
presynaptic effect.

3.5.3 EFFECTS OF STP ARE DEVELOPMENTALLY REGULATED
STP has been shown to act at all α subunits, however it has the highest
activity at α3-containing GABAA receptors (Fisher, 2009). In rat, expression of the
α3 subunit is strongly developmentally regulated. In embryonic and newborn
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brain α3 subunits are expressed in most regions (Laurie et al., 1992). However,
with maturation α3 mRNA expression decreases becoming restricted to neurons
primarily in the cortex and thalamus. The developmental loss of α3 subunit
expression likely explains the observed age dependence in both the ability of
STP to potentiate the IPSC and its anticonvulsant activity.

However, it is

important to note that the developmental profile of α3 subunit expression in
humans has not been reported.

Furthermore, the mechanism by which a

developmental loss of α3 subunits could cause a shift in STP potency has not
been explored. Further studies will be required to resolve these issues.
In the present study the ED50 for DZP to terminate SE and the extent of
the rightward shift in the DZP ED50 during prolonged SE are in agreement with
previous studies in the Li-Pilo model (Walton and Treiman, 1988; Kapur and
Macdonald, 1997; Jones et al., 2002; Goodkin et al., 2003). The observed shift
in DZP ED50 was similar in both juvenile and adult animals. Under the same
conditions, STP displayed markedly less pharmacoresistance than DZP at both
developmental time points. However, in juvenile animals there was a slight trend
for the STP ED50 to increase (~ 2 fold) after prolonged SE; a trend which
disappeared in adult animals. This observation in juvenile animals may be
explained by the developmental decrease in α3 subunit expression. Thus, in
juvenile animals the action of STP on α3-containing GABAA receptors may have
accounted for a greater proportion of the drugs effect than in adult animals.
Consequently, internalization of α3-containing GABAA receptors during SE would
have caused have caused a greater impact on the anticonvulsant activity of STP
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in juvenile than in adult animals.

3.5.4 STP IS EFFECTIVE AT THERAPEUTICALLY RELEVANT CONCENTRATIONS
STP is used clinically to treat Dravet Syndrome in children at doses that
result in plasma concentration of 4 – 22 µg/mL (Farwell et al., 1993; Chiron et al.,
2000), a value that corresponds to approximately 16 – 90 µM. The present study
determined that in granule cells from 5 to 7 day old rats STP potentiated the
IPSC with an EC50 of 45 µM, a value well within the established therapeutic
range.

Previous studies examining the effects of STP have focused on its

anticonvulsant effects in adult animals. The concentrations of STP used in these
reports are similar to those used in adult animals in the present study. For
example, Shen et al. (1990) found that STP applied alone produced a maximal
anticonvulsant effect in adult animals at concentrations above 120 µg/mL,
equivalent to ~500 µM. In agreement, the present study reported that STP
terminated SE in adult animals with an ED50 of 378 mg/kg, corresponding to a
plasma concentration of approximately 110 µg/mL. In younger rats (20 – 25 days
old), STP became more potent, terminating SE with an ED50 of 100 mg/kg. This
corresponds to a plasma concentration of 30 µg/mL, equivalent to ~120 µM. The
concentration corresponding to this ED50 for the anticonvulsant effect of STP
measured in vivo agreed well with the EC50 of 102 µM determined for STP
prolongation of the IPSC in vitro from animals of the same age. The similarity
between these values is consistent with the idea that potentiation of GABAergic
transmission underlies the anticonvulsant effect of STP.
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3.5.5 STP ACTS AT A DISTINCT SITE ON THE GABAA RECEPTOR
The site of action of STP on the GABAA receptor is not known.

The

actions of STP on the IPSC were similar to those of BZDs in that they both
prolonged the decay of the IPSC without increasing its peak amplitude.
However, results of the present study, as well as previous work (Quilichini et al.,
2006; Fisher, 2009), indicate that STP acts at a distinct site on the GABA A
receptor; a site separate from BZD binding sites as well as binding sites for
neurosteroids and some anesthetics.

In support of this, the present study

determined that the actions of STP were not blocked by a BZD site antagonist,
and were additive with co-applied BZDs. This finding suggests a potential role for
STP as add-on therapy with BZDs for the treatment of SE.
The current study also reported that at concentrations above 300 µM, STP
depressed the evoked IPSC.

This finding is consistent with the previous

suggestion that STP acts as a partial agonist (Fisher, 2009). The ability of STP to
directly activate the receptor may have contributed to the strong sedation
produced by the drug at high doses. Based on similarities to the actions of
barbiturates, Quilichini et al. (2006) suggested that STP may act at the
barbiturate site. However, unlike barbiturates, STP did not increase the peak
amplitude of the IPSC. Fisher (2009) also reported that the subunit dependence
of STP is distinct from that of the barbiturates (Thompson et al., 1996),
suggesting that STP acts at a unique site on the GABAA receptor. Barbiturates
and STP also differ in their activity at other sites. For example, barbiturates
decrease glutamate release and block AMPA receptors (Ho and Harris, 1981;
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Miljkovic and MacDonald, 1986), whereas the present study determined that STP
enhanced glutamate release. STP also enhanced GABA release and this effect
persisted during prolonged SE, suggesting that it could have contributed to the
anticonvulsant effect of the drug. This presynaptic effect differentiates STP from
both barbiturates and BZDs, further demonstrating the unique pharmacological
profile of STP.

3.6 SIGNIFICANCE
The present study determined that STP increased GABA release,
potentiated both phasic and tonic GABAergic currents and was anticonvulsant in
the Li-Pilo model of SE. Most notably, STP remained effective during prolonged
SE at a time when seizures had become pharmacoresistant to BZDs. The
actions of STP were age-dependent with the greatest effect in younger animals.
These findings suggest that STP may be effective in treatment of prolonged SE.
The need for novel therapies for prolonged SE is highlighted by clinical studies
showing that the majority of patients undergoing SE do not receive treatment
within 30 min (Jordan, 1994; Pellock et al., 2004; Shinnar et al., 2008). Results of
the present study suggest that STP, either alone or as add-on therapy, would be
effective in treating prolonged and BZD-resistant seizures.
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CHAPTER 4
TEMPORAL ALTERATIONS IN KAINATE RECEPTOR SUBUNIT EXPRESSION
FOLLOWING STATUS EPILEPTICUS

4.1 INTRODUCTION
Alterations in both glutamatergic and GABAergic receptor populations
have been identified in patients suffering from seizure disorders such as status
epilepticus (SE) (Grigorenko et al., 1997; Mathern et al., 1998; Mathern et al.,
1999; Das et al., 2012; Houser et al., 2012). While some of these modifications
can occur during a single SE event others emerge during the progression of the
disease, representative of enduring alterations in receptor expression. The ability
to develop effective therapeutics for the treatment of SE and epilepsy rests in our
understanding of the diseased brain and the available receptor targets.
Kainate receptors (KARs) contribute to excitatory neurotransmission in the
cerebrum, specifically throughout the hippocampus, a region central to the
development of epilepsy (Chang and Lowenstein, 2003; Sloviter, 2005). In
particular, KARs densely populate the mossy fiber – CA3 pathway, a region of
the hippocampus prone to excitotoxicity and seizure development (Nadler et al.,
1978). KARs in this pathway are believed to be composed of GluK2/3, GluK4 and
GluK5 receptor combinations (Darstein et al., 2003). KARs are also responsible
for mediating a portion of the excitatory circuit that appears in the epileptic brain
following the aberrant sprouting of mossy fibers into the inner molecular layer of
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the dentate gyrus (DG) (Epsztein et al., 2005).
In addition to the role of KARs in regulating neurotransmission, direct
activation of the receptor via kainate has long been used as a model of SE and
leads to the development of epilepsy (Nadler, 1981; Ben-Ari, 1985).

In

agreement, knockout of the GluK2 subunit increases seizure threshold,
demonstrating that low doses of kainate initiate seizures through GluK2containing KARs (Mulle et al., 1998; Fritsch et al., 2014). KARs have also been
implicated in several comorbidities and possible disorders associated with
epilepsy. Alterations in KAR subunit expression and localization have been
observed in disorders with increased prevalence in epilepsy, including anxiety
and depression (Catches et al., 2012; Lerma and Marques, 2013). Together,
these studies create a framework in which the KAR could serve as a potential
therapeutic target for the treatment of epilepsy and related comorbidities.
Despite this potential relationship few studies have examined possible
alterations in KAR subunit expression post-SE. Studies from patients with
epilepsy have consistently demonstrated that KAR subunit expression is altered
in the epileptic brain (Grigorenko et al., 1997; Mathern et al., 1998; Li et al., 2010;
Das et al., 2012). However the observed changes in individual subunit
expression remain inconsistent, likely due to differences in seizure etiology and
treatment methods, as well as differences in the duration of the disorder. In
agreement with human studies, animal models of SE have also demonstrated
that KAR subunit expression and localization is altered (Kamphuis et al., 1995;
Porter et al., 1996; Lason et al., 1997; Tandon et al., 2002; Zhang et al., 2004;
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Ullal et al., 2005; Porter et al., 2006). However, the literature on animal studies is
also severely inconsistent, likely due to different animal models utilized as well as
the lack of exploring region-specific changes.
The goal of the current study was to explore how the expression of
GluK2/3, GluK4 and GluK5 KAR subunits are altered at three distinct time-points
following the induction of SE. Expression of the GluK1 subunit was not explored
as its expression is essentially absent from postsynaptic neurons and is
predominately expressed in hippocampal interneurons (Wisden and Seeburg,
1993). In addition, this study explored region specific alterations by examining
tissue from microdissected DG, CA3 and CA1 hippocampal subfields.
Together, the data collected from this study provide the first long-term,
region-specific exploration of alterations in KAR subunit expression following the
induction of SE and the development of epilepsy.

4.2 HYPOTHESIS
Collectively, the scientific literature demonstrates that in both human and
animal studies, KAR subunit expression and localization is altered following SE.
Based on the limited human and animal studies, we hypothesize that distinct
changes in KAR subunit expression will be observed within each of the three
different hippocampal subfields explored. In addition, we postulate that these
changes will vary as the disease progresses following the induction of SE.
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4.3 MATERIALS AND METHODS
4.3.1 ANIMAL MODEL OF SE
All animal care and use procedures were carried out in accordance with
protocols written under the guidance of the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and approved by the Institutional Animal
Care and Use Committee at the University of South Carolina. Following induction
of SE, rats were housed 1 per cage with ad libitum access to food and water.
Rats were housed in a climate controlled facility with a light/dark cycle of 12/12
hours.
SE was induced in adult male Sprague-Dawley rats (Harlan, Indianapolis,
IN). Animals received intraperitoneal (i.p.) injections of scopolamine methyl
bromide and terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min later by
pilocarpine hydrochloride (390 mg/kg). After 2 hours of continuous SE, seizures
were terminated by diazepam (DZP, 25 mg/kg). This group of animals served as
the ‘pilo’ group. A separate group of animals received identical treatment with the
exception of receiving saline (390 mg/kg) instead of pilocarpine hydrochloride.
This group of animals served as the ‘sham’ group. More detailed methods
concerning induction of SE are described in Chapter 2.3.

4.3.2 WESTERN BLOT ANALYSIS
Animals 5, 60, and 200 days post-SE were anesthetized, the brain
removed, and immediately placed on dry ice. Brains were sectioned at 100 µM
on a freezing microtome (Microm, Waldorf, Germany). Tissue from hippocampal
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regions- DG, CA3 and CA1, in addition to prefrontal cortex, amygdala and
striatum were collected. Microdissected regions collected from the hippocampus
are outlined in Figure 2.3.

Individual regions were homogenized with the

resulting pellet resuspended in PBS and stored at -80°C prior to use.
Aliquots of 2 – 10 µg of crude plasma membrane protein were loaded onto
a 4 – 15% pre-cast polyacrylamide gel. Sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) was used to separate the proteins prior to being
transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were
blocked with TBS + 5% non-fat dry milk for 60 min at room temperature followed
by primary antibody incubation overnight at 4°C. Primary antibodies are listed in
Table 2.2. Enhanced chemiluminescence reagents (ECL, Pierce) were used for
antibody detection. Images were captured on Kodak BioMax XAR film and
densitometric analysis performed using ImageJ 1.47v (National Institutes of
Health, USA). More detailed methods concerning western blot analysis are
described in Chapter 2.8.

4.3.3 IMMUNOHISTOCHEMISTRY
Animals 60 and 200 days post-SE were anesthetized and perfused for 4 –
5 minutes with ice cold, oxygenated (95% O 2 / 5% CO2) PBS followed by ice cold
4% paraformaldehyde for approximately 20 minutes. Whole brains were removed
and post-fixed at 4°C in 4% paraformaldehyde or 3 hours and then transferred to
0.1M PB until sectioned at 50 µM thick coronal sections on a vibratome (Leica,
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VT1000S, Nussloch, Germany). Slices were stored at 4°C in 0.1M PB and 0.1%
sodium azide until used for immunohistochemical processing.
Free floating sections were washed for approximately 40 minutes in TBS.
Tissue was then exposed to an antigen retrieval step in which sections were
placed for 5 min in Na-Citrate buffer heated to 85°C and then cooled to room
temperature for 5 – 10 min. Primary antibodies utilized for immunohistochemical
analysis are listed in Table 2.3. Tissue was processed using a standard
immunohistochemical protocol described in detail in Chapter 2.9, and then coverslipped using cover glass and DPX mounting solution (Sigma, St. Louis, MO).
Slides were left to dry completely prior to analysis with MCID Elite 7.0 (Imaging
Research, Inc., St. Catharines, Canada) or ImageJ 1.47v (National Institutes of
Health, USA).

4.4 RESULTS
4.4.1 ALTERATIONS IN KAR SUBUNIT EXPRESSION IN THE DENTATE GYRUS
As the first stop in the trisynaptic pathway, the DG serves to gate
information entering the hippocampus from the entorhinal cortex (EC; Figure 1.2)
(Henze et al., 2002; Acsady and Kali, 2007). This feature is critical in that it
allows dentate granule cells (DGCs) to resist the propagation of seizures that
may originate from the EC (Collins et al., 1983; Stringer and Lothman, 1989;
Lothman et al., 1992). However in human temporal lobe epilepsy, as well as the
pilocarpine model of SE, dramatic alterations in the anatomy and circuitry of the
DG have been observed. One such change involves the aberrant sprouting of
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mossy fibers into the inner molecular layer of the DG (Figure 1.6) (Tauck and
Nadler, 1985; Represa et al., 1987; Sutula and Dudek, 2007). This pathological
sprouting creates a recurrent excitatory network between granule cells and likely
serves to facilitate the synchronous firing of DGCs and promote seizure
propagation (Tauck and Nadler, 1985; Gabriel et al., 2004; Timofeeva and
Nadler, 2006). In addition, KARs have been shown to mediate a portion of this
new excitatory network (Epsztein et al., 2005). We explored the impact of
pilocarpine-induced SE on the KAR subunit expression within the DG, in hopes
of shedding light on the subunit composition mediating this newly formed
excitatory circuit in the epileptic brain.
We determined that expression of the GluK2/3 subunit is significantly
reduced in the DG at 5 days post-SE (70.0 ± 5.2% of control, n = 7 – 8; p < 0.01)
and remains significantly reduced at 60 and 200d post-SE (60d: 56.8 ± 7.1% of
control, n = 8; p < 0.01; 200d: 71.1 ± 4.8% of control, n = 6 – 10; p < 0.001;
Figure 4.1A). Our observation that the GluK2/3 subunit is reduced shortly after
SE is supported by a previous study in which GluK2/3 subunit expression was
also decreased in the DG at 20 days following induction of SE (Porter et al.,
2006). We failed to observe any alterations in GluK4 subunit expression at 5d
(91.7 ± 9.1% of control, n = 7 – 8; p > 0.05) and 60d post-SE (93.8 ± 14.2% of
control, n = 8; p > 0.05). However, by 200d post-SE a significant reduction in
GluK4 expression was observed in the DG (63.1 ± 4.8% of control, n = 6 – 9; p <
0.01); Figure 4.1B).The lack of change in GluK4 expression at 5 and 60d timepoints is supported by previous findings in which expression of the GluK4 subunit
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Figure 4.1. Alterations in KAR subunit expression in the dentate
gyrus in animals post-SE. Western blot analysis of microdissected DG from
animals 5d, 60d and 200d post pilocarpine-induced SE. A. Expression of the
GluK2/3 subunit was significantly reduced at all three time-points examined. B.
GluK4 subunit expression was unchanged at 5d and 60d post-SE and
significantly decreased by 200d post-SE. C. GluK5 subunit expression was
initially decreased at 5d post-SE, recovered to baseline by 60d and was
decreased at 200d post-SE. S, sham-treated; P, pilo-treated. n = 6 – 10; **p <
0.01; ***p < 0.001, t-test.
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was unaltered days to weeks following induction of SE (Kamphuis et al., 1995;
Porter et al., 1996).
We observed that the GluK5 subunit is significantly decreased at 5d postSE (69.2 ± 4.2% of control, n = 7; p < 0.01), and recovers to baseline by 60d
(88.9 ± 5.5% of control, n = 7; p > 0.05). However, by 200d post-SE we observed
another significant decrease in expression (74.7 ± 4.5% of control, n = 6 – 10; p
< 0.01; Figure 4.1C). The observed decrease in GluK5 subunit expression within
the DG following induction of SE disagrees with Porter et al. (2006), in which
GluK5 expression was increased in DGCs at 20 days post-SE. This disparity may
be attributed to differences in tissue preparation as Porter et al. (2006) utilized
isolated DGCs and the current study employed microdissected DG which also
contained portions of the supragranular layer and hilar interneurons.
To substantiate the above findings immunohistochemical analysis was
performed on tissue collected from animals 60d post-SE (Figure 4.2). In
agreement with previous studies, we observed that GluK2/3, GluK4 and GluK5
subunit proteins were widely expressed throughout the DG, including robust
labeling throughout the polymorphic layer and hilar interneurons (Wisden and
Seeburg, 1993; Darstein et al., 2003). Of particular interest was the observation
that GluK2/3 labeling within the molecular layer was not uniform, as was
observed for GluK4 and GluK5 subunits. In contrast, GluK2/3 expression
appeared higher in the outer molecular layer, creating a distinct separation
between the inner and outer molecular layers of the DG. In animals 60d postSE, there is a striking decrease in labeling of hilar interneurons for each of the
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Figure 4.2. KAR subunit immunoreactivity in the hippocampus and
DG in animals 60d post-SE. GluK2/3, GluK4 and GluK5 subunits exhibit distinct
hippocampal labeling patterns. A. GluK2/3 expression was significantly reduced
between Ai. sham-treated and Aii. pilocarpine-treated animals 60d post-SE. B.
GluK4 immunoreactivity between Bi. sham-treated and Bii. pilocarpine-treated
animals was unaltered within the DG. C. There was no change in GluK5
immunoreactivity in the DG among Ci. sham-treated and Cii. pilocarpine-treated
animals. ML, molecular layer; IML, inner molecular layer, DGCL, dentate granule
cell layer. Scale bars: A – C, 200 µM; Ai – Cii, 100 µM.
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three subunits, particularly GluK4 labeling which appears nearly absent. In
support of western blot analysis demonstrating a decrease in GluK2/3 and GluK5
expression in the DG, we observed that GluK2/3 and GluK5 labeling was
dramatically reduced throughout the dentate granule cell layer. In addition, we
noted that GluK2/3 labeling throughout the molecular layer appeared more
uniform post-SE. This observation is suggestive of the idea that dendritic
localization of the GluK2/3 subunit is altered post-SE, and may play a role in
mossy fiber sprouting and KAR-mediated neurotransmission.

4.4.2 ALTERATIONS IN KAR SUBUNIT EXPRESSION IN AREA CA3
Hippocampal region CA3 is composed primarily of CA3 pyramidal cells
and stratum lucidum (Figure 1.4). The well characterized mossy fiber – CA3
pathway, the second synapse within the trisynaptic pathway, serves as the
primary means of communication between the DG and area CA3 (Figure 1.2).
This synapse has been referred to as the ‘detonator synapse’ in that input from a
single mossy fiber is sufficient to fire a CA3 pyramidal cell (Urban et al., 2001).
The strength of this mossy fiber input contributes to the highly susceptible nature
of CA3 to epileptogenic activity and the associated excitotoxicity (Nadler et al.,
1978; Lothman et al., 1991; Ben-Ari and Cossart, 2000). The mossy fiber – CA3
pathway was also the first synapse demonstrated to utilize KARs as a means of
regulating excitatory neurotransmission (Castillo et al., 1997; Vignes and
Collingridge, 1997). Immunohistochemical and electrophysiological analysis
further revealed that KARs, likely composed of GluK2, GluK4 and GluK5
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subunits, densely populate area CA3 contributing to transmission on mossy fiber
axons, presynaptic mossy fiber terminals and postsynaptic CA3 pyramidal cells
(for review see, Lerma and Marques, 2013). Given the various avenues in which
area CA3 may be implicated in seizures and the extensive role of KARs within
this region, we explored how pilocarpine-induced SE and the development of
epilepsy altered KAR subunit expression in area CA3.
Similar to findings in the DG, we determined that at 5 days post-SE in area
CA3 there is a significant decrease in GluK2/3 subunit immunoreactivity (57.0 ±
5.6% of control, n = 7 – 8; p < 0.001). This decrease persists at both the 60 day
(56.7 ± 6.3% of control, n = 7 – 8; p < 0.001) and 200 day time points (67.6 ±
7.0% of control, n = 6 – 8; p < 0.01; Figure 4.3A). In contrast to the dramatic
decrease in GluK2/3 expression, the GluK4 subunit remains unaltered at 5 days
post-SE (91.3 ± 10.4% of control, n = 7 – 8; p > 0.05), but is significantly reduced
by 60d (59.4 ± 3.4% of control, n = 7 – 8; p < 0.001) and remains reduced at
200d post-SE (54.0 ± 7.1% of control, n = 6 – 10; p < 0.001; Figure 4.3B). In
agreement, a decrease in GluK4 subunit expression in area CA3 was observed
in a separate seizure model (Porter et al., 1996). Alterations in GluK5 subunit
expression appear almost opposite to those of the GluK4 subunit in that
expression is significantly decreased at 5d post-SE (63.1 ± 5.1% of control, n = 7
– 8; p < 0.001), but returns to baseline by the 60 and 200d time-points (60d: 85.5
± 8.1% of control, n = 8; p > 0.05; 200d: 82.9 ± 7.0% of control, n = 6 – 10; p >
0.05; Figure 4.3C). The overall decrease in KAR subunit expression, particularly
in GluK2/3 and GluK4 subunits, following pilocarpine-induced SE is in agreement
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Figure 4.3. Alterations in KAR subunit expression in area CA3 in
animals post-SE. Western blot analysis of microdissected CA3 from animals 5d,
60d and 200d post pilocarpine-induced SE. A. Expression of the GluK2/3
subunit was significantly reduced at all three time-points examined. B. GluK4
subunit expression was unchanged at 5d post-SE and was significantly reduced
by 60d and 200d post-SE. C. GluK5 subunit expression was initially decreased at
5d post-SE and recovered to baseline by 60d and 200d post-SE. S, shamtreated; P, pilo-treated. n = 6 – 10; **p < 0.01; ***p < 0.001, t-test.
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with a previous finding in which a significant decrease in 3H-kainate binding was
observed in area CA3 following repeated injection of kainate (Tandon et al.,
2002).
The observed decrease in GluK2/3 and GluK4 subunit expression in area
CA3 is supported by immunohistochemical analysis of animals 60d post-SE,
(Figure 4.4). In agreement with previous studies we observed intense labeling
of GluK2/3, GluK4 and GluK5 subunits within CA3 pyramidal cells and stratum
lucidum (Wisden and Seeburg, 1993; Darstein et al., 2003). Labeling of GluK2/3
and GluK5 was also observed in interneurons located in stratum radiatum and to
a lesser degree stratum oriens, with no apparent interneuron labeling by GluK4.
In support of western blot analysis at 60d post-SE, we observed a dramatic
decrease in GluK2/3 and GluK4 labeling within individual CA3 pyramidal cells, as
well as a reduction in labeling throughout stratum lucidum. Expression of the
GluK5 subunit did not appear to change following SE, a finding also in support of
western blot analysis.

4.4.3 ALTERATIONS IN KAR SUBUNIT EXPRESSION IN AREA CA1
Neurotransmission between area CA3 and CA1 via the Schaffer
collaterals serves as the final synapse within the trisynaptic pathway (Figure 1.2).
Epileptogenic activity that initiates in area CA3, or propagates to this area from
the DG, likely spreads to hippocampal area CA1. While KAR subunits are
localized in area CA1, particularly mRNA for the GluK2 and GluK5 subunits, and
to a lesser extent the GluK4 subunit, they are dramatically less abundant than in
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Figure 4.4. KAR subunit immunoreactivity in area CA3 in animals 60d postSE. Distinct KAR subunit labeling in area CA3. A. GluK2/3 subunit expression
was reduced in SP and SL between Ai. sham-treated and Aii. pilocarpine-treated
animals 60d post-SE. B. GluK4 immunoreactivity among Bi. sham-treated and
Bii. pilocarpine-treated animals was noticeably reduced within SP and SL. C. No
alteration in GluK5 immunoreactivity within area CA3 was observed between Ci.
sham-treated and Cii. pilocarpine-treated animals. SR, stratum radiatum; SL,
stratum lucidum; SP, stratum pyramidale; SO, stratum oriens. Scale bars, 100
µM.
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neighboring CA3 and DG (Bahn et al., 1994; Bureau et al., 1999; Paternain et
al., 2000; Darstein et al., 2003; Isaac et al., 2004). KARs have been shown to
regulate excitatory current in CA1 interneurons (Cossart et al., 1998; Frerking et
al., 1998) and as demonstrated by knockout studies, GluK2-containing KARs are
capable of producing inward current in CA1 pyramidal cells (Bureau et al., 1999).
Despite the availability of seemingly functional KARs in CA1, they have not been
shown to contribute to synaptic transmission. However, applied kainate and
synaptically released glutamate have been shown to act on second-messenger
metabotropic KARs to inhibit the slow afterhyperpolarization (AHP) (Melyan et
al., 2002; Melyan et al., 2004). Reduction of the slow AHP increases the ability of
neurons to fire more rapidly and thus can contribute to the propagation of
seizures through area CA1 (Robinson and Deadwyler, 1981; Ashwood et al.,
1986). While distinct from their role in CA3 and DG, KARs localized in CA1 may
contribute to the spread of seizures. We investigated alterations in KAR subunit
expression in area CA1 following pilocarpine-induced SE.
In agreement with the immediate and persistent decrease observed in
area CA3 and the DG, we determined that GluK2/3 subunit expression is
significantly reduced in area CA1 at all three time points explored (5d: 59.8 ±
9.2% of control, n = 8; p < 0.01; 60d: 59.2 ± 4.0% of control, n = 7 – 8; p < 0.01;
200d: 63.4 ± 8.5% of control, n = 7 – 8; p < 0.01; Figure 4.5A). Alterations in
GluK5 subunit expression are similar to those observed in area CA3 in that
expression is significantly decreased at 5d post-SE (52.3 ± 8.8% of control, n = 7
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Figure 4.5. Alterations in KAR subunit expression in area CA1 in
animals post-SE. Western blot analysis of microdissected CA1 from animals 5d,
60d and 200d post pilocarpine-induced SE. A. Expression of the GluK2/3 subunit
was significantly reduced at all three time-points examined. B. GluK5 subunit
expression was initially decreased at 5d post-SE and recovered to baseline by
60d and 200d post-SE. S, sham-treated; P, pilo-treated. n = 6 – 8; **p < 0.01;
***p < 0.0001, t-test.
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– 8; p < 0.001) and then recovers to baseline by 60d (97.3 ± 4.5% of control, n =
6 – 8; p > 0.05) and 200d post-SE (87.2 ± 14.2% of control, n = 7 – 8; p > 0.05;
Figure 4.5B). Western blot analysis utilizing a GluK4 antibody failed to produce a
detectable signal on tissue collected from area CA1.
Immunohistochemical

analysis

of

tissue

collected

60d

post-SE

demonstrated robust labeling of GluK2/3 and GluK5 subunits Figure 4.6. We
observed immunoreactivity of the GluK2/3 subunit throughout area CA1,
including labeling in the somata and dendrites of pyramidal cells, as well as
robust labeling of interneurons throughout stratum radiatum and stratum oriens
(Figure 4.6A). In agreement with mRNA expression, we observed the strongest
immunoreactivity with GluK5 labeling throughout area CA1 (Wisden and
Seeburg, 1993). In addition we observed GluK5 immunoreactivity throughout the
dendrites of CA1 pyramidal cells, extending into stratum radium. GluK5
expression was also noted in interneurons throughout stratum radiatum and
stratum oriens (Figure 4.6C). Our observed expression of GluK2/3 and GluK5
immunoreactivity throughout area CA1, including interneuron labeling, is in
agreement with previous studies (Wisden and Seeburg, 1993; Paternain et al.,
2000; Christensen et al., 2004). In animals 60d post-SE we observed a decrease
in GluK2/3 immunoreactivity in both CA1 pyramidal cells as well as the remaining
interneurons, and no apparent difference in GluK5 immunoreactivity, findings in
support of western blot analysis of CA1 tissue.
It is worthwhile noting that while our GluK4 antibody failed to detect
protein expression in western blots from area CA1, we did observe distinct
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Figure 4.6. KAR subunit immunoreactivity in area CA1 in animals 60d
post-SE. Distinct KAR subunit labeling in area CA1. A. GluK2/3 subunit
expression was dramatically reduced in SP in Ai. sham-treated and Aii.
pilocarpine-treated animals. B. GluK4 immunoreactivity among Bi. sham-treated
and Bii. pilocarpine-treated animals was weak and did not appear to change
post-SE. C. GluK5 immunoreactivity remained unaltered in Ci. sham-treated and
Cii. pilocarpine-treated animals. SO, stratum oriens; SP, stratum pyramidale; SR,
stratum radiatum. Scale bars, 100 µM.
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labeling of CA1 pyramidal cells in immunohistochemical analysis (Figure 4.6B).
In support of our observation, previous studies have also reported the presence
of GluK4 immunoreactivity in area CA1 (Fogarty et al., 2000; Darstein et al.,
2003; Vargas et al., 2013), but also see Wisden and Seeburg (1993). Based on
immunohistochemical observations we did not observe any noticeable alterations
in GluK4 immunoreactivity in area CA1 from animals 60d post-SE. Our ability to
detect GluK4 in immunohistochemical analysis, but not through western blots,
may be due to differences in tissue preparation and handling or antibody
selectivity.

4.4.4

REDUCTION IN

GLUK2/3

SUBUNIT EXPRESSION IS RESTRICTED TO LIMBIC

REGIONS

We observed a significant decrease in GluK2/3 subunit expression in each
of the three hippocampal regions explored- DG, CA3 and CA1. This decrease
was apparent as early as 5 days post-SE and appeared to be permanent, as
data collected from 60d and 200d post-SE also displayed a reduction in GluK2/3
expression. We collected tissue from different brain regions from animals 60
days post-SE to determine if the decrease in GluK2/3 subunit expression was
part of a global reduction. We found that similar to hippocampal tissue, there was
a significant reduction in GluK2/3 expression within the amygdala (68.2 ± 4.1% of
control, n = 6; p < 0.01) and prefrontal cortex (PFC; 48.4 ± 7.4% of control, n = 5
– 7; p < 0.05; Figure 4.7). In contrast, GluK2/3 subunit expression remained
unaltered in tissue collected from striatum (90.0 ± 14.1% of control, n = 8; p >
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Figure 4.7. Reduction in GluK2/3 subunit expression is restricted to
limbic regions. Western blot analysis of microdissected or punched tissue from
sham or pilocarpine-treated animals 60d post-SE. GluK2/3 subunit expression is
significantly reduced within limbic regions including the hippocampus (DG, CA3
and CA1 regions), amygdala and prefrontal cortex. However GluK2/3 expression
was not altered in other brain regions (striatum and cerebellum), demonstrating
the impact of SE on GluK2/3 subunit expression throughout the limbic system.
S,sham-treated; P, pilo-treated Amyg, amygdala; PFC, prefrontal cortex; Cb,
cerebellum. n = 5 – 8; *p < 0.05; **p < 0.01; ***p < 0.0001, t-test.
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0.05) and cerebellum (Cb; 116.3 ± 9.6% of control, n = 8; p > 0.05; Figure 4.7).
These results demonstrate that GluK2/3 expression does not appear to be
global, in that the observed reduction was restricted to structures involved in the
limbic system- hippocampus, cortex and amygdala (Noebles et al., 2012). These
limbic regions are tightly interconnected to memory formation as well as the
emotional response of anxiety (Shin and Liberzon, 2010). The dramatic reduction
in GluK2/3 subunit expression within these regions may be associated to
comorbid conditions of cognitive impairment and increased levels of anxiety
reported by patients (Jacoby and Austin, 2007).

4.4.5 GFAP LABELING IS SIGNIFICANTLY INCREASED IN ANIMALS POST-SE
Many studies of epileptic tissue have explored alterations in neuronal cell
loss and mossy fiber sprouting, while the role of reactive gliosis is fairly limited.
Given that astrocytes are ubiquitously expressed throughout the CNS and play
critical roles in regulating synaptic transmission, alterations in their expression in
the epileptic brain may have dramatic consequences. Studies from both human
and animal models of epilepsy have established that astrogliosis is significantly
increased, even as early as one week post-SE (Babb et al., 1996; SchmidtKastner and Ingvar, 1996; Binder and Steinhauser, 2006; Vargas et al., 2013).
We determined that GFAP labeling of astrocytes was significantly increased in
areas CA1, CA3 and DG at all three time-points examined (Figure 4.8). Within
area CA1 we found a significant increase in GFAP labeling at 5d (206.4 ± 24.1%
of control, n = 8; p < 0.01) 60d (197.9 ± 30.2% of control, n = 7 – 8; p < 0.05) and
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Figure 4.8. GFAP expression is increased in all hippocampal regions
post-SE. Western blot analysis of microdissected A. CA1 B. CA3 and C. dentate
gyrus from animals 5d, 60d and 200d post-SE demonstrate significant increase
in GFAP labeling at all three time-points examined. S, sham-treated; P, pilotreated. n = 6 – 9; *p < 0.05; **p < 0.01, t-test.
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200d post-SE (181.0 ± 23.4% of control, n = 7; p < 0.05; Figure 4.8A). Similarly,
a significant increase was observed in area CA3 at all three points explored (5d:
161.3 ± 10.7% of control, n = 8; p < 0.01; 60d: 134.4 ± 11.8% of control, n = 8; p
< 0.05; 200d: 187.2 ± 20.2% of control, n = 6 – 9; p < 0.05; Figure 4.8B). In
agreement with the observed increases in CA1 and CA3, we saw significant
increases in GFAP labeling throughout the DG at all time-points (5d: 189.7 ±
23.1% of control, n = 6 – 7; p < 0.01; 60d: 133.2 ± 10.0% of control, n = 6 – 7; p <
0.05; 200d: 170.0 ± 15.6% of control, n = 5 – 10; p < 0.05; Figure 4.8C).
Immunohistochemical analysis of GFAP expression is depicted in Figure 1.7).
While the dramatic increase in GFAP labeling throughout the hippocampus as
early as 5d post-SE was shocking, it is in agreement with previous studies and
emphasizes the potential impact that astrogliosis can have on neuronal signaling
in the epileptic brain.

4.5 DISCUSSION
The results of this study provide the first long-term examination of regionspecific changes in hippocampal KARs following pilocarpine induction of SE.
These findings are summarized in Figure 4.9. We determined that as early as 5
days post-SE there is a universal downregulation of the GluK2/3 subunit
throughout the hippocampus. This decrease appears permanent as it was
observed at both 60d and 200d time-points. In contrast to this dramatic reduction
in GluK2/3 expression, the apparent decrease in GluK4 and GluK5 subunit
expression appear more time and region specific. In addition to our findings
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Figure 4.9. Summary of region specific reductions in KAR subunit
expression in animals 5d, 60d and 200d post-SE.

133

regarding alterations in KAR subunit expression, we also observed significant
increases in GFAP labeling of astrocytes as early as 5 days post-SE in all three
hippocampal regions examined. This increase in GFAP was consistently
observed at 5d, 60d and 200d post-SE. Our findings from western blot and
immunohistochemical analysis definitively demonstrate that pilocarpine induced
SE produces significant alterations in KAR subunit expression throughout the
hippocampus and possibly throughout surrounding limbic regions.

4.5.1 EPILEPTOGENESIS

AND

ASSOCIATED

CHANGES

IN

HIPPOCAMPAL

CIRCUITRY

We examined alterations in KAR subunit expression at three distinct timepoints following induction of SE. These points were chosen based on known
alterations

in

hippocampal

circuitry

as

well

as

the

development

of

epileptogenesis following SE. Epileptogenesis refers to the interval between the
occurrence of a brain insult, such as SE, and the development of spontaneously
occurring seizures. It is widely believed that during this ‘latent period’ a host of
changes occur that transform the healthy, non-epileptic brain into one
characterized by recurring seizures (Herman, 2002; Loscher, 2002; Pitkanen,
2002; Stables et al., 2002; Walker et al., 2002; Andre et al., 2007; Pitkanen et al.,
2007; Dichter, 2009b, a; Jacobs et al., 2009; Pitkanen and Lukasiuk, 2009;
Pitkanen, 2010). The process of epileptogenesis has been well documented in
the patient population, with the development of seizures occurring an average of
7.5 years following the precipitating event (French et al., 1993). Several animal
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models, including the pilocarpine model of SE utilized in the current study, have
also been identified as producing periods of epileptogenesis. Following induction
of SE through administration of pilocarpine animals typically experience a seizure
free ‘latent period’ ranging from days to several weeks prior to the development
of spontaneous recurring seizures (Walker et al., 2002; Stables et al., 2003;
Morimoto et al., 2004; Curia et al., 2008).
Following the latent period and the beginning of spontaneous seizures
both human and animal studies demonstrate the appearance of mossy fiber
sprouting, which serves as an anatomical hallmark of epilepsy (Sutula et al.,
1989; Houser et al., 1990; Babb et al., 1991). As described in detail in Chapter
1.7, aberrant mossy fibers synapse within the inner molecular layer of the DG,
creating a new excitatory circuit partially mediated by KARs (Cronin et al., 1992;
Wuarin and Dudek, 1996; Sutula et al., 1998; Epsztein et al., 2005). This well
characterized occurrence can be seen as early as several days post-SE, but
tends to plateau by 2 – 3 months post-SE (Mello et al., 1993; Okazaki et al.,
1995). In addition to mossy fiber sprouting neuronal cell loss and the proliferation
of astrocytes is also evident within the first few weeks to months following SE
(Corsellis and Bruton, 1983; Mathern et al., 1997; Garzillo and Mello, 2002;
Binder and Steinhauser, 2006).
In regards to these dramatic alterations in hippocampal circuitry and
anatomy following SE definitive time-points were examined in the current study.
The 5d post-SE time-point corresponds to a time when animals have recovered
from the precipitating SE insult, but are extremely unlikely to be experiencing

135

spontaneously occurring seizures. In contrast, by 60d post-SE animals have
developed spontaneous seizures, and are likely reaching the height of mossy
fiber sprouting, neuronal cell loss as well as astrocyte proliferation. In addition to
these two distinct time-points we also explored alterations in KAR subunits in
animals 200d post-SE. This point provides an extremely chronic view of epilepsy
and is likely more similar to the human condition than earlier time-points.

4.5.2 REDUCED KAR

SUBUNIT EXPRESSION IN

DG

DESPITE MOSSY FIBER

SPROUTING

Mossy fiber sprouting into the inner molecular layer of the DG has become
an anatomical hallmark of epilepsy in both humans and animal models (Tauck
and Nadler, 1985; Represa et al., 1987; Sutula and Dudek, 2007). Previous
studies, as well as those detailed in Chapter 5, have demonstrated that KARs
mediate a portion of this newly formed excitatory circuit (Epsztein et al., 2005).
Conflicting with these studies is the current observation that KAR subunit
expression is significantly decreased within the DG in animals both 60d and 200d
post-SE. Several factors could contribute to this apparent discrepancy.
In

the

present

study

western

blot

analysis

was

performed

in

microdissected hippocampal tissue. The section of tissue collected for each
region is identified in Figure 2.3. In contrast to areas CA1 and CA3, which
predominately contain pyramidal cell layers, the region collected for DG analysis
also contains a large portion of the supragranular layer as well as area CA4.
Therefore the observed alterations in DG samples may not be reflective of pure
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dentate granule cells. Another possibility is that the observed reduction in KAR
subunits is reflective of extrasynaptic KARs, whereas synaptic KARs, which
contribute to the newly formed mossy fiber synapse, remain intact.
In addition, KAR subunit localization and antibody selectivity could also
contribute to the incongruity between anatomical and electrophysiological
observations.

While

the

GluK2

subunit

is

expressed

throughout

the

hippocampus, GluK3 expression is essentially restricted to the DG (Bureau et al.,
1999; Darstein et al., 2003). The present study utilized an antibody that targeted
both GluK2 and GluK3 KAR subunits. Therefore, while conclusions reached
about GluK2/3 immunoreactivity and expression in area CA1 and CA3 are
reflective of the GluK2 subunit, the presence of GluK3 within the DG complicates
our results. It is possible that our findings actually represent a reduction in GluK2
or GluK3 subunit expression, while the other subunit may actually increase or
remain unaltered. More selective antibodies or analysis of mRNA expression
could be used to determine which low affinity KAR subunit is actually impaired in
animals post-SE.

4.5.3 TEMPORAL ALTERATIONS IN KAR SUBUNIT EXPRESSION WITHIN THE DG
Through western blot analysis we observed distinct alterations in KAR
subunit expression following the induction of SE. These time-sensitive changes
were most apparent within the DG. In this region at 60d post-SE we observed
significant reduction in the expression of the GluK2/3 subunit only. However, by
200d post-SE all three subunits, GluK2/3, GluK4 and GluK5 were significantly
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reduced. By 60d post-SE animals were extremely likely to experience
spontaneous seizures, so the decrease at 200d post-SE was likely not due to
seizure activity. However, it has been suggested that seizure frequency and
severity increases in chronically epileptic animals (Loscher and Brandt, 2010),
which may further impact KAR subunit expression in this region.
Another possible, and more likely, explanation for the delay in KAR
subunit expression may involve the process of neurogenesis, the generation of
new neurons. This process has been well established within the DG as the
appearance of newly formed DGCs persists into adulthood (Eriksson et al., 1998;
Gould et al., 1999; Cameron and McKay, 2001; Kempermann, 2002). It has been
demonstrated that SE significantly increases the number of DGCs by increasing
the process of neurogenesis 5 – 10x following the latent period of SE (Parent et
al., 1997; Gray and Sundstrom, 1998). However by 3 – 4 weeks post-SE the rate
of DGC proliferation returns to baseline (Parent et al., 1997), and by 5 months
post-SE there is a significant reduction in adult dentate granule cell proliferation
believed to be associated with chronic epilepsy (Hattiangady et al., 2004).
Based on these studies we suggest that at 60d post-SE animals likely
experience fairly robust neurogenesis. Porter et al. (2006) determined that GluK2
subunit expression was significantly reduced in newly born DGCs following SE.
In agreement with this study we also observed a reduction in GluK2/3 expression
at 60d post-SE. However, by 200d post-SE the process of neurogenesis in our
animals was likely significantly impaired. Thus the reduction in KAR subunit
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expression could be affected. In addition, the observed reduction could also be
due to fewer DGCs than what is seen at 5 or 60d post-SE.

4.5.4 ASTROCYTE PROLIFERATION IN ANIMALS POST-SE
Astrocytes are star-shaped glial cells that essentially cover the entire
CNS. While not widely discussed, astrocytes are believed to play a prominent
role in synaptic transmission through their release and regulation of active
molecules including glutamate and GABA (Nedergaard et al., 2003; Halassa et
al., 2007; Shigetomi et al., 2008; Perea et al., 2009). The extent of their role has
given rise to the term ‘tripartite synapse’ which proposes that astrocytes play an
essential role in regulating synaptic neurotransmission (Araque et al., 1999;
Halassa et al., 2007; Perea et al., 2009). Both human and animal models of
epilepsy have demonstrated robust increases in astrogliosis (Babb et al., 1996;
Binder and Steinhauser, 2006), even as early as one week post-SE (SchmidtKastner and Ingvar, 1996; Vargas et al., 2013). In agreement with these previous
studies we observed significant increases in GFAP labeling of astrocytes in all
three hippocampal brain regions at all time-points explored.
It should be noted that a recent publication also demonstrated an increase
in GFAP labeling post kainate-induced SE but also reported colocalization of
KAR subunits GluK1, GluK2/3, GluK4 and GluK5 in GFAP-positive astrocytes in
area CA1 (Vargas et al., 2013). In direct contrast, we did not observe any
immunoreactivity in cells resembling astrocytes in any brain region at any of the
three time-points explored. Several factors could contribute to these apparent
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differences. Vargas et al. (2013) utilized the kainate model of SE as well as
enriched astroglial tissue fractions for western blot analysis. The current study
employed the pilocarpine model of SE, thus avoiding direct activation of KARs. In
addition we performed western blot analysis on crude plasma membrane
fractions not enriched with astroglia and were still able to detect dramatic
increases in GFAP labeling in tissue collected from animals post-SE. While our
findings regarding the increase in GFAP labeling are in agreement with previous
findings, we do not have any evidence supporting the notion that KAR
subunitsare colocalized with astrocytes (Vargas et al., 2013).

4.5.5 KAR SUBUNIT EXPRESSION AND COMORBIDITIES
While epilepsy is first and foremost considered a seizure disorder, it is
also accompanied by a variety of comorbidities including alterations in psychiatric
and cognitive functioning. The diagnosis of psychiatric comorbidities is
significantly increased in patients with epilepsy, with nearly 50% of patients
reporting depressive-like symptoms (Jackson and Turkington, 2005). In addition,
patients commonly report impairments in memory, attention and describe a
feeling of general mental slowness (van Rijckevorsel, 2006). Studies examining
the role of hippocampal KARs have begun to elucidate a possible correlation
between KARs and comorbidities associated with epilepsy.
Of note is the recent identification that the GluK4 subunit is likely involved
in regulating anxiety and depressive-like phenotypes (Catches et al., 2012),
however findings from this study do not rule out the likely role of the GluK5
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subunit. The GluK4 subunit has also been linked to response to antidepressant
treatment in patients (Paddock et al., 2007). In addition to the possible correlation
between altered KAR subunit expression and disorders associated with epilepsy,
KARs have also been linked to other severe disorders such as bipolar disorder
and schizophrenia (for review see Lerma and Marques, 2013). Given the role of
KARs in a variety of diseases, the findings of this study suggest that the dramatic
reduction in KAR subunit expression we identified may be implicated in epilepsy
comorbidities. Thus, KARs may serve as potential targets for treatment of these
disorders.

4.5.6 ALTERED KAR

SUBUNIT EXPRESSION AND

CA3

NEUROTRANSMISSION

POST-SE

In the current study we observed significant reductions in both GluK2/3
and GluK4 subunit expression in area CA3 from epileptic animals (60d and 200d
post-SE). Previous studies have demonstrated that the GluK5 subunit contains
several endoplasmic reticulum (ER) retention motifs that block surface
expression unless bound to a GluK1 – 3 subunit, thus promoting the formation of
heteromeric KARs (Gallyas et al., 2003; Ren et al., 2003).

However, recent

findings have demonstrated that agonist binding to the GluK5 subunit was
sufficient to promote heteromeric receptor trafficking (Fisher and Housley, 2013).
In light of these studies we suggest that in epileptic animals there may be fewer
functional KARs, and that the KARs that do remain likely contain GluK2/5
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subunits, a shift from predominately GluK2/4-containing receptors in control
animals. The potential shift from Glu2/4 to GluK2/5-containing KARs would
dramatically impact receptor pharmacology as well as the kinetics of the KARmediated current.

4.6 SIGNIFICANCE
The results of this study demonstrate that pilocarpine-induced SE
produces dramatic alterations in KAR subunit expression in both a region- and
time-specific manner. Hippocampal KARs have been implicated in seizure
disorders as well as comorbidities such as anxiety and depression (Catches et
al., 2012; Lerma and Marques, 2013). The observed alterations in KAR subunit
expression following SE may shed light on the role of individual KAR subunits in
the generation and propagation of seizures as well as observed comorbidities.
We

suggest

that

these

alterations

likely

influence

KAR-mediated

neurotransmission in both the DG and area CA3 following pilocarpine-induced
SE, a topic explored in detail in Chapter 5. Together these results provide further
evidence that healthy and diseased brains are strikingly different and that
understanding these differences may be the key to the development of
therapeutics for treatment of diseases such as epilepsy.
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CHAPTER 5
ALTERATIONS IN KAINATE RECEPTOR MEDIATED NEUROTRANSMISSION AT
THE MOSSY FIBER – CA3 SYNAPSE OF EPILEPTIC ANIMALS
5.1 INTRODUCTION
Kainate receptors (KARs) are ionotropic glutamate receptors that mediate
fast excitatory neurotransmission. Functional KARs are tetramers that can be
composed of a homomeric combination of the low glutamate affinity GluK1 – 3
subunits. The GluK4 and GluK5 subunits have higher glutamate sensitivity and
only form functional receptor complexes when paired with GluK1 – 3 subunits.
KARs are widely distributed throughout the CNS with the strongest expression
noted within the dentate gyrus (DG) and area CA3 of the hippocampus (Wisden
and Seeburg, 1993; Bahn et al., 1994; Darstein et al., 2003).
The role of hippocampal KARs has been most strongly characterized at
the mossy fiber – CA3 synapse. In this region postsynaptic KARs mediate a
small excitatory current with slow decay kinetics, which allows for temporal
summation and serves to enhance the depolarization envelope (Castillo et al.,
1997; Vignes and Collingridge, 1997; Frerking and Ohliger-Frerking, 2002).
These

characteristics

of

postsynaptic

KARs

emphasize

their

potential

contribution to a hyperexcitable network. In contrast to their widespread role in
area CA3, KARs have not been found to contribute to synaptic transmission in
the naïve DG. The lack of KAR-mediated transmission within the DG is also
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noted in area CA1, where despite an abundance of KAR subunits there is no
synaptic contribution (Bureau et al., 1999).
The DG has been identified as the ‘gatekeeper’ of the hippocampus,
acting to restrict excitatory transmission entering area CA3, a region prone to
hyperexcitability and epileptiform activity (Nadler et al., 1978). An anatomical
hallmark of epilepsy is the appearance of sprouted mossy fibers in the inner
molecular layer of the DG (Tauck and Nadler, 1985; Represa et al., 1987; Sutula
and Dudek, 2007). In addition to this axonal rewiring, KARs have been implicated
in mediating a portion of the newly formed excitatory circuit in the epileptic brain
(Epsztein et al., 2005). Most notably, KARs located on these aberrant mossy
fibers have been shown to increase the hyperexcitability and synchronization of
DGCs by altering their intrinsic firing pattern (Artinian et al., 2011). These actions
significantly impair the ability of

the DG to properly gate excitatory

neurotransmission in epilepsy.
These alterations in the ‘gatekeeper’ function of the DG likely impact
transmission and epileptiform activity throughout the other regions of the
hippocampus, most notably, area CA3. In addition, given the dramatic shift in the
role of KARs within the epileptic DG, it is likely that KARs located in area CA3 are
also modified. The goal of this study was to explore these possible alterations in
KAR-mediated neurotransmission at the mossy fiber – CA3 synapse in epileptic
animals. Findings from this study have provided the first in-depth look at the
impact of epilepsy on the function of KARs localized to area CA3 and provide
evidence for their divergent role within hippocampal mossy fibers.
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5.2 HYPOTHESIS
Anatomical data presented in Chapter 4 demonstrated a robust and
significant decrease in both GluK2/3 and GluK4 subunit expression in area CA3
in epileptic animals. Based upon these data we hypothesize that KAR-mediated
neurotransmission in the mossy fiber – CA3 pathway will be reduced in epileptic
animals. Given the significant increase in excitatory drive within the DG, the
observed reduction in KAR-mediated transmission in area CA3 of epileptic
animals may serve as a compensatory modification to limit hyperexcitability and
the generation of epileptiform activity.

5.3 MATERIALS AND METHODS
5.3.1 ANIMAL MODEL OF SE
All animal care and use procedures were carried out in accordance with
protocols written under the guidance of the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and approved by the Institutional Animal
Care and Use Committee at the University of South Carolina. Following induction
of SE, rats were housed 1 per cage with ad libitum access to food and water.
Rats were housed in a climate controlled facility with a light/dark cycle of 12/12
hours.
SE was induced in adult male Sprague-Dawley rats (Harlan, Indianapolis,
IN). Animals received intraperitoneal (i.p.) injections of scopolamine methyl
bromide and terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min later by
pilocarpine hydrochloride (390 mg/kg). After 2 hours of continuous SE, seizures
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were terminated by diazepam (DZP, 25 mg/kg). This group of animals served as
the ‘pilo’ group. A separate group of animals received identical treatment with the
exception of receiving saline (390 mg/kg) instead of pilocarpine hydrochloride.
This group of animals served as the ‘sham’ group. More detailed methods
concerning induction of SE are described in Chapter 2.3.

5.3.2 WHOLE CELL ELECTROPHYSIOLOGY
Transverse (300 µM thick) hippocampal slices were prepared from shamand pilocarpine-treated adult male Sprague-Dawley rats as described in detail in
Chapter 2.6. Briefly, animals were deeply anesthetized with isoflurane and
transcardially perfused with a sucrose-based aCSF. Slices were prepared in ice
cold (4°C) sucrose-based aCSF and incubated in room-temperature oxygenated
(95% O2 / 5% CO2) NaCl-based solution.
Excitatory postsynaptic currents (EPSCs) recorded from dentate granule
cells from animals 169 ± 10 days post-treatment were evoked with a 50 ms puff
of 10 µM domoate applied every 60 seconds through a Pneumatic PicoPump
(PV800, WPI, Sarasota, FL), located approximately 70 µM from the recorded cell.
EPSCs were pharmacologically isolated in an antagonist cocktail containing
bicuculline methochloride (Bic, 15 µM), CGP (1 µM), MK-801 (10 µM) and TTX (1
µM). KAR-mediated currents were isolated using GYKI53655 (50 µM). CNQX
(100 µM) was applied at the end of the experiments to block any residual
glutamatergic transmission. All drugs were purchased from Abcam with the
exception of bicuculline methochloride (Ascent Scientific).

146

5.3.3 FIELD POTENTIAL ELECTROPHYSIOLOGY
Transverse (500 µM thick) hippocampal slices were prepared from shamand pilocarpine-treated adult male Sprague-Dawley rats as described in detail in
Chapter 2.7. Briefly, animals were deeply anesthetized with isoflurane and
transcardially perfused with a sucrose-based aCSF. Slices were prepared in ice
cold (4°C), and then incubated for 30 minutes in heated (37°C) oxygenated (95%
O2 / 5% CO2) sucrose-based aCSF prior to a gradual transition to roomtemperature oxygenated (95% O2 / 5% CO2) NaCl-based solution.
Field EPSPs (fEPSPs) were evoked from animals 157 ± 9 days posttreatment in the DG and area CA3 using two distinct paradigms. 1) Mossy fiber –
CA3 fEPSPs were evoked in the dentate gyrus granule cell layer every 30 sec
and recorded in CA3 stratum lucidum. 2) Recurrent mossy fiber fEPSPs in the
dentate gyrus of epileptic animals were evoked in the inner one-third of the
molecular layer every 60 sec and recorded in the granule cell layer. Figure 2.2
depicts each of the two experimental paradigms utilized, blue and green
electrodes, respectively. fEPSPs were evoked at 50% of the maximal response
determined through an I/O curve. fEPSPs evoked from mossy fibers were
identified based upon their large paired pulse facilitation (PPF) as well as
inhibition by the group II metabotropic glutamate receptor antagonist DCG-IV,
which selectively inhibits mossy fiber-evoked, but not fEPSPs evoked from
stimulation of associational/commissural fibers (Yeckel et al., 1999). In our hands
DCG-IV (1 µM) blocked 91.8 ± 1.2% of the response in sham (n = 6), and 88.9 ±
1.5% in pilo-treated animals (n = 6; Figure 5.1A). In addition, we utilized

147

Figure 5.1. Selective inhibition of fEPSPs. A. DCG-IV (1 µM) inhibited
AMPA-fEPSPs evoked from selective stimulation of the mossy fiber – CA3
pathway in sham (n = 6) and pilo-treated animals (n = 6). Control waveforms
evoked from sham and pilo-treated animals demonstrate large PPF (black
traces) and inhibition by DCG-IV (gray traces). B. UBP310 (3 µM) inhibits KAfEPSPs evoked from stimulation of the mossy fiber – CA3 pathway in both sham
(n = 7) and pilo-treated animals (n = 5). Control waveforms evoked from sham
and pilo-treated animals demonstrate PPF (black traces) and inhibition by
UBP310 (gray traces). ***p < 0.001, t-test.

148

willardine derivative UBP310 to inhibit KAR-mediated transmission (Jane et al.,
2009; Perrais et al., 2009; Pinheiro et al., 2013). We demonstrated that UBP310
(3 µM) blocked 93.9 ± 0.8% of the response in sham-treated animals (n = 7), and
93.0 ± 2.0% in pilo-treated animals (n = 5; Figure 5.1B).
fEPSPs were pharmacologically isolated in an antagonist cocktail
containing bicuculline methochloride (Bic, 20 µM) and MK-801 (10 µM). AMPA
receptors were blocked by application of GYKI53655 (50 µM), and KARs were
blocked by UBP310 (3 µM) or ACET (300nM). Residual transmission was
blocked by application of CNQX (100 µM). All drugs were purchased from Abcam
with the exception of bicuculline methochloride (Ascent Scientific) and ACET
(Tocris bioscience).

5.4 RESULTS
5.4.1 KAR-MEDIATED TRANSMISSION IS INCREASED IN THE DENTATE GYRUS OF
EPILEPTIC ANIMALS

Puff application of the glutamate receptor agonist domoate (10 µM) in the
inner molecular layer of the DG elicited a large current mediated by the
extrasynaptic receptor population. Application of the AMPA receptor (AMPAR)
antagonist GYKI53655 (50 µM) revealed a large KAR-mediated component
(Figure 5.2A). This suggests that functional extrasynaptic KARs are present and
fail to contribute to synaptic neurotransmission, a finding similar to what has been
observed in area CA1 (Bureau et al., 1999).

KARs have been shown to

contribute to the excitatory circuit formed by the aberrant sprouting of mossy
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Figure 5.2. KARs mediate transmission in dentate granule cells from
epileptic animals. A. EPSCKA amplitude is significantly increased in pilo-treated
animals following puff application of domoate (10 µM) on dentate granule cells (n
= 6). No change in the EPSCAMPA amplitude between sham and pilo-treated
animals was observed (n = 6). Waveforms evoked by domoate in sham (black
traces) and pilo-treated animals (gray traces) demonstrate an increase in
ESPCKA but not EPSCAMPA. B. Stimulation of recurrent mossy fibers elicits a
KAR-mediated fEPSP in pilo-treated animals (n = 5). No change in the
fEPSPAMPA amplitude was observed between sham and pilo-treated animals (n =
5 – 6). Waveforms evoked by stimulation of the inner molecular layer
demonstrate the appearance of a fEPSPKA in pilo-treated animals (gray traces),
and no change in the amplitude of the fEPSPAMPA. C. The KA:AMPA amplitude
ratio is significantly increased in pilo-treated animals due to the appearance of a
KAR-mediated response (n = 5 – 6). **p < 0.01; ***p < 0.001, t-test.
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fibers into the inner molecular layer of the DG in epileptic animals (Epsztein et
al., 2005). Therefore we explored the effects of 10 µM domoate on DGCs from
pilo-treated animals. We determined that the amplitude of the current was
significantly increased following application of 10µM domoate (169.7 ± 16.3% of
control, n = 6; p < 0.01; Figure 5.2A), while the EPSCAMPA was unaltered (108.3 ±
16.4% of control, n = 6; p > 0.05; Figure 5.2A). These findings were further
explored using field potential electrophysiology.
fEPSPs were elicited with a stimulating electrode placed in the inner
molecular layer of the DG with the recording electrode placed within the granule
cell layer (Figure 2.2, green electrodes). In sham-treated animals we evoked a
large fEPSP that was completely inhibited by GYKI53655, a finding in agreement
with previous observations demonstrating a lack of synaptic KAR-mediated
transmission in the DG. However, in epileptic animals we observed a GYKIresistant component that was sensitive to the KAR antagonist UBP310 (3 µM),
demonstrating the appearance of KAR-regulated synaptic transmission in the DG
of pilo-treated animals (740.8 ± 107.3% of control, n = 5; p < 0.001; Figure 5.2B).
Furthermore, we determined that transmission mediated by AMPARs was
unaltered (127.3 ± 15.2% of control, n = 5 – 6; p > 0.05; Figure 5.2B),
demonstrating a selective increase in KAR-mediated transmission. In agreement
the KA:AMPA amplitude ratio was significantly increased in pilo-treated animals
(sham: 0.006 ± .0001, n = 5; pilo: 0.04 ± 0.007, n = 6; p < 0.01; Figure 5.2C).
Input-output (I/O) curves were conducted to examine the impact of
stimulation intensity on the observed increase in KAR-mediated transmission.
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The fEPSPKA amplitude increased with stimulation strength in pilo-, but not shamtreated animals (n = 3 – 6, Figure 5.3A). At maximal stimulation strength the
fEPSPKA evoked from pilo-treated animals was significantly greater than that
from sham-treated animals (sham: 31.1 ± 11.5 µV; pilo: 136.4 ± 28.8 µV, n = 3 –
5; p < 0.05; Figure 5.3A). In agreement with our observation that the increase in
KAR-mediated transmission is a selective modification, no difference in the
amplitude of the fEPSPAMPA was observed over many stimulus intensities, even
at the highest intensity (sham: 187.6 ± 84.3 µV; pilo: 237.2 ± 56.2 µV, n = 3 – 5, p
> 0.05; Figure 5.3B). These findings are in agreement with observations by
Epsztein et al. (2005) demonstrating the appearance of a KAR-mediated
response in the inner molecular layer of the DG in epileptic animals.

5.4.2 SYNAPTIC INTEGRATION IS IMPAIRED IN THE DENTATE GYRUS OF EPILEPTIC
ANIMALS

As fast synaptic transmission enters the DG it must be synaptically
integrated by the intrinsically sparse firing DGCs, a process that serves to limit
transmission (Jung and McNaughton, 1993; Schmidt-Hieber et al., 2007). In
epilepsy, the KARs located on aberrant mossy fibers create a shift in the firing
properties of DGCs from sparse firing to sustained, rhythmic firing thus
increasing the window for synaptic integration and increasing hyperexcitability
(Artinian et al., 2011). We examined the contribution of AMPA and KA-receptor
mediated transmission at varying frequency intensities in pilo-treated animals.
We determined that in pilo-treated animals there was a significant increase in the
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Figure 5.3. I/O curves of fEPSPs in the dentate gyrus demonstrate
the appearance of KAR-mediated transmission in epileptic animals. A. At
stimulus intensities of 50µA and above a KAR-mediated fEPSP is apparent in
pilo-treated animals (closed gray squares, n = 5 – 6) but not sham-treated
animals (open circles, n = 3 – 5). Representative waveforms from sham-treated
(black traces) illustrate the lack of a fEPSPKA in sham-treated animals, and the
development of a fEPSPKA in pilo-treated animals (gray traces). B. The amplitude
of the fEPSPAMPA evoked from pilo-treated animals (closed gray squares, n = 5 –
6) is not significantly different that the fEPSPAMPA evoked from sham-treated
animals (open circles, n = 3 – 5) at any of the stimulus intensities examined.
Representative waveforms from sham-treated (black traces) and pilo-treated
(gray traces) are not different at two different stimulus intensities. *p < 0.05; **p <
0.01, t-test.
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area of the fEPSPAMPA/KA at all frequencies explored (Figure 5.4A) representative
of an increase in synaptic integration. In addition, the area of the fEPSP AMPA/KA
induced by higher frequencies (10 – 100 Hz) was significantly greater than the
area of very low (0.017 Hz) stimuli. We specifically examined a 5 pulse, 50 Hz
train, which increased the total MF-evoked area in pilo-treated animals (sham:
26.5 ± 3.9 mV/ms, n = 5; pilo: 60.4 ± 7.1 mV/ms, n = 5; p < 0.01; Figure 5.4B).
We further explored the isolated fEPSPKA and fEPSPAMPA in response to a 50 Hz
train and determined that the increase in area was due solely to the appearance
of a KAR-mediated component (pilo: 20.4 ± 4.6 mV/ms, n = 5; Figure 5.4C) as
the area of the isolated AMPAR-mediated train was unaltered (sham: 26.2 ± 2.8
mV/ms; pilo: 28.6 ± 3.1 mV/ms, n = 5; p > 0.05; Figure 5.4C).
To further exemplify the appearance of a KAR-mediated response in pilotreated animals we used the same 5 pulse, 50 Hz train to elicit a substantial
KAR-mediated component and examined inhibition produced by the KAR
antagonist UBP310 (Pinheiro et al., 2013). We determined that 3 µM UBP310
significantly inhibited the response in pilo-treated (32.2 ± 8.9% of control, n = 4; p
< 0.01; Figure 5.5), but not sham-treated animals (91.9 ± 6.8% of control, n = 4; p
> 0.05; Figure 5.5). These findings were in agreement with Pinheiro et al. (2013)
in which UBP310 significantly blocked EPSCKA elicited in dentate granule cells at
recurrent mossy fiber synapses in epileptic animals. We also explored the ability
of a different KAR antagonist, ACET, to block the KAR-mediated response in
pilo-treated animals. Our initial data suggested that ACET (300 nM) blocks the
response to a similar degree to that of UBP310 (26.8 ± 0.8% of
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Figure 5.4. Synaptic integration is impaired in the dentate gyrus of
epileptic animals. Trains were evoked by stimulation of the inner molecular
layer of the dentate gyrus. A. The area of the fEPSPAMPA/KA was significantly
increased at all frequencies examined in pilo-treated animals (n = 5 – 7). The
area evoked by higher frequencies (10 – 100 Hz) was significantly increased
relative to the lowest frequency examined. B. The fEPSPAMPA/KA area of a 5
pulse, 50 Hz train was significantly increased in pilo-treated animals (n = 5).
Representative waveform demonstrates the increased area and decay of the
fESPSAMPA/KA in sham (black trace) and pilo-treated animals (gray trace). C. Area
of the fEPSPAMPA is not different between sham and pilo-treated animals (n = 5).
There is the appearance of a KAR-mediated fEPSP in pilo-treated animals (n =
5). Waveforms illustrate no change in the fEPSPAMPA in sham (black trace) and
pilo-treated animals (gray trace) and the appearance of a fEPSPKA in pilo-treated
animals (gray trace). *p < 0.05; **p < 0.01; ***p < 0.001, t-test.
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Figure 5.5. UBP310 inhibits KAR-mediated transmission at recurrent
mossy fiber synapses. The selective KAR antagonist UBP310 is ineffective in
sham-treated animals (n = 4), but significantly inhibits fEPSPs evoked from the
recurrent mossy fibers of pilo-treated animals (n = 4). This demonstrates the
appearance of a KAR-mediated response in the dentate gyrus of pilo-treated
animals. Representative waveforms illustrate the lack of inhibition by UBP (gray
traces) on control responses (black traces) in sham-treated animals, and the
significant reduction in the fEPSP in pilo-treated animals. **p < 0.01; ##p < 0.01 ttest.

156

control, n = 2, p = 0.08, data not shown). These data further demonstrate that a
UBP310-sensitive KAR-mediated response appears within the inner molecular
layer of pilo-treated animals and contributes to the excitatory circuit. In addition,
we demonstrated that this new KAR component significantly contributes to both
high and low frequency transmission, which likely contributes to hyperexcitability
and the generation of epileptiform activity within the DG.

5.4.3 KAR-MEDIATED TRANSMISSION AT THE MOSSY FIBER – CA3 SYNAPSE IS
SIGNIFICANTLY REDUCED IN EPILEPTIC ANIMALS

Mossy fiber – CA3 fEPSPs were elicited with a stimulating electrode
placed along the hilar border of the dentate granule cell layer with the recording
electrode placed within CA3 stratum lucidum (Figure 2.2, blue electrodes). In
direct contrast to the increase in KAR-mediated transmission observed in the
DG, we observed that the fEPSPKA was significantly reduced in pilo-treated
animals (48.9 ± 5.0% of control, n = 7 – 8; p < 0.001; Figure 5.6A). This dramatic
decrease in KAR-mediated transmission is selective, in that the fEPSPAMPA was
not different in pilo-treated animals (98.3 ± 20.2% of control, n = 5 – 9; p > 0.05;
Figure 5.6A). In support of these findings, we observed that the KA:AMPA
amplitude ratio was significantly reduced (sham: 0.274 ± 0.026, n = 4; pilo: 0.146
± 0.02, n = 5; p < 0.01; Figure 5.6B), as well as the KA:AMPA area ratio (sham:
6.63 ± 0.86, n = 3; pilo: 1.71 ± 0.61, n = 5; p < 0.01; Figure 5.6C). I/O curves at
stimulus intensities from 10 – 400 µA were performed on isolated KA- and
AMPA-receptor mediated responses. We observed a significant difference in the
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Figure 5.6. KAR-mediated transmission is significantly reduced in
the mossy fiber – CA3 pathway of epileptic animals. A. The amplitude of the
mossy fiber evoked KAR-mediated fEPSP is significantly reduced in pilo-treated
animals (n = 7 – 8). No change in the AMPAR-mediated fEPSP was observed
between sham and pilo-treated animals (n = 5 – 9). Waveforms evoked by
stimulation of the mossy fiber pathway demonstrate the reduction in fEPSP KA
amplitude in sham (black traces) and pilo-treated animals (gray traces), with no
apparent change in fEPSPAMPA amplitude. B. The KA:AMPA amplitude ratio is
significantly reduced in pilo-treated animals due to the decrease of a KARmediated response (n = 4 – 5). C. The KA:AMPA area ratio is also significantly
reduced in pilo-treated animals (n = 3 – 5). **p < 0.01; ***p < 0.001, t-test.
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amplitude of the fEPSPKA between sham and pilo-treated animals at stimulus
intensities of 70 µA and above (Figure 5.7A). At maximal stimulation the fEPSPKA
evoked from pilo-treated animals was significantly smaller than that of shamtreated animals (sham: 177.8 ± 33.2% of control, n = 3; pilo: 59.6 ± 10.2% of
control, n = 4; p < 0.05; Figure 5.7A). In support of the selective alteration in
KAR-mediated transmission we did not observe any difference in the amplitude
of the fEPSPAMPA at any stimulus intensity (Figure 5.7B). These findings
demonstrate that there is a downregulation in excitatory neurotransmission
mediated by KARs, but not AMPARs. These findings are supported by the
anatomical data collected in Chapter 4 demonstrating a significant reduction in
GluK2/3 and GluK4 subunit expression in area CA3 of animals 60 and 200d postSE, Figure 4.3 – 4.4).

5.4.4 SYNAPTIC INTEGRATION AT THE MOSSY FIBER – CA3 SYNAPSE OF
EPILEPTIC ANIMALS IS IMPAIRED

The ability of CA3 pyramidal cells to properly integrate information
stemming from the DG and synapsing via the mossy fiber pathway is believed to
be an integral step in the process of encoding and retrieving episodic memory
(Herrmann et al., 2004; Bartos et al., 2007). In addition higher frequency, gamma
oscillations have been demonstrated to be necessary for induction of long-term
potentiation (LTP), a synaptic correlate of learning (Rosenzweig et al., 1997;
Traub et al., 1998). Given the significant decrease in KAR-mediated
neurotransmission in area CA3 in pilo-treated animals we explored synaptic
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Figure 5.7. I/O curves of mossy fiber evoked fEPSPs demonstrate a
selective decrease in KAR-mediated transmission. A. The amplitude of the
fEPSPKA evoked from pilo-treated animals (closed gray squares, n = 4 – 6) is
significantly reduced compared to the fEPSPKA evoked from sham-treated
animals (open circles, n = 3 – 6) at stimulus intensities of 70 – 400 µA.
Representative waveforms from sham-treated (black traces) and pilo-treated
(gray traces) demonstrate the reduced potentiation of fEPSPKA at two different
stimulus intensities. B. The amplitude of the fEPSPAMPA evoked from pilo-treated
animals (closed gray squares, n = 3 – 5) is not significantly different that the
fEPSPAMPA evoked from sham-treated animals (open circles, n = 4 – 10) at any of
the stimulus intensities examined. Representative waveforms from sham-treated
(black traces) and pilo-treated (gray traces) are not different at two different
stimulus intensities. *p < 0.05; **p < 0.01, t-test.
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integration at several different frequencies within the mossy fiber – CA3 pathway
(Figure 5.8A). We determined that at lower frequencies (0.03 – 10 Hz) there was
no difference in area of fEPSPAMPA/KA. However at higher frequencies, closer to
that of gamma frequency (30 – 100 Hz), there was a significant decrease in the
fEPSPAMPA/KA, indicative of a reduction in signal integration within the mossy fiber
– CA3 pathway in pilo-treated animals. Similar to data collected from the DG, we
examined a 5 pulse, 50 Hz train and concluded that the area of the train was
significantly reduced in pilo-treated animals (sham: 56.8 ± 6.2% of control, n = 8;
pilo: 27.6 ± 5.0% of control, n = 5; p < 0.01; Figure 5.8B). As anticipated we
discovered that this decrease was attributed to the selective reduction in the
fEPSPKA (sham: 35.7 ± 4.3 mV/ms, n = 7; pilo: 18.6 ± 3.1 mV/ms, n = 6; p < 0.01;
Figure 5.8C) as the fEPSPAMPA remained unaltered (sham: 10.9 ± 2.0 mV/ms, n =
5; pilo: 11.1 ± 2.1 mV/ms, n = 5; p > 0.05; Figure 5.8C).
We examined the ability of the KAR antagonist UBP310 to inhibit the
fEPSPAMPA/KA induced by a 5 pulse, 50 Hz train stimuli. Given the large KARmediated component at the mossy fiber – CA3 synapse in sham-treated animals,
we observed a significant inhibition following application of 3 µM UBP (33.5 ±
6.6% of control, n = 5; p < 0.01; Figure 5.9), a finding in agreement with a
previous study demonstrating inhibition of postsynaptic KARs at mossy fiber –
CA3 synapses (Pinheiro et al., 2013).Given the significant reduction in KARmediated transmission in pilo-treated animals we anticipated that UBP310 (3µM)
would produce less inhibition of the fEPSPAMPA/KA. We found that UBP310 still
blocked a significant portion of fEPSP AMPA/KA in pilo-treated animals (60.3 ± 3.8%
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Figure 5.8. Frequency dependent alterations in synaptic integration
at the mossy fiber – CA3 synapse of epileptic animals. Trains were evoked
by stimulation of the mossy fiber – CA3 pathway. A. Frequency-dependent
alterations in KAR-mediated transmission were observed in the mossy fiber –
CA3 pathway (n = 4 – 8). Significant reduction in the area fEPSPAMPA/KA was
observed in pilo-treated animals at higher frequencies (30 – 100 Hz). B. The
fEPSPAMPA/KA area of a 5 pulse, 50 Hz train was significantly reduced in pilotreated animals. Representative waveform demonstrates the decrease in area
and decay of the fEPSPAMPA/KA in sham (black trace) and pilo-treated animals
(gray trace). C. Area of the fEPSPAMPA is not different between sham and pilotreated animals (n = 5). There is a significant decrease in the fEPSPKA in pilotreated animals (n = 6 – 7). Waveforms illustrate the lack of change in the
fEPSPAMPA in sham (black trace) and pilo-treated animals (gray trace) and the
significant decrease in the area fEPSPKA in pilo-treated (gray trace) relative to
sham-treated animals (back trace). *p < 0.05; **p < 0.01, t-test.
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Figure 5.9. UBP310 inhibits KAR-mediated transmission at mossy
fiber – CA3 synapses in sham and epileptic animals. The selective KAR
antagonist UBP310 significantly inhibits fEPSPs evoked by stimulation of the
mossy fiber – CA3 pathway in sham (n = 5) and pilo-treated animals (n = 4).
There was a trend towards a significant reduction in UBP310 inhibition in pilocompared to sham-treated animals (p = 0.087). Representative waveforms
illustrate the inhibition produced by UBP310 (gray traces) compared to control
traces (black traces) in both sham and pilo-treated animals. *p < 0.05; **p < 0.01,
t-test.
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of control, n = 4, p < 0.05; Figure 5.9). While not significant, we did observe a
trend towards the reduced inhibition by UBP310 in pilo- vs. sham-treated animals
(p = 0.087).

Similar to the actions of UBP310, we observed a significant

inhibition by ACET (300nM) on the fEPSPAMPA/KA in both sham (27.2 ± 6.6% of
control, n = 4; p < 0.05) and pilo-treated animals (28.3 ± 2.9% of control, n = 3; p
< 0.05; data not shown). Together these data demonstrate that KAR-mediated
transmission within the mossy fiber – CA3 pathway is significantly reduced in
pilo-treated animals. This finding is in direct opposition to the observed increase
in KAR-mediated transmission within the DG. We suggest that this decrease may
serve as a compensatory mechanism to limit hippocampal excitability and the
development of seizures within the highly epileptogenic CA3 region.

5.4.5 PAIRED PULSE FACILITATION IS NOT ALTERED IN EPILEPTIC ANIMALS
A prominent feature of the mossy fiber – CA3 synapse is extremely large
PPF (Henze et al., 2000), thought to be mediated in part by KARs (Kamiya et al.,
2002). We explored whether PPF at the mossy fiber – CA3 synapse is altered in
pilo-treated animals. We determined in sham-treated animals that the pairedpulse ratio (PPR) at 50 ms was significantly increased in both isolated AMPA (1.7
± 0.1, n = 8; p < 0.001), and KA-receptor mediated fEPSPs (1.2 ± 0.1, n = 8; p <
0.05; Figure 5.10A). In addition the PPR mediated by the KAR was significantly
lower than that of the AMPAR (p < 0.01). These findings are supported by
previous studies and have been demonstrated to hold true for a variety of
stimulus intervals, demonstrating that during paired stimuli KARs exhibit less
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Figure 5.10. Paired pulse facilitation is not altered epileptic animals.
Alterations in the paired pulse ratio at an interval of 50 ms were examined at the
mossy fiber – CA3 synapse (A. and B.) and in the dentate of sham and pilotreated animals (C.). A. In sham-treated animals the fEPSPKA (n = 8) and the
fEPSPAMPA (n = 8) PPR50 were significantly increased. The ratio of the
fEPSPAMPA was significantly greater than that observed for the fEPSP KA.
Representative waveforms illustrate PPF mediated by KA and AMPA-receptors.
B. Relative to sham-treated animals there was no difference in the PPR50 for
fEPSPKA (n = 5) or fEPSPAMPA (n = 5) elicited from pilo-treated animals.
Representative waveforms demonstrate similar levels of PPF in pilo-treated
animals to what was observed in sham-treated animals. C. The fEPSPAMPA
PPR50 was not significantly different in sham (n = 5) or pilo-treated animals (n =
6). Representative waveforms illustrate the lack of PPF or PPD observed within
the dentate of sham- and pilo-treated animals. *p < 0.05; ***p < 0.001; ##p < 0.01,
t-test.
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facilitation than AMPARs at the mossy fiber synapse (Contractor et al., 2001; Ito
et al., 2004). In pilo-treated animals we observed that the PPR for fEPSPKA and
fEPSPAMPA were not different than those noted in sham-treated animals (KA: 98.5
± 11.0% of sham, n = 5; p > 0.05; AMPA: 112.5 ± 13.4% of sham, n = 5; p >
0.05; Figure 5.10B). We also explored the ability of UBP310 (3 µM) to alter PPF.
In agreement with Perrais et al. (2009), UBP310 had no effect on the PPF in
either sham-treated (97.1 ± 3.7, n = 7; p > 0.05) or pilo-treated animals (89.6 ±
68% of control, n = 5; p > 0.05), suggesting that presynaptic KARs are composed
of the UBP310-insensitive heteromeric GluK2/3, or homomeric GluK2- subunit
combination. Together these data demonstrate that the relative contribution of
AMPARs and KARs to the presynaptic regulation of PPF is not altered in
epilepsy. It should be noted that this observation is in contrast to the report that
the PPR of the fEPSPAMPA/KA at the mossy fiber synapse is significantly reduced
in kainate-treated animals several weeks post-SE (Goussakov et al., 2000).
Unlike the distinct PPF observed at the mossy fiber – CA3 synapse,
stimulation of the perforant path input in the DG is not as well-defined. A general
consensus reveals that stimulation of the lateral perforant path input results in
PPF, while stimulation of the medial perforant path produces paired-pulse
depression (PPD) (McNaughton, 1980; Christie and Abraham, 1992b, a; Colino
and Malenka, 1993; Froc et al., 2003). However, these findings have been widely
scrutinized and in general it is believed that simply relying on observed PPF or
PPD is not sufficient to demonstrate proper stimulation of the lateral or medial
perforant path (Petersen et al., 2013). We briefly examined whether the PPR of
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fEPSPAMPA was altered in the DG of epileptic animals and determined that the
PPR at a 50 ms interval was unaltered in sham-treated (0.9 ± 0.05, n = 5, p >
0.05) and pilo-treated animals (0.91 ± 0.06, n = 6, p > 0.05; Figure 5.10C).

5.5 DISCUSSION
The results of this study provide the first examination of specific alterations
in KAR-mediated neurotransmission in area CA3 of epileptic animals. Despite the
abundance of KARs in this region and the significant role they play in both preand postsynaptic regulation of neurotransmission there are no reports exploring
their function in epilepsy. In agreement with previous studies in the DG of
epileptic animals we observed the appearance of a KAR-mediated response
(Epsztein et al., 2005). In direct contrast to this increase within the DG, we
observed for the first time, a significant reduction in KAR-mediated transmission
in area CA3 in pilo-treated animals. We believe that these effects are limited to
KARs located on postsynaptic CA3 pyramidal cells, as we did not observe any
difference in presynaptic regulation of PPF. The results of this study suggest that
the observed reduction in KAR-mediated transmission in area CA3 may serve as
a compensatory modification in response to the significant increase in
synchronization and excitatory transmission observed in the DG of epileptic
animals. Figure 5.11 summarizes the principal finding of this study, the reduction
in KAR-mediated transmission at the mossy fiber – CA3 synapse.
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Figure 5.11. Summary of findings detailed in Chapter 5. Epilepsy differentially
alters KARs at two synapses of the same axon. In epileptic animals aberrant
mossy fiber sprouting (light blue), is associated with an appearance in KARmediated transmission. In contrast, transmission mediated by KARs at the
mossy fiber – CA3 synapse is significantly reduced. Sham fEPSPKA: black traces;
Pilo fEPSPKA: gray traces.
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5.5.1 KAR-MEDIATED TRANSMISSION IS REDUCED AT THE MOSSY FIBER – CA3
SYNAPSE

In pilo-treated animals we observed a selective reduction in the mossy
fiber evoked fEPSPKA, as the fEPSPAMPA remained unaltered. In agreement, we
observed significant reduction in the fEPSPKA of epileptic animals over several
different stimulus intensities while the fEPSPAMPA was not changed. This finding
clearly demonstrates that KAR-, but not AMPAR-mediated transmission, is
significantly reduced in epilepsy. These data are in contrast to the report by
Goussakov et al. (2000) in which the mossy fiber evoked fEPSP was increased
in the kainate model of SE. The discrepancy between these studies is likely
attributed to several factors. The most likely rationale is the age of the animals
and their epileptic background. The current study utilized animals considered to
be chronically epileptic (189 ± 9 days post-SE), while Goussakov et al. (2000)
examined alterations in animals only several weeks post-SE. It is widely noted
that while anatomical alterations and neuronal rewiring can occur within days
following SE, many of these changes do not plateau until many months after the
event (Loscher and Brandt, 2010). Thus it is likely that the current study and that
conducted by Goussakov et al. (2000) examined different hippocampal networks.

5.5.2 POTENTIAL ALTERATIONS IN HIPPOCAMPAL KAR SUBUNIT COMBINATION
An underlying goal of this study was to determine if the KAR subunit
composition at postsynaptic CA3 cells was altered in the epileptic brain. This type
of alteration could have a dramatic impact on receptor agonist affinity,
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biophysical properties of the receptor, and the development of potential
therapeutics. Given the lack of subunit selective KAR antagonists we attempted
to use UBP310 and ACET to determine if KAR subunit composition was altered
in area CA3 of epileptic animals.
The willardine-derivative UBP310 has been identified as a potent
antagonist at homomeric GluK3 and heteromeric GluK2/5-containing KARs
(Perrais et al., 2009; Pinheiro et al., 2013). Furthermore, this compound was
shown to be ineffective at blocking homomeric GluK2-containing KARs and
heteromeric GluK2/3-containing KARs (Perrais et al., 2009). We observed rapid
and robust inhibition of KAR-mediated transmission in area CA3 from both sham
and pilo-treated animals following application with UBP310. Furthermore,
UBP310 did not affect presynaptically regulated PPF. In agreement with previous
studies, these data suggest that presynaptic KARs are likely composed of
homomeric GluK2-containing KARs and/or heteromeric GluK2/3-containing
KARs, as UBP310 failed to inhibit the response (Perrais et al., 2009; Pinheiro et
al., 2013).
In regards to postsynaptic KARs, the observed inhibition by UBP310
suggests they contain GluK2/5 subunits (Pinheiro et al., 2013). However, the
ability of UBP310 to inhibit GluK2/4-containing KARs has not been explored, and
thus it is quite possible that KARs localized to postsynaptic CA3 cells may
contain an abundance of GluK2/4-contaning receptors. In addition, anatomical
data from Chapter 4 demonstrated a significant reduction in GluK2/3 and GluK4
subunits, suggesting that residual KARs in area CA3 may be composed of
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GluK2/5 subunits. In an attempt to elucidate this possibility we utilized the KAR
antagonist ACET. While ACET was initially developed as a GluK1 antagonist
(Dolman et al., 2007; Dargan et al., 2009), preliminary data from our lab has
suggested that it may selectively inhibit GluK2/4-containing KARs. However, we
observed similar inhibition by ACET in both sham and pilo-treated animals. This
finding could demonstrate a lack of ACET selectivity, or demonstrate that the
KAR subunit composition on the membrane surface is not altered in area CA3 of
pilo-treated animals. Given the differences that the GluK4 and GluK5 subunits
bestow upon the receptor, having a clear understanding of their expression is
essential. However, this lies within our ability to develop subunit-selective KAR
antagonists which as of yet has proved quite challenging.

5.5.3 ALTERATIONS IN PRESYNAPTIC KAR-MEDIATED TRANSMISSION AT THE
MOSSY FIBER – CA3 SYNAPSE

In addition to their postsynaptic localization KARs are also located on
presynaptic mossy fiber terminals where they have been shown to regulate
several forms of both short-term and long-term synaptic plasticity (Nicoll and
Malenka, 1995; Salin et al., 1996). Synaptically released glutamate can activate
these presynaptic KARs to facilitate or depress glutamate release and have also
been shown to be integral in the induction of mossy fiber LTP (Bortolotto et al.,
1999; Contractor et al., 2001; Lauri et al., 2001; Schmitz et al., 2001a; Schmitz et
al., 2003; Pinheiro et al., 2007; Scott et al., 2008). In the current study we
examined possible alterations in the presynaptic regulation of PPF at the mossy
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fiber – CA3 synapse and did not observe any difference in pilo-treated animals,
thus attributing the observed decrease in KAR-mediated transmission to
postsynaptic modifications. In contrast to this finding, Goussakov et al. (2000)
reported a decrease in PPF at the mossy fiber – CA3 pathway from kainate
treated animals. As previously discussed this discrepancy is likely due to the
substantial difference in the length in which epilepsy progressed following
induction of SE, weeks vs. months.
Previous studies have demonstrated that differential alterations in
presynaptically regulated processes such as PPF and frequency facilitation can
be observed (Contractor et al., 2001; Fernandes et al., 2009). These
observations led to the suggestion that two populations of presynaptic KARs may
exist; those that mediate a single release event, and those responsible for
mediating low frequency stimulations (Fernandes et al., 2009). While data
collected in the current study as well as anatomical data presented in Chapter 4
are supportive of a postsynaptic alteration in KAR function, the possibility that
other presynaptically mediated processes, such as frequency facilitation or even
mossy fiber LTP, may be altered cannot be completely excluded.

5.5.4 IMPACT OF COMPROMISED DENTATE GYRUS ‘GATEKEEPER’ FUNCTION
The concept that the DG may serve as a gate to limit or filter transmission
into the hippocampus was first established in the 1960s (Andersen et al., 1966).
This role was re-examined following the observation that in both patients and
animal models of SE there is abnormal sprouting of mossy fibers into the DG
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which creates an excitatory network (Tauck and Nadler, 1985; Represa et al.,
1987;

Sutula

and

Dudek,

2007).

In

addition

to

regulating

excitatory

neurotransmission mossy fibers, including those sprouted into the DG, release
extremely high levels of synaptically sequestered zinc (Perez-Clausell and
Danscher, 1985). This release of zinc has been found to accelerate and increase
epileptiform bursting within the DG (Timofeeva and Nadler, 2006). More recently
it was demonstrated that KARs located on sprouted mossy fibers contribute to
regulation of glutamatergic activity and actually alter the intrinsic firing properties
of dentate granule cells (Epsztein et al., 2005; Artinian et al., 2011). The switch
from the normal sparse firing to more sustained activity significantly increases the
synchronization of dentate granule cells and reduces their ability to properly
integrate transmission entering from the entorhinal cortex (Artinian et al., 2011).
In agreement with these reports the data in the current study revealed an
increase in KAR-mediated transmission with the DG and subsequent impairment
of synaptic integration, as demonstrated by a significant increase in the area of
the fEPSPKA at varying frequencies. This well-established increase in excitatory
transmission within the DG could have huge consequences for the generation of
epileptiform activity in area CA3. We suggest that the observed decrease in
KAR-mediated transmission in area CA3 may serve as a compensatory
mechanism to limit the impact of synchronous activity in the DG. Of particular
note in this study is the observation that on two different synapses of the same
axon we have observed opposite alterations of the same receptor population.
Aberrant mossy fibers synapsing into the inner molecular layer of the DG exhibit
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increased KAR-mediated transmission, while mossy fibers synapsing into area
CA3 exhibit decreased KAR-mediated transmission. A similar finding has not
been observed in other synapses or brain regions, adding to the uniqueness of
hippocampal mossy fibers.

5.5.5 COMORBIDITIES AND EPILEPSY
As previously discussed epilepsy is associated with severe comorbidities
and recent literature has suggested that KARs and alteration in subunit
expression may be implicated. We suggest that the apparent downregulation of
KAR subunit expression and KAR-mediated transmission within area CA3, while
likely a compensatory modification, may be associated with noted comorbidities.
As previously elaborated upon, the reduction in KAR function may be a
compensatory mechanism to limit excitability. However the trade-off may be the
occurrence of comorbidities, particularly those linked to the mossy fiber – CA3
pathway. While controversy surrounds mossy fiber induced LTP (Henze et al.,
2000), it is apparent that the mossy fiber – CA3 synapse demonstrates the ability
to undergo long-term or even permanent alterations. The observed decrease in
KAR function at this synapse may likely contribute to cognitive impairment,
specifically associated with memories. The process of encoding and retrieving
memories has been associated with gamma frequencies, ~30 – 80 Hz (Herrmann
et al., 2004; Bartos et al., 2007). In the current study we observed a selective
reduction in the area of the fEPSPKA at frequencies of 30 – 100Hz, those similar
to gamma frequency. This finding suggests that the impairment of signal
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integration at frequencies responsible for memory and learning may contribute to
the cognitive comorbidities associated with epilepsy.

5.6 SIGNIFICANCE
The results of this study demonstrate that in the epileptic brain KARs
localized to mossy fibers are differentially altered. We demonstrated for the first
time that KAR-mediated transmission is significantly reduced in area CA3. In
stark contrast to the decrease in KARs at the mossy fiber – CA3 synapse, we
observed a significant increase in KARs localized to aberrant mossy fibers
synapsing in the DG, a finding in agreement with previous reports (Epsztein et
al., 2005). We suggest that the reduction in KAR-mediated excitatory
transmission in area CA3 is a compensatory modification in response to the
dramatic increase in DGC synchronization and inability of the DG to properly
integrate transmission. In addition we suggest that this compensatory decrease
in KAR-mediated transmission may precede the development of comorbidities
associated with epilepsy, including anxiety, depression and cognitive impairment.
Given the vast alterations in KAR-mediated transmission within the DG and area
CA3, and the potential impact of those alterations on cognitive and psychiatric
comorbidities, KARs may prove to be valuable therapeutic targets. However,
further investigation into subunit composition and the relationship between KARs
and comorbidities associated with epilepsy should be conducted.
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CHAPTER 6
ALTERATIONS IN KAINATE RECEPTOR MEDIATED REGULATION OF AXON
EXCITABILITY IN EPILEPTIC ANIMALS

6.1 INTRODUCTION
Excitatory neurotransmission mediated by kainate receptors (KARs) has
been most thoroughly examined at the hippocampal mossy fiber – CA3 synapse.
At this synapse KARs localized to postsynaptic CA3 cells regulate a small, but
slowly decaying excitatory current that significantly contributes to temporal
summation and a large depolarizing envelope (Castillo et al., 1997; Vignes and
Collingridge, 1997; Frerking and Ohliger-Frerking, 2002). KARs localized to
presynaptic mossy fiber (MF) terminals have been shown to contribute to forms
of both short-term and long-term plasticity, including paired-pulse facilitation,
frequency facilitation and long-term potentiation (Bortolotto et al., 1999;
Contractor et al., 2001; Lauri et al., 2001; Schmitz et al., 2001a; Kamiya et al.,
2002; Pinheiro et al., 2007). Several studies have also examined the role of
presynaptic KARs in regulating glutamate release at the MF terminal. These
studies report that low concentrations of the KAR agonist kainate (KA) facilitate
the release of glutamate, while higher concentrations of glutamate depress
transmitter release (Contractor et al., 2000; Kamiya and Ozawa, 2000; Schmitz
et al., 2001a). In support of these findings utilizing exogenously applied kainate, it
was found that released glutamate following brief and prolonged trains produces
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was found that released glutamate following brief and prolonged trains produces
similar effects on presynaptic KAR regulation of transmitter release (Bettler et al.,
1990; Schmitz et al., 2000; Schmitz et al., 2001a).
In addition to these diverse pre- and postsynaptic roles of KARs at the
mossy fiber – CA3 synapse, KARs are thought to be present along the length of
mossy fibers as well as along the axons of CA3 pyramidal cells where they have
been shown to regulate axon excitability (Kamiya and Ozawa, 2000; Schmitz et
al., 2000; Frerking et al., 2001). Similar to the findings of presynaptic KARregulated glutamate release, it has been determined that KARs located along
MFs regulate excitability in a bidirectional manner, as low concentrations of
kainate facilitate and higher concentrations depress axon excitability (Kamiya
and Ozawa, 2000; Schmitz et al., 2000). Whereas KARs localized to MFs
demonstrate bimodal actions, those receptors along the axons of CA3 pyramidal
cells have been shown to purely reduce axon excitability in a concentration
dependent manner (Frerking et al., 2001; Mott et al., 2008). It should be noted
that KAR regulation of axon excitability, determined through observation of
orthodromic fiber volleys or antidromic action potentials is a separate and
distinguishable phenomenon than that of presynaptic regulation of glutamate
release. However, alterations in axon excitability are typically consistent with
observed presynaptic changes in glutamate release.
KARs localized to MF or CA3 axons are likely key regulators of
glutamatergic transmission and may ultimately serve to govern excitatory drive
through the hippocampus, specifically area CA3 and CA1 via the mossy fiber and
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CA3 axons, respectively. Given observations of dramatic alterations in KAR
subunit expression in the hippocampus of status epilepticus-experienced animals
(Lason et al., 1997; Tandon et al., 2002; Zhang et al., 2004; Ullal et al., 2005;
Porter et al., 2006) and Chapter 4, in conjunction with the hyperexcitable and
epileptogenic nature of CA3, it is conceivable that KAR-regulation of axonal
excitability may be altered. Therefore the goal of this study was to determine
possible alterations in KAR-regulation of axon excitability in epileptic animals.

6.2 HYPOTHESIS
We previously observed significant alterations in KAR subunit expression
and localization throughout the hippocampus, specifically a reduction in GluK2/3
and GluK4 within the mossy fibers terminating in CA3 stratum lucidum (Chapter
4). In addition, in Chapter 5, we suggested that in epileptic animals the increase
in the excitatory circuitry of the dentate gyrus may lead a compensatory
downregulation of KAR-mediated excitatory in area CA3. Based on these
observations, we hypothesize that the ability of KARs to regulate axon excitability
will be reduced in the epileptic brain. This potential outcome could serve to either
recover or exacerbate the epileptic condition.

6.3 MATERIALS AND METHODS
6.3.1 ANIMAL MODEL OF SE
All animal care and use procedures were carried out in accordance with
protocols written under the guidance of the National Institutes of Health Guide for
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the Care and Use of Laboratory Animals and approved by the Institutional Animal
Care and Use Committee at the University of South Carolina. Following induction
of SE, rats were housed 1 per cage with ad libitum access to food and water.
Rats were housed in a climate controlled facility with a light/dark cycle of 12/12
hours.
SE was induced in adult male Sprague-Dawley rats (Harlan, Indianapolis,
IN). Animals received intraperitoneal (i.p.) injections of scopolamine methyl
bromide and terbutaline hemisulfate (2 mg/kg) followed 30 – 45 min later by
pilocarpine hydrochloride (390 mg/kg). After 2 hours of continuous SE, seizures
were terminated by diazepam (DZP, 25 mg/kg). This group of animals served as
the ‘pilo’ group. A separate group of animals received identical treatment with the
exception of receiving saline (390 mg/kg) instead of pilocarpine hydrochloride.
This group of animals served as the ‘sham’ group. More detailed methods
concerning induction of SE are described in Chapter 2.3.

6.3.2 FIELD POTENTIAL ELECTROPHYSIOLOGY
Transverse (500 µM thick) hippocampal slices were prepared from shamand pilocarpine-treated adult male Sprague-Dawley rats 145 ± 10 days posttreatment as described in detail in Chapter 2.7. Briefly, animals were deeply
anesthetized with isoflurane and transcardially perfused with a sucrose-based
aCSF. Slices were prepared in ice cold (4°C), and then incubated for 30 min in
heated (37ºC) oxygenated (95% O2 / 5% CO2) sucrose-based aCSF prior to a
gradual transition to room-temperate oxygenated Na-Cl based solution.
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In contrast to orthodromic stimulation in which action potentials travel
away from the soma, antidromic stimulation involves stimulation of the dendrite
or axon as the action potential travels backwards towards the soma. This type of
stimulation paradigm is commonly used to examine dendritic or axonal
projections. The current project utilized antidromic spikes to directly explore KARmediated hippocampal axon excitability. Antidromic population spikes were
evoked in two distinct pathways. 1) Mossy fibers were stimulated in CA3 stratum
lucidum and the response was recorded in the dentate granule cell layer. 2) CA3
axons were stimulated in stratum radiatum and the response was recorded in the
CA3 pyramidal cell layer. Figure 2.2 depicts each of these two experimental
paradigms utilized, purple and red electrodes, respectively. Antidromic spikes
were pharmacologically isolated in an antagonist cocktail containing bicuculline
methochloride (Bic, 20 µM) and MK-801 (10 µM). KAR antagonists, UBP310 (3
µM), ACET (300 nM), and kynurenic acid (KYN, 3 mM) were used to explore
kainate-induced axon excitability or depression. All drugs were purchased from
Abcam with the exceptions of Bic (Ascent Scientific), ACET (Tocris Bioscience),
and KYN (Sigma-Aldrich).

6.4 RESULTS
6.4.1 KAR- MEDIATED FACILITATION, BUT NOT DEPRESSION OF MOSSY FIBER
EXCITABILITY IS REDUCED IN EPILEPTIC ANIMALS

KARs located along mossy fibers regulate MF excitability in a bimodal
manner, as low concentrations facilitate and high concentrations of kainate
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depress excitability (Kamiya and Ozawa, 2000; Schmitz et al., 2000). Alterations
in the ability of KARs to properly regulate this action would dramatically impact
the excitatory drive into area CA3 resulting in alterations in both short-term and
long-term plasticity at this synapse. Antidromic spikes were evoked by
stimulation of the mossy fibers in CA3 stratum lucidum and recorded in the
dentate granule cell layer (Figure 2.2, purple electrodes).
In agreement with previous studies we observed concentration-dependent
effects on axon excitability following bath application of KA with low
concentrations potentiating the amplitude of the MF antidromic spike, and higher
concentrations inhibiting the spike amplitude (Figure 6.1A). However, in pilotreated animals we found that while depression induced by high KA was intact,
the facilitation produced by low KA was completely absent (Figure 6.1A). Based
on these studies we further examined alterations in MF excitability produced by
0.3 µM KA due to its selective activation of the KAR at this low concentration
(Mulle et al., 1998). We concluded that 0.3 µM KA significantly increases the
amplitude (121.5 ± 2.9% of control, n = 7; p < 0.001; Figure 6.1B) and area
(117.6 ± 4.4% of control, n = 7, p < 0.01; Figure 6.1C) of the MF antidromic
spike. In contrast, the actions of 0.3 µM KA were significantly different in pilotreated animals, as KA produced no effect on the amplitude (98.9 ± 2.8% of
control, n = 5, p > 0.05; Figure 6.1B) or area (95.3 ± 2.0% of control, n = 5; p >
0.05; Figure 6.1C) of the antidromic spike.

We also examined possible

alterations in the half width of the antidromic spike following application of 0.3 µM
and found no difference in sham (97.6 ± 1.3% of control, n = 7; p > 0.05; Figure
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Figure 6.1. KAR-mediated facilitation but not depression of mossy
fiber excitability is reduced in epileptic animals. A. Kainate concentration
response curves from sham-treated (black squares, n = 5 – 7) and pilo-treated
animals (gray circles, n = 4 – 7). Facilitation produced by low KA was significantly
reduced in pilo-treated animals. Depression produced by high KA was not
different between groups. Right, Waveforms from sham and pilo-treated animals.
Baseline antidromic spikes (Con, light gray traces), were potentiated by 0.3 µM
KA in sham, but not pilo-treated groups (black traces), and depressed by 10 µM
KA (dark gray traces). Application of 0.3 µM significantly increased the amplitude
(B.) and area (C.) of sham-treated, but not pilo-treated animals. KA (0.3 µM) had
no effect on the half width of the MF antidromic spike (D.) **p < 0.01; ***p <
0.001; ##p < 0.01; ###p < 0.001, t-test.
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6.1D) and pilo-treated animals (101.2 ± 3.2% of control, n = 5; p > 0.05; Figure
6.1D). These findings demonstrate that bimodal regulation of axon excitability is
absent in epileptic animals as low concentrations of KA now produce more
inhibitory than facilitatory effects. Furthermore we suggest that this loss of KARmediated facilitation of MF excitability may be due to a decrease in GluK4
subunit expression in area CA3 (Chapter 4). In support of this notion, it has been
reported that facilitation of MF excitability is significantly reduced in GluK4 -/animals (Catches et al., 2012).

6.4.2 UBP310 SELECTIVELY BLOCKS KA-INDUCED FACILITATION, BUT NOT
DEPRESSION OF MOSSY FIBER EXCITABILITY

We next explored whether the observed facilitation of MF excitability by
low kainate (0.3 µM) or the depression by high KA could be blocked by
application of a KAR antagonist. The selective KAR antagonist UBP310, while
originally characterized as a GluK1 antagonist, has been shown to potently block
current at homomeric GluK3 and heteromeric GluK2/5-containing KARs, while it
is ineffective at homomeric GluK2 and heteromeric GluK2/3-containing KARs
(Perrais et al., 2009; Pinheiro et al., 2013). It should be noted that while it has not
been reported, it is likely that UBP310 also antagonizes GluK4-containing
receptors. We first demonstrated that UBP310 (3 µM) was capable of reversing
the facilitation produced by 0.3 µM KA in sham-treated animals (Figure 6.2A). We
next explored the ability of UBP310 to prevent KA-induced facilitation or
depression of the MF antidromic spike (Figure 6.2B). We found that in both sham
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Figure 6.2. UBP310 blocks KA-induced facilitation but not depression
of mossy fiber excitability. A. Representative time-course experiment
demonstrating facilitation induced by low KA (0.3 µM) and reversal by 3 µM
UBP310. Sample waveforms illustrate the antidromic spike at each point during
the experiment. B. Bar graphs demonstrate that that application of 3 µM UBP did
not alter the baseline amplitude of the MF-antidromic spike but was able to block
the ability of low (0.3 µM KA) to facilitate excitability in sham-treated animals.
Depression by high KA (10 µM) was not prevented by UBP310. Sham-treated
group: black bars (n = 5); pilo-treated group: gray bars (n = 5). ***p < 0.001, ttest.
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(106.3 ± 1.0% of control, n = 5; p > 0.05; Figure 6.2B) and pilo-treated animals
(101.3 ± 1.4% of control, n = 5; p > 0.05; Figure 6.2B), bath application of
UBP310 (3 µM) had no effect on the baseline antidromic spike amplitude.
However, we determined that in sham-treated animals pre-application of UBP310
significantly blocked the anticipated facilitatory effects of 0.3 µM KA (without
UBP310: 121.5 ± 2.9% of control; n = 7; with UBP310: 108.7 ± 3.1% of control, n
= 5; p < 0.01; Figure 6.2B). In pilo-treated animals the presence of UBP310 did
not affect the observed lack of potentiation produced by 0.3 µM KA (p > 0.05;
Figure 6.2B).
Given the capacity of UBP310 to block KA-induced facilitation by low KA
we also examined its ability to block depression induced by high KA (10 µM). We
found that pre-application of UBP310 (3 µM) was unable to block the significant
depression induced by 10 µM KA in sham (without UBP: 15.5 ± 8.0% of control, n
= 5; with UBP: 8.9 ± 0.8% of control, n = 5; p > 0.05) and pilo-treated animals
(without UBP: 14.3 ± 2.2% of control, n = 5; with UBP: 13.1 ± 5.2% of control, n =
5; p > 0.05;Figure 6.2B). Given that UBP310 selectively inhibits KARs over
AMPA or NMDA-receptors (Perrais et al., 2009; Pinheiro et al., 2013), these
findings demonstrate that facilitation by low KA is in fact KAR-mediated. In
addition we suggest that the KARs located on mossy fibers are likely composed
of heteromeric GluK2/4 or GluK2/5-containing receptors and possibly homomeric
GluK3-cotaining receptors.

However, this is less likely as GluK3 subunit

expression is restricted to the dentate gyrus (Wisden and Seeburg, 1993; Bureau
et al., 1999; Darstein et al., 2003).
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6.4.3 ACET SELECTIVELY BLOCKS KA-INDUCED FACILITATION, BUT NOT
DEPRESSION OF MOSSY FIBER EXCITABILITY

Similar to UBP310, the compound ACET (UBP316) was originally
characterized as an antagonist of GluK1-containing KARs (Dolman et al., 2007;
Dargan et al., 2009). However studies have suggested that ACET may also
antagonize KARs composed of homomeric GluK3 subunits (Perrais et al., 2009),
and has even shown to be partially effective in blocking transmission at the
mossy fiber – CA3 synapse (Pinheiro et al., 2013). In addition, to these studies
preliminary data from our lab has suggested that ACET may demonstrate
increased selectivity for GluK2/4, over GluK2/5-containing KARs. We examined
the ability of ACET to prevent KA-induced facilitation and/or depression of mossy
fiber excitability.
A time course experiment demonstrates the ability of ACET (1 µM) to
block the facilitation produced by 0.3 µM KA in sham-treated animals (Figure
6.3A). We next explored the ability of ACET to prevent the observed facilitation
and depression of MF excitability produced by KA (Figure 6.3B), and found
results essentially identical to those produced by application of UBP310. Briefly,
bath application of ACET (1 µM) had no effect on the baseline amplitude of the
antidromic spike in either sham (99.7 ± 2.4% of control, n = 5; p > 0.05; Figure
6.3B) or pilo-treated animals (109.5 ± 6.8% of control, n = 3; p > 0.05; Figure
6.3B). In agreement with our results with UBP310, we found that ACET
significantly prevented the facilitatory action of 0.3 µM KA in sham-treated
animals (without ACET: 121.5 ± 2.9% of control; n = 7; with ACET: 101.0 ± 2.6%
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Figure 6.3. ACET blocks KA-induced facilitation but not depression
of mossy fiber excitability. A. Representative time-course experiment
demonstrating facilitation induced by low KA (0.3 µM) and reversal by 1 µM
ACET. Sample waveforms illustrate the antidromic spike at each point during the
experiment. B. Bar graphs demonstrate that that application of 1 µM ACET did
not alter the baseline amplitude of the MF antidromic spike but was able to block
the ability of low KA (0.3 µM) to facilitate excitability. Depression by high KA (10
µM) was not prevented by ACET. Sham-treated group: black bars (n = 4 – 5);
pilo-treated group: gray bars (n = 2 – 3). ***p < 0.001, t-test.
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of control, n = 5; p < 0.001; Figure 6.3B). The lack of potentiation by 0.3 µM in
pilo-treated animals was not significantly different in the presence of ACET (p >
0.05; Figure 6.3B). In addition, we determined that ACET (1 µM) was not able to
prevent the depression induced by 10 µM KA in sham (without ACET: 15.5 ±
8.0% of control, n = 5; with ACET: 23.8 ± 6.9% of control, n = 5; p > 0.05) or pilotreated animals without ACET: 14.3 ± 2.2% of control, n = 5; with ACET: 6.0 ±
1.3% of control, n = 2; p > 0.05; Figure 6.3B).
The above findings are not surprising given the similarities in the UBP310
and ACET pharmacological profiles. However, the possibility of distinguishing
whether the actions of KA on mossy fiber excitability were mediated by GluK2/4or GluK2/5-containing KARs was encouraging. Regardless, the results from
these experiments support the idea that KARs located on mossy fiber axons are
likely comprised of the GluK2/4- and/or GluK2/5 subunit combination. However,
the inability of either UBP310 or ACET to prevent inhibition by 10 µM KA
suggests either that the inhibition is mediated by AMPA receptors and not KARs,
or perhaps that the observed inhibition occurs through a metabotropic function.

6.4.4 KYN BLOCKS BOTH KA-INDUCED FACILITATION AND DEPRESSION OF
MOSSY FIBER EXCITABILITY

While UBP310 and ACET were originally designed as KAR antagonists,
kynurenic acid (KYN) has been characterized as a more general glutamate
receptor antagonist (Ganong et al., 1983; Alt et al., 2004). In regards to KARs, it
has been demonstrated that KYN has a much higher affinity for GluK2 over
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GluK5 KAR subunits (Alt et al., 2004). KYN has also been shown to potentiate
current at recombinant GluK2/5 and GluK3/5 KARs, through its removal of GluK2
or GluK3-induced desensitization (Fisher and Mott, 2011).

We explored the

actions of KYN on KA-induced potentiation and depression of MF excitability.
We first demonstrated that KYN (3 mM) was able to reverse the
potentiation observed by 0.3 µM KA in sham-treated animals (Figure 6.4A).
Similar to previous experiments we then wanted to determine if pre-application of
KYN was able to prevent the observed facilitation or depression of MF excitability
by 0.3 µM (Figure 6.4B). In agreement with our previous experiments, we found
that KYN (3 mM) did not significantly alter the amplitude of the MF antidromic
spike in sham (95.7 ± 2.2% of control, n = 5; p > 0.05) or pilo-treated animals
(100.7 ± 2.7% of control, n = 5; p > 0.05; Figure 6.4B). Similar to our studies of
UBP and ACET, we found that KYN significantly prevented the expected
facilitation induced by 0.3 µM KA in sham-treated animals (without KYN: 121.5 ±
2.9% of control, n = 7; with KYN: 95.7 ± 1.6% of control, n = 5; p < 0.001; Figure
6.4B). In addition the lack of potentiation observed by 0.3 µM KA in pilo-treated
animals was not significantly different in the presence of CNQX (p > 0.05; Figure
6.4B).
In stark contrast to the inability of both UBP and ACET to block the
depressive effects of high KA, we observed that pre-application of 3 mM KYN
significantly blocked the depression induced by 10 µM KA in pilo-treated animals
(without KYN: 14.3 ± 2.2% of control, n = 5; with KYN: 87.5 ± 8.0% of control, n =
5; p < 0.001; Figure 6.4B). Perhaps even more intriguing is that in sham-treated
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Figure 6.4. Kynurenate prevents KA-induced facilitation and
depression of mossy fiber excitability. A. Representative time-course
experiment demonstrating facilitation induced by low KA (0.3 µM) and reversal by
3 mM KYN. Sample waveforms illustrate the antidromic at each point during the
experiment. B. Bar graphs demonstrate that that application of 3 mM KYN did not
alter the baseline amplitude of the MF antidromic spike but was able to block the
ability of low KA (0.3 µM) to facilitate excitability. In the presence of KYN, 10 µM
KA significantly increased the MF-antidromic spike amplitude in sham-treated
animals, and prevented inhibition in pilo-treated animals. Sham-treated group:
black bars (n = 5); pilo-treated group: gray bars (n = 5). *p < 0.05; #p < 0.05, ttest.
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animals, in the presence of 3 mM KYN, 10 µM KA actually significantly increased
the amplitude of the MF antidromic spike (without KYN: 15.5 ± 8.0% of control, n
= 5; with KYN: 122.6 ± 8.4% of control, n = 5; p < 0.001; Figure 6.4B).
Based upon the data collected from experiments using UBP310 and
ACET, we anticipated the ability of KYN to block the facilitation of MF excitability
induced by 0.3 µM KA. Blockade of KA-induced depression by KYN may be
reflective of its more general antagonistic action of glutamate receptors, as
opposed to selectively targeting KARs. The observed increase in MF excitability
in sham-treated animals in the presence of KYN is perplexing, and likely involves
a more intricate interaction between KYN and the KAR and/or AMPAR
complexes. Nevertheless, this set of experiments clearly demonstrates that
depression induced by high KA can be blocked and is perhaps regulated by
AMPA receptors.

6.4.5 CNQX SELECTIVELY BLOCKS KA-INDUCED FACILITATION, BUT NOT
DEPRESSION OF MOSSY FIBER EXCITABILITY

To explore the possibility that KA-induced depression is possibly mediated
by AMPA receptors, we utilized CNQX, an extremely potent antagonist at AMPA
receptors with an IC50 of ~400 nM (Honore et al., 1988; Sheardown et al., 1990).
To ensure absolute blockade of both AMPA and KA-receptors we utilized 100 µM
CNQX, an extremely high concentration. Very surprisingly, we found that similar
to UBP and ACET, CNQX (100 µM) was able to block the facilitation, but not the
depression of MF excitability induced by KA. Bath application of CNQX (100 µM)
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did not significantly alter the baseline MF antidromic spike amplitude in sham
(103.5 ± 9.0% of control, n = 5; p > 0.05) or pilo-treated animals (101.5 ± 7.3% of
control, n = 3; p > 0.05; Figure 6.5). Furthermore, similar to UBP and ACET, we
determined that CNQX significantly blocked the ability of 0.3 µM KA to potentiate
the antidromic spike (without CNQX: 121.5 ± 2.9% of control, n = 7; with CNQX:
100.3 ± 3.0% of control, n = 5; p < 0.001; Figure 6.5). In addition, the lack of
potentiation by 0.3 µM KA in pilo-treated animals was not significantly different in
the presence of CNQX (p > 0.05; Figure 6.5). We next explored the actions of 10
µM KA in the presence of CNQX, fully anticipating CNQX to prevent the dramatic
depression induced by high KA. However, we determined that CNQX (100 µM) in
fact did not prevent the depression in sham (without CNQX: 15.5 ± 8.0% of
control, n = 5; with CNQX: 48.0 ± 17.0% of control, n = 5; p > 0.05) or pilo-treated
animals without CNQX: 14.3 ± 2.2% of control, n = 5; with CNQX: 40.7 ± 14.8%
of control, n = 3; p > 0.05; Figure 6.5).
It is worthwhile noting that in the presence of CNQX the observed
depression in both sham and pilo-treated animals by high KA was quite variable.
In sham-treated animals, in the presence of CNQX, inhibition by 10 µM KA
ranged from a minimal 4.6% to almost complete inhibition at 91.5%. Similarly in
pilo-treated animals, in the presence of CNQX, inhibition by 10 µM KA ranged
from 44.5 – 89%. We suggest that perhaps with additional experiments it would
become clear that while CNQX does not completely block the depressive action
of 10 µM KA, it is likely that it would at least limit the extent of this depression.
However, these results further suggest that the facilitatory actions of low KA
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Figure 6.5. CNQX blocks KA-induced facilitation but not depression
of mossy fiber excitability. Application of CNQX (100 µM) did not affect the
baseline amplitude of the mossy fiber antidromic spike, but was able to prevent
the facilitation of low KA (0.3 µM) in sham-treated animals. In the presence of
100 µM CNQX, high KA (10 µM) continued to significantly reduce axon
excitability in both sham and pilo-treated animals. Representative waveforms
from a sham-treated animal demonstrate the lack of effect of CNQX (100 µM) on
the amplitude of the antidromic spike, its blockade of 0.3 µM KA-induced
facilitation, and the continued depressive actions of 10 µM KA. Sham-treated
group: black bars (n = 5); pilo-treated group: gray bars (n = 3). *p < 0.05, t-test.
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(0.3 µM) are extremely likely to be occurring through KARs, while the depressive
actions by 10 µM KA are likely not ionotropic, or are at least partially mediated
through a second-messenger metabotropic function.

6.4.6 KAR-MEDIATED DEPRESSION OF CA3 AXON EXCITABILITY IS
SIGNIFICANTLY REDUCED IN EPILEPTIC ANIMALS

In contrast to the bidirectional regulation of MF excitability, KARs localized
to the axons of CA3 pyramidal cells reduce excitability in a concentrationdependent manner (Frerking et al., 2001; Mott et al., 2008). Similar to the issues
mentioned with alterations in MF excitability, the inability of KARs to properly
regulate axon excitability in area CA3 could have huge implications in the
epileptic brain and increase hyperexcitability. Antidromic spikes from the axons of
CA3 pyramidal cells were evoked by stimulation of CA3 stratum radiatum and
recorded in the CA3 pyramidal cell layer (Figure 2.2, red electrodes).
In agreement with Mott et al. (2008) we observed concentrationdependent inhibition of CA3 axons with bath applied kainate (Figure 6.6A).
However, in pilo-treated animals we found that while depression remained intact
it was significantly less than that observed in sham-treated animals at 0.1 µM (p
< 0.01), 1 µM (p < 0.001) and 10 µM (p < 0.001). We found that 0.1 µM KA
significantly reduces the amplitude (59.9 ± 8.7% of control, n = 6; p < 0.001;
Figure 6.6B) and area (87.6 ± 5.0% of control, n = 5; p > 0.05; Figure 6.6C) of the
CA3 axon antidromic spike in sham-treated animals. However in pilo-treated
animals, while 0.1 µM KA did significantly reduce the amplitude, it was minimal

194

Figure 6.6. KAR-mediated depression of CA3 axon excitability is
impaired in epileptic animals. A. Kainate concentration response curves from
sham-treated (black squares, n = 4 – 6) and pilo-treated animals (gray circles, n
= 2 – 6). Depression produced by low KA was significantly reduced in pilo-treated
animals. Right, Waveforms from sham and pilo-treated animals. Baseline
antidromic spikes (Con, light gray traces) were depressed by 0.1 µM KA (black
traces), and further depression induced by 10 µM KA (gray traces). Depression
by 0.1 µM and 10 µM KA was significantly reduced in pilo-treated animals.
Application of 0.1 µM significantly decreased the amplitude (B.) of both shamand pilo-treated animals. KA significantly reduced the area (C.) of sham-treated,
but not pilo-treated animals. KA (0.1 µM) significantly increased the half-width in
sham- and pilo-treated animals (D.) *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.05,
t-test.
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and was significantly different than that observed in sham-treated animals (91.5 ±
2.7% of control, n = 5; p < 0.05; Figure 6.6B). In addition, we did not observe any
change in the area of the CA3 axon antidromic spike with 0.1 µM, a finding also
different from sham-treated animals (101.3 ± 1.2% of control, n = 5; p < 0.01;
Figure 6.6C). We also examined possible alterations in the half width of the CA3
antidromic spike and determined that it was significantly increased in both shamtreated (141.6 ± 9.5% of control, n = 6; p < 0.01) and pilo-treated animals (110.6
± 3.1% of control, n = 4; p < 0.05; Figure 6.6D), but to significantly different levels
(p < 0.05; Figure 6.6D). This finding of an increase in the half width of the CA3
antidromic spike by KA is in agreement with Mott et al. (2008). Overall these
findings demonstrate that KA-induced depression of CA3 axon excitability is
significantly impaired in epileptic animals. Thus we suggest that in the epileptic
brain the inhibitory tone of CA3 axonal projections is reduced, and may lead to
increased hyperexcitability and potentially increased transmission into area CA1.

6.4.7 UBP310 BLOCKS KA-INDUCED DEPRESSION OF CA3 AXON EXCITABILITY
Similar to previous experiments with MF excitability, we examined the
ability of the KAR antagonist UBP310 to block the KA-induced depression in
sham- and pilo-treated animals (Figure 6.7). We found that in both sham (102.6 ±
9.0% of control, n = 3; p > 0.05; Figure 6.7) and pilo-treated animals (102.0 ±
2.2% of control, n = 2; p > 0.05; Figure 6.7) bath application of UBP310 (3 µM)
had no effect on the amplitude of the CA3 antidromic spike. However, we
determined that in sham-treated animals pre-application of UBP310 significantly
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Figure 6.7. UBP310 blocks KA-induced depression of CA3 axon
excitability. Application of UBP310 (3 µM) did not affect the baseline amplitude
of the CA3 axon antidromic spike in sham or pilo-treated animals. The presence
of UBP310 was sufficient to block the depression by low 0.1 µM KA observed in
sham-treated animals. Representative waveforms from a sham-treated animal
demonstrate the lack of effect of UBP310 (3 µM) on the amplitude of the CA3
antidromic spike as well its blockade of 0.1 µM KA-induced depression. Shamtreated group: black bars (n = 3); pilo-treated group: gray bars (n = 2).
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blocked the anticipated depression by 0.1 µM KA (without UBP310: 59.9 ± 8.7%
of control, n = 6; with UBP310: 106.0 ± 13.4% of control, n = 3; p < 0.05; Figure
6.7). In pilo-treated animals the presence of UBP310 appeared to block the
depressive actions of 0.1 µM KA, however the difference was not significant likely
due to variability and a low n-value (without UBP: 91.5 ± 2.7% of control, n = 2;
with UBP310: 101.6 ± 4.1% of control, n = 2; p > 0.05; Figure 6.7). The
selectively of UBP310 for KARs demonstrates that the depression of CA3 axon
excitability is mediated by KARs. In Chapter 4 we observed a significant
reduction in KAR subunit expression in area CA3 at both 60d and 200d post-SE.
This reduction in KAR subunit expression likely serves as a rationale for the
observed decrease in KAR-regulation of CA3 axon excitability.

6.5 DISCUSSION
Together the results of this study provide the first known examination of
alterations in KAR-mediated regulation of hippocampal axon excitability in
epileptic animals.

In

agreement

with previous studies

we determined

concentration-dependent actions of KA on both MF and CA3 axon excitability in
sham-treated animals (Kamiya and Ozawa, 2000; Schmitz et al., 2000; Mott et
al., 2008). These results are in line with the observation that low concentrations
of KA induce opposing actions on MF and CA3 axons, as low KA facilitates MF
excitability and reduces CA3 axon excitability (Mott et al., 2008). In epileptic
animals we observed that the facilitation of MF excitability by low KA (0.3 µM)
and depression of CA3 axon excitability by low KA (0.1 µM) were both
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significantly impaired. This finding suggests the possibility that synaptic
transmission, including into areas CA3 and CA1, may be critically impaired in
epileptic animals. In addition these changes may reflect compensatory changes
to limit network excitability in the epileptic brain.

6.5.1 POSSIBLE ROLE OF METABOTROPIC KARS
KARs localized to presynaptic mossy fiber terminals have been reported
to regulate transmission in a bidirectional, concentration-dependent manner,
where low concentrations of KA facilitate, and high concentrations of KA depress
the EPSC (Contractor et al., 2000; Kamiya and Ozawa, 2000; Schmitz et al.,
2000; Schmitz et al., 2001a). In agreement with these findings KA has also been
shown to have the same bidirectional control on axon excitability, with low KA
facilitating and high KA depressing MF excitability (Kamiya and Ozawa, 2000;
Schmitz et al., 2000). While these two functions of KARs are distinct from one
another, KA does appear to have the same effect. Therefore, alterations in KARregulation of axon excitability can likely be extrapolated to suggest similar
findings in transmitter release.
While the actions of KA on axon excitability and presynaptic transmitter
release are well documented, the mechanism regulating these actions is not as
clear. The facilitatory effects of KA on axon excitability are likely due to a slight
depolarization of the axon with serves to increase excitability (Schmitz et al.,
2000). This is observed as a potentiation of the antidromic spike or orthodromic
fiber volley, as well as an increase in transmitter release and potentiation of the

199

EPSC. In contrast, the decrease in axon excitability by high concentrations is not
as straight-forward. Some studies have suggested that the depression is due to a
substantial increase in depolarization resulting in the inactivation of Na + channels
and a subsequent blockade of action potentials (Contractor et al., 2000; Kamiya
and Ozawa, 2000; Schmitz et al., 2000). In support of this line of reasoning is
that the effects of KA

on transmitter release can be mimicked by raising

extracellular K+ levels to increase depolarization (Schmitz et al., 2000). These
findings support an ionotropic mechanism of KA-induced facilitation and
depression of axon excitability as well as presynaptic regulation of transmitter
release.
A metabotropic mechanism has also been identified as a possible
explanation of high KA-induced depression of presynaptic transmitter release,
and likely also explains the decrease in axon excitability observed in the current
study. Negrete-Diaz et al. (2006) reported that KA-induced depression of
transmitter release could be blocked by application of the G-protein inhibitor
pertussis-toxin (PTX), a finding indicative of a metabotropic action. In support of
this mechanism, while high K+ does in fact produce significant depression of
transmitter release, it recovers to baseline fairly quickly, while the depressive
actions of KA are significantly longer lasting.
While Negrete-Diaz et al. (2006) demonstrated a metabotropic mechanism
of high KA-induced depression of transmitter release, we believe that these
findings can be generalized to our examination of axon excitability. We found that
while facilitation induced by low concentrations of KA was blocked by all
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antagonists examined, the depressive actions were much more complicated.
Most surprising was the inability of the glutamate receptor antagonist CNQX to
block the depression. While we did not directly explore a metabotropic action, we
feel that our findings are suggestive of this mechanism. Therefore, we propose
that while facilitation of axon excitability is mediated by ionotropic KARs, the
depression induced by high KA is likely through a metabotropic action.

6.5.2 ACTIONS OF KYN ON MF EXCITABILITY
We observed that facilitation of MF excitability by low concentrations of KA
was readily blocked by all antagonists we examined. In contrast, the KA-induced
depression of MF excitability by high KA was only inhibited by KYN. As
previously mentioned, KYN is commonly used as a more global glutamate
antagonist and at high concentrations inhibits AMPA, NMDA, and KA-receptors
(Ganong et al., 1983; Alt et al., 2004). While KYN does demonstrate some KAR
subunit selectively, by preferentially blocking the GluK2 subunit, its most notable
action at KARs is potentiating current from GluK2/5-containing KARs (Fisher and
Mott, 2011). Regardless of these actions of KYN the ability of this compound to
not only block but potentiate axon excitability with 10 µM KA is perplexing. One
possible explanation, although improbable, could be that if depression is
mediated through a metabotropic action, which we believe is likely, that perhaps
the high concentration of KYN (3 mM) used in the current study had inhibitory
effects on metabotropic glutamate receptors. This would explain the ability of
KYN, but not CNQX, UBP or ACET to inhibit the KA-induced depression of MF
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excitability. It should also be noted that many of the studies examining
antagonistic properties of not only KYN, but most compounds, have utilized
glutamate as the agonist (Ganong et al., 1983; Alt et al., 2004; Fisher and Mott,
2011). It is entirely possible, and quite likely, that the antagonistic actions of KYN
are significantly different when kainate is used as the agonist.

6.5.3 ROLE OF ZINC ON MOSSY FIBER KARS
High quantities of zinc are found within the hippocampus, particularly
within the hippocampal mossy fibers (Maske, 1955; McLardy, 1962). Within the
mossy fiber terminals zinc is actually co-localized with glutamate and is released
in a Ca2+-dependent manner (Assaf and Chung, 1984; Howell et al., 1984). Zinc
has also been reported to play critical roles in cognition and aging (Szewczyk,
2013). Furthermore, synaptically released zinc has been shown to inhibit both
NMDA and GABAA receptors (Vogt et al., 2000; Ueno et al., 2002; Ruiz et al.,
2004), but seemingly has minimal effects on AMPA receptors (Mayer et al., 1989;
Dreixler and Leonard, 1994; Lin et al., 2001; Mott et al., 2008). More recently it
was demonstrated that synaptically released zinc inhibits postsynaptic KARs
localized to the mossy fiber – CA3 synapse, and preferentially acts on GluK4, or
GluK5-contaiing KARs (Mott et al., 2008).
In addition to a significant role in regulating synaptic transmission at the
mossy fiber – CA3 synapse, zinc has also been shown to regulate axon
excitability. Mott et al. (2008) demonstrated that facilitation of MF excitability
produced by low concentrations of KA could be prevented by exogenously
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applied zinc. In contrast, zinc did not appear to effect the depressive actions of
KA on CA3 axons. Increases in synaptic activity, as noted in epilepsy, as well as
the aberrant sprouting of mossy fibers, have been shown to increase levels of
zinc (Assaf and Chung, 1984; Howell et al., 1984; Li et al., 2001a; Li et al.,
2001b; Lin et al., 2001).
In the current study we determined that facilitation, but not depression of
MF excitability is significantly reduced in epileptic animals. In light of the current
studies, we suggest that this may be due to the apparent increase in the
concentration of zinc in the MFs, which serves to block the facilitatory effects of
KA. In regards to CA3 axons, we observed that KA-induced depression is
significantly reduced in epileptic animals. While Mott et al. (2008) demonstrated
that zinc was not able to block KA-induced depression of CA3 axons in control
animals, we cannot rule out the possibility that the increased levels of zinc in
epilepsy may now function to inhibit KA-induced depression. To explore these
possibilities experiments utilizing a zinc chelator would be beneficial, and allow
us to essentially lower the levels of zinc in epileptic slices back to baseline levels
and determine if we see the appropriate KA-induced facilitation of MF excitability
and KA-induced depression of CA3 axon excitability.

6.5.4 POSSIBLE CHANGES IN KAR SUBUNIT COMPOSITION
While the possibility that increased levels of zinc may be responsible for
the lack of observed KA-induced facilitation of MFs and depression of CA3 axons
in epileptic animals, based on our previous data, we suggest that alterations in
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KAR subunit expression may also serve as an explanation. In regards to MF
excitability we determined that facilitation, but not depression was absent in
epileptic animals. We also observed that expression of the GluK4 subunit was
significantly reduced in area CA3 of animals 60 and 200d post-SE (Chapter 4),
suggesting that the lack of facilitation may be due to the reduction in GluK4
subunit expression. In support of this proposition, studies utilizing knockout
animals have demonstrated that animals lacking the high affinity GluK4 and/or
GluK5 subunits display impaired facilitation, but not depression (Contractor et al.,
2003; Fernandes et al., 2009; Catches et al., 2012). Therefore, we believe that
the loss of KA-induced facilitation of MF axon excitability is most likely due to the
significant reduction in GluK4 subunit expression.
While many studies have explored the KAR subunit composition
responsible for MF facilitation and depression, few studies have examined KARregulation of CA3 axon excitability. Mott et al. (2008), reported that zinc
preferentially inhibits GluK4 or GluK5-containing KARs and that zinc did not block
the KA-induced depression of CA3 axon excitability. This suggests that KARs
localized to CA3 axons are likely GluK2/3-containing KARs. Our anatomical data
from epileptic animals (Chapter 4), demonstrated a significant decrease in
GluK2/3 expression in area CA3. If KA-induced depression of CA3 axons is in
fact mediated by GluK2/3-containing KARs, our observation of reduced inhibition
could be explained via alterations in subunit expression. However, we still cannot
rule out the possibility that increased levels of zinc may contribute to these
findings. In addition, it should be noted that auxiliary proteins, such as Neto1 and
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Neto2, have been demonstrated to dramatically impact KAR trafficking and
pharmacology. As the current study did not directly explore the interaction
between Neto1 and/or Neto2 on KARs, we cannot rule out the possibility that
observed alterations are not due to changes in expression of the Neto proteins.

6.6 SIGNIFICANCE
The findings of this study provide the first look at alterations in KARmediated regulation of hippocampal axon excitability in epileptic animals. We
demonstrated that facilitation of MF excitability is absent in epileptic animals,
likely due to alterations in KAR subunit expression. This reduction in facilitatory
drive into area CA3 of epileptic animals could serve as a compensatory
mechanism to limit epileptogenic activity. Alternatively, it also reveals that the
mossy fiber pathway, the main source of communication between the dentate
gyrus and area CA3, is significantly impaired in epileptic animals. In addition this
study suggests that the depressive actions of high KA on MF excitability are likely
through a metabotropic action, a finding supported by previous studies (Cunha et
al., 1999; Negrete-Diaz et al., 2006). Furthermore, we report that KA-induced
depression of CA3 axon excitability is significantly impaired in epileptic animals,
likely due to alterations in KAR subunit expression.

This reduced inhibition of

CA3 axons would likely contribute to bursting within the highly interconnected
CA3 network and would most likely increase synaptic input into area CA1 in the
epileptic brain. Overall we suggest that the observed changes in axon excitability
in both the mossy fibers and area CA3 are due to the reduction in KAR subunit
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expression in the epileptic brain. Further studies would need to be conducted to
solidify the impact that the observed changes would have on network excitability
within the epileptic brain.
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CHAPTER 7
GENERAL DISCUSSION AND SIGNIFICANCE
7.1 DISCUSSION
The data collected from these studies significantly contribute to the
scientific literature regarding the impact of status epilepticus and the
development of epilepsy on alterations in both inhibitory and excitatory networks.
We have demonstrated that while GABAAR subunit composition is dramatically
altered following a prolonged SE event, agents such as stiripentol remain
effective in terminating SE, and thus may serve as potential therapeutic targets.
We also examined changes in excitatory neurotransmission mediated by the
kainate receptor and demonstrated a significant decrease in receptor subunit
expression and a subsequent decrease in KAR-mediated transmission in the
epileptic brain. We feel that these studies are extremely valuable to our
understanding and knowledge of SE and epilepsy, as well as anatomical
changes that occur in the brain. These studies may serve as building blocks for
potential therapeutic targets for the treatment of epilepsy and/or associated
comorbidities. The findings revealed in this document are summarized in Tables
7.1 – 7.4.
SE is a neurologic emergency which requires prompt medical attention
and immediate therapeutic intervention. As nearly 50% of SE cases occur in
children under the age of 2, our ability to develop safe and effective therapeutics
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Table 7.1 Summary of results detailed in Chapter 3
Hypothesis
 STP will



γ2-containing

remain effective

prolonged SE

GABAARs to

in a model of

terminate SE

BZD-resistant SE



Question
BZDs require

Findings
STP terminates brief and



Less pharmacoresistance

As SE

progresses γ2containing GABAARs
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are internalized


Actions of STP



STP potentiates GABAergic

transmission in an age-

most effective in younger
animals




STP does not act through
the BZD-binding site



STP, not DZP, potentiates

phasic and tonic GABAergic

in terminating SE

transmission after prolonged

when resistance to

SE

developed?

STP is effective in all

dependent manner

 Is STP effective

BZDs has



age groups examined but is

do not require γ2containing GABAARs

effective in terminating
BZD-resistant prolonged SE

develops to STP than to DZP




Impact/Significance
STP remains



STP alone, or in

conjunction with other
AEDs would be effective in
the treatment of brief and
prolonged SE


Development of

additional therapeutics with
STP, not DZP, potentiates

mIPSCs after prolonged SE

pharmacological profiles
similar to STP

Table 7.2 Summary of results detailed in Chapter 4


Question
KARs have

Hypothesis
 Distinct

been implicated in

alterations in

seizure disorders as

KAR subunit

well as their

expression will

comorbidities

be observed in
hippocampal



KARs are widely

expressed throughout

regions DG, CA3
and CA1
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the hippocampus, a

Findings
DG:
5d-

GluK2/3 & GluK5

60d-

GluK2/3

200d-

GluK2/3, GluK4 & GluK5

Impact/Significance
 Pilo-induced SE
produces significant
alterations in KAR subunit
expression

CA3:
5d- GluK2/3 & GluK5



60d-

independent of region

200d-

GluK2/3 & GluK4
GluK2/3 & GluK4

Alterations are

and duration of epilepsy

CA1:
5d- GluK2/3 & GluK5



seizure generation and that the

60d-

changes in KAR-

propagation

progression of

200d-

epilepsy will



differentially alter

at all time-points in all regions

region prone to

 How does the
progression of
epilepsy alter the
expression of KAR
subunits throughout
the hippocampus?



We anticipate

GluK2/3
GluK2/3

GFAP expression increased

KAR subunits


Reduced GluK2/3 expression

is restricted to limbic regions

Likely precede

mediated transmission
throughout hippocampus


Likely correlated to

observed comorbidities of
epilepsy i.e., cognition,
anxiety and depression

Table 7.3 Summary of results detailed in Chapter 5


Question
KAR-mediated



Hypothesis
Neurotransmission

Findings
In epileptic animals:

Impact/Significance
 Epilepsy generates

transmission is increased

mediated by KARs will 

in DG of epileptic animals

be significantly

transmission at mossy

KAR-mediated

reduced at the

fiber – CA3 synapse is

transmission at two

mossy – fiber CA3

significantly reduced

different synapses of



KARs regulate

transmission in area CA3


KAR subunit

KAR-mediated

synapse of epileptic
animals

the same axon


Synaptic integration at

this synapse is impaired
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expression is significantly


epileptic animals

to KARs- no change in

Reduction is specific

AMPAR-mediated

Observed reduction

mechanism resulting
from the increased
excitatory circuit in DG

transmission

transmission at the mossy



fiber – CA3 synapse



altered in the epileptic

of PPF was not different

brain?



is likely a compensatory

reduced in area CA3 of

 Is KAR-mediated

opposing alterations in

Presynaptic regulation

Reduction may

contribute to observed
comorbidities in
epilepsy

Table 7.4 Summary of results detailed in Chapter 6


Question
Axon excitability



Hypothesis
The ability of

Findings
Mossy fibers:

Impact/Significance
 KAR regulation of
axon excitability is

influences synaptic

axonal KARs to



transmission

regulate excitability

depression is absent in

impaired in epileptic

will be reduced in the

epileptic animals

animals

axon excitability is





subunit dependent

by KAR antagonists



KAR-mediated

Facilitation but not

epileptic brain
Facilitation is blocked

In MFs, reduction

may supplement
compensatory
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KAR subunit



Depression is likely

expression is

regulated by metabotropic

significantly

KARs

excitatory transmission


reduced in epileptic
animals

downregulation of

CA3 axons:


Depression is

 Is KAR-

significantly reduced in

mediated regulation

epileptic animals

of axon excitability

In CA3 axons,

reduction likely contributes
to epileptogenic activity


Alterations likely

influence synaptic

altered in epileptic



animals?

blocked by a KAR antagonist

Depression is

transmission into CA3 and
CA1

is essential. Our data demonstrates that in a model of prolonged SE, when
resistance to BZDs develops, STP continues to terminate SE, in an agedependent manner. Of note from this study was the observation that the actions
of STP are independent of the BZD-binding site of the GABAA receptor, a finding
in agreement with a previous study (Quilichini et al., 2006). While this allows for
STP to work in conjunction with additional AEDs, such as clobazam, the exact
mechanism of STP remains elusive. It remains a possibility that STP may act on
a separate and distinct site of the GABAA receptor. In addition we feel that the
ability of STP to potentiate tonic GABAergic transmission, a mechanism which is
maintained following prolonged SE, greatly contributes to its anticonvulsant
effects. As extrasynaptic δ-containing receptors are not altered during prolonged
SE (Goodkin et al., 2008), this population of GABAA receptors provide a unique
target for the development of new AEDs. The findings provided in Chapter 3 are
the first examination of the ability of STP to terminate BZD-resistant SE.
KARs have been implicated in several disease states, specifically
epilepsy, where systemic administration of kainate induces SE and the
development of spontaneously occurring seizures through activation of GluK2containing KARs (Mulle et al., 1998; Fritsch et al., 2014). KAR subunits GluK1 –
5 are expressed throughout the brain and hippocampus, specifically at the mossy
fiber – CA3 synapse, a region considered to be highly epileptogenic and
sensitive to excitotoxicity. Despite the relationship between KARs and seizure
disorders, few studies have explored KARs in the epileptic brain. Furthermore,
the studies that have explored this interaction have focused on the DG, a region
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characterized by aberrant mossy fiber sprouting in epilepsy. As a whole, the
experiments discussed in Chapters 4 – 6 provide the first in-depth examination of
KAR subunit expression and neurotransmission in epilepsy.
One aspect of KAR-mediated neurotransmission that we did not explore in
the current study is the role of the auxiliary transmembrane proteins Neto1 and
Neto2. While both proteins are expressed in the hippocampus, data suggests
that expression of Neto1 is more abundant and appears restricted to area CA3
and the DG (Copits et al., 2011; Straub et al., 2011b). In addition, studies utilizing
Neto1-/- animals have demonstrated that KAR-mediated ionotropic and
metabotropic transmission is significantly impaired at the mossy fiber – CA3
synapse (Straub et al., 2011b; Tang et al., 2011; Wyeth et al., 2014). Reportedly
this reduction in KAR-mediated transmission is due to a decrease in surface
trafficking of the GluK2/3 subunit to the postsynaptic CA3 cell (Wyeth et al.,
2014). In the current study we observed a rapid and sustained decrease in
GluK2/3 expression in hippocampal regions, specifically area CA3 which was
also accompanied by a reduction in KAR-mediated transmission. Due to
limitations in antibody availability and selectivity we did not explore alterations in
Neto1 or Neto2 expression in epileptic animals. It is possible that Neto1 may be
significantly impaired in animals following SE and this reduction impairs proper
trafficking of the GluK2/3 subunit and thus reduces transmission.
The current study focused predominately on the ionotropic actions of
KARs. While we suggest that the depression of mossy fiber excitability induced
by high KA (10 µM) is likely through a metabotropic action we did not specifically
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explore this possibility. Nevertheless, the concept that KARs mediate both
ionotropic and metabotropic transmission in the hippocampus should be
appreciated. In addition to their role in regulating excitatory transmission,
activation of KARs by kainate has been demonstrated to depress GABA release
at inhibitory synapses (Rodriguez-Moreno et al., 1997). This inhibition was
determined to occur through a presynaptic activation of metabotropic KARs
linked to the inhibitory Gi/o protein, representing the first identification of
metabotropic KARs (Rodriguez-Moreno and Lerma, 1998). The ability of KARs to
regulate metabotropic transmission prompted additional studies which eventually
established that glutamate release at the Schaffer collateral – CA1 synapse is
regulated by metabotropic KARs (Frerking et al., 2001), and that the depression
of axon excitability and glutamate release observed at the mossy fiber – CA3
synapse likely involves metabotropic KARs (Negrete-Diaz et al., 2006). In
addition, it is well documented that KARs mediate postsynaptic excitability
through metabotropic regulation of the slow and medium AHP (Melyan et al.,
2002; Melyan et al., 2004; Fisahn et al., 2005; Grabauskas et al., 2007). Overall
these studies emphasize the diverse role of KARs within the hippocampus and
demonstrate their ability to regulate both excitatory and inhibitory transmission
through ionotropic and metabotropic mechanisms.

7.2 IMPACT

OF REDUCED

KAR-MEDIATED

TRANSMISSION ON HIPPOCAMPAL NETWORK

EXCITABILITY

Our data concerning altered expression of KARs likely has significant
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implications for hippocampal network activity. SE and the progression to
spontaneous seizures is associated with an increase in network excitability within
the DG due to sprouting of aberrant mossy fibers and the subsequent
development of an excitatory circuit partially mediated by KARs (Cronin et al.,
1992; Wuarin and Dudek, 1996; Sutula et al., 1998; Epsztein et al., 2005). To
compensate for this increase in excitability, we suggest that KAR subunit
expression is reduced in area CA3 leading to a decrease in excitatory
transmission in this region. This decrease in excitatory transmission in area CA3
was specific to KARs, as AMPAR-mediated transmission was unaltered. In
addition, facilitation but not depression of MF excitability, which likely influences
presynaptic glutamate release was also reduced in epileptic animals. These
studies suggest that the reduction in KAR subunit expression and function serves
to limit network excitability in area CA3 of epileptic animals.
At the Schaffer collateral – CA1 synapse, activation of KARs by kainate or
domoate has been reported to depress glutamate release in area CA1, thus
reducing excitatory transmission (Chittajallu et al., 1996; Kamiya and Ozawa,
1998; Vignes et al., 1998; Frerking et al., 2001). Our observation that KARmediated depression of CA3 axon excitability is reduced in epilepsy suggests
that excitatory transmission into area CA1 may be increased. Thus while the
reduction in KAR subunit expression and function at the mossy fiber – CA3
synapse may help reduce network excitability, the reduction in KAR regulation of
CA3 axons may increase network excitability at the Schaffer collateral – CA1
synapse. However, this concept is based solely on our studies of CA3 axon
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excitability, and thus additional studies would need to be conducted to further
determine the impact of this alteration on CA1 network excitability.

7.3 FUTURE DIRECTIONS
Our data demonstrating that STP is effective in terminating BZD-resistant
status epilepticus could potentially impact the treatment algorithms currently used
for refractory SE. However, in order for STP to be used clinically to treat SE
additional studies need to be performed. While our data clearly demonstrates
that STP effectively terminates both brief and prolonged SE, these findings were
based purely on the appearance of behavioral convulsions. While these
behavioral affects are correlated to electrographic activity (Racine, 1972), we did
not specifically explore this relationship. In addition, the ability to demonstrate
that STP is effective over several animal models of SE would add tremendous
validity to our findings. Therefore, future studies would need to determine the
impact of STP on EEG activity as well as determine the effectiveness of STP in
additional models of SE. Furthermore, STP is commonly utilized in conjunction
with other compounds such as clobazam (CLB) (Chiron et al., 2000; Ng and
Collins, 2007). While the current study did explore the ability of STP and CLB to
potentiate GABAergic transmission in SE-experienced animals, we did not
examine the impact of these compounds together on behavioral seizures,
something that would provide direct clinical relevance to the method in which
STP is currently utilized.
Our anatomical data demonstrates that KAR subunit expression is
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significantly reduced in all brain regions post-SE. The electrophysiological data
collected from area CA3 is in agreement with these anatomical alterations,
particularly the observed decrease in GluK2/3 and GluK4 subunit expression.
However, in the DG we observed a significant increase in KAR-mediated
transmission, a finding in agreement with a previous study (Epsztein et al., 2005).
However, this does not correlate with the decreases in KAR subunit expression
in the DG. Future experiments should be aimed at understanding this
discrepancy, which likely involves the process of neurogenesis which is unique to
the DG. We feel that anatomical data collected from epileptic animals may be
hindered by the massive increase, and subsequent decrease, in neurogenesis
that takes place post-SE (Parent et al., 1997; Gray and Sundstrom, 1998;
Hattiangady et al., 2004). Future studies should be aimed at unraveling the
impact of neurogenesis on KAR subunit expression. Similarly, a previous study
has suggested that KARs are colocalized with astrocytes (Vargas et al., 2013).
While the current study did not observe the appearance of any astrocytic labeling
in immunohistochemical analysis of KAR subunit expression this possibility
should be explored further, as we did find significant increases in GFAP
expression in all brain regions, and all time-points explored. As previously
discussed the current study did not explore potential alterations in Neto1 and
Neto2 expression in the epileptic brain. Given the apparent role of Neto1 in
trafficking of KAR subunits, particularly in area CA3 (Copits et al., 2011; Straub et
al., 2011b; Wyeth et al., 2014), future experiments should unquestionably explore
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the impact of SE and epilepsy on expression of the auxiliary proteins Neto1 and
Neto2 in regulating KAR subunit expression and function.
We concluded that the apparent decrease in KAR-mediated excitatory
neurotransmission in area CA3 may be a compensatory modification. This notion
was based on our finding, in agreement with other studies, that KAR-mediated
transmission is increased in the DG, and that this increase significantly impairs
the ability of the DG to properly integrate transmission entering the hippocampus
(Epsztein et al., 2005; Artinian et al., 2011). Thus KARs in area CA3 are reduced
in an attempt to limit transmission into this hyperexcitable region. Future
experiments should be specifically aimed at determining if transmission entering
the DG via the perforant path produces a weakened KAR-mediated current in
area CA3. This finding would add support to the idea of a compensatory
downregulation of KARs in epileptic animals. Additionally, we made several
claims that the reduction in KAR subunit expression and the functional impact of
these changes could precede the development of comorbid conditions common
in epilepsy, such as anxiety, depression and cognitive impairment. A recent study
has concluded that the GluK4 subunit may play a role in anxiety and depressivephenotypes in animals (Catches et al., 2012). However, future experiments
would need to focus on specifically addressing this as of yet unclear, but likely
relationship.
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7.4 HYPOTHESIS REVISITED
The overarching hypothesis that served as the catalyst for the studies
outlined in this manuscript was that status epilepticus and the development of
epilepsy produce striking alterations in GABAA and kainate receptor populations.
Furthermore, that these alterations significantly impact receptor pharmacology
and neurotransmission in the SE-experienced brain.
The findings detailed in Chapters 3 – 6 of this document support this
hypothesis. Briefly, previous studies had demonstrated that SE resulted in
subunit selective internalization of the GABAA receptor resulting in the
development of pharmacoresistance to commonly prescribed BZDs (Walton and
Treiman, 1988; Kapur and Macdonald, 1997; Jones et al., 2002; Goodkin et al.,
2008).

In

conjunction

with

these

studies

we

demonstrated

that

the

pharmacological profile of STP, a compound utilized as add-on therapy for
treatment of Dravet syndrome, was effective in terminating both brief and
prolonged SE by sustaining its potentiation of GABAergic transmission. In
addition we studied alterations in excitatory neurotransmission mediated by the
KAR following induction of SE. We demonstrated that SE produces significant
and region specific reductions in the expression of KAR subunits, and that these
alterations yield a significant decrease in KAR-mediated transmission at the
mossy fiber – CA3 synapse, as well as reducing the ability of KARs to properly
regulate axon excitability. Together these studies support our hypothesis that SE
and the development of epilepsy, significantly alters both the pharmacology and
physiology of hippocampal receptor populations.
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7.5 SIGNIFICANCE REVISITED
Status epilepticus, characterized as a prolonged seizure, is an extremely
serious event that requires immediate medical attention. Nearly 40% of people
who experience a single SE event go on to develop epilepsy, making it the most
challenging long-term consequence associated with SE (Hesdorffer et al., 1998).
While several lines of treatment options for SE are available, approximately 20 –
40% of people prove refractory to these agents, significantly increasing their risk
for development of epilepsy, associated comorbidities and death (French, 2007).
In light of the staggering impact that SE and seizure disorders can impart, the
development of more effective therapeutics is essential. However, in order to
develop these drugs we must better understand the impact that SE and the
development of epilepsy have on the brain, particularly how receptor populations
are altered and the impact of those alterations on neurotransmission.
The studies in this document provide new and essential information
regarding how both GABAergic and glutamatergic receptor populations are
altered following SE. While BZDs are considered the first-line of therapy for
treatment of SE, they develop significant pharmacoresistance that can put
patients in extreme danger as the seizures progress. We have demonstrated that
STP, a compound already clinically used for Dravet syndrome, is highly effective
in terminating SE and develops less pharmacoresistance. This finding will
hopefully lead to further exploration of STP as a potential treatment method in
the patient population. In addition, our findings demonstrate the types of
compounds and their pharmacological profiles that are effective in treating BZD-
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resistant SE, and suggest that the development of additional compounds with
similar profiles may be advantageous.
The final set of studies explored alterations in KAR subunit expression and
neurotransmission. Our understanding of KARs and their role in hippocampal
neurotransmission has dramatically increased over the past couple decades.
Emerging from these studies was the relationship between KARs and epilepsy.
The studies outlined in this document further this field by demonstrating that SE
and the progression of epilepsy significantly alter the expression of KAR subunits
throughout the three central regions of the hippocampus- DG, CA3 and CA1. In
support of the reduction in KAR subunit expression we observed a significant and
selective decrease in KAR-mediated transmission, as transmission mediated by
AMPA

receptors

was

unaltered.

These

findings

likely

demonstrate

a

compensatory downregulation of KAR-mediated excitatory neurotransmission in
the epileptic brain. However, a consequence of this reduction to limit
epileptogenic activity may be the development of comorbidities associated with
epilepsy. In addition these studies could potentially serve as a rationale for the
selective targeting of KARs for therapeutic agents. Together these studies
contribute new and exciting information to our knowledge concerning the impact
of SE and the development of epilepsy on the inhibitory and excitatory systems
of the brain.
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